UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ______ TO _____


COMMISSION FILE NUMBER 000-25132

MYMETICS CORPORATION
(Exact name of Registrant as specified in its charter)

           DELAWARE                                           25-1741849
(State or other jurisdiction of                            (I.R.S. Employer
incorporation or organization)                            Identification No.)

150 CHESTNUT STREET
PROVIDENCE, RHODE ISLAND 02903
(Address of principal executive offices)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 401-861-7604

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:


COMMON STOCK, $0.01 PAR VALUE
(Title of Class)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to

Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

The aggregate market value of the voting common stock held by non-affiliates of the Registrant (assuming officers, directors and 10% stockholders are affiliates) was approximately U.S. $96,051,812.50 as of June 28, 2002, computed on the basis of the average of the bid and ask prices on such date. The Registrant has no non-voting common stock.

As of March 24, 2003, there were 50,944,505 shares of the Registrant's Common Stock outstanding (of which 16,393,316 shares are Exchangeable Preferred Shares of the Registrant's subsidiary, 6543 Luxembourg S.A., which Exchangeable Preferred Shares are directly convertible into the Registrant's Common Stock).



DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant's 2003 Proxy Statement to be filed within 120 days after December 31, 2002 are incorporated by reference into Part III of this annual report on Form 10-K.

USE OF EUROS

The financial information contained in this Form 10-K is provided in Euros (E) (except in "Item 5. Market for Registrant's Common Equity and Related Stockholder Matters" which is provided in United States Dollars, and except as expressly indicated otherwise herein). See Note 1 to the Consolidated Financial Statements contained in this Form 10-K for further explanation. As of March 26, 2003, 1 Euro was convertible into 1.06530 United States Dollars.

FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. These risks are described below and in "Item 1. Business," "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Item 7A. Quantitative and Qualitative Disclosures About Market Risk" included in this Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date the statements were made.

1

RISK FACTORS

You should carefully consider the risks described below together with all of the other information included in this report on Form 10-K. An investment in our common stock is very risky. If any of the following risks materialize, our business, financial condition or results of operations could be adversely affected. In such an event, the trading price of our common stock could decline, and you may lose part or all of your investment.

We are a company engaged exclusively in research and development activities, focusing primarily on human and veterinary biology and medicine. When used in these risk factors, the terms "we" or "our" refer to Mymetics Corporation and its subsidiaries.

IF WE ARE UNABLE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE OUR RESEARCH AND INTELLECTUAL PROPERTY, WE MAY NEVER GENERATE SIGNIFICANT REVENUES OR ACHIEVE PROFITABILITY.

Our current objective is to develop vaccine and therapeutic compounds and specific therapies for certain retroviral diseases or diseases with a viral autoimmune content. All of our potential products and production technologies are in the research or pre-development stages and no revenues have been generated from product sales. The first products and applications target human immunodeficiency virus, or HIV, and feline immunodeficiency virus, or FIV, the precursors to human and feline acquired immunodeficiency syndrome, or AIDS. We will not become profitable, if ever, unless we develop our intellectual property to a point where it can be licensed to third parties on financially favorable terms or applied in the creation and development of one or more products that can generate revenues.

Although our due diligence has indicated that Mymetics S.A.'s (our subsidiary) research and discovery regarding "mimicry" may lead to important discoveries in the scientific community regarding the HIV infection process, other discoveries may be necessary to develop an effective vaccine, and we may never be able to develop our research and intellectual property into a commercially profitable product.

Our success will depend on our ability to:

- effectively commercialize the research through collaborative relationships with third parties;

- prepare acceptable protocols necessary to obtain regulatory approvals;

- effectively conclude clinical trials;

- effectively establish commercial viability; and

- effectively establish marketing and manufacturing relationships.

If we are unable to commercialize the current research, we do not have other products from which to derive revenue.

WE MUST OVERCOME SIGNIFICANT OBSTACLES TO SUCCESSFULLY DEVELOP OR MARKET PRODUCT CANDIDATES.

The development of product candidates is subject to significant risks of failure, which are inherent in the development of new medical products and products based on new technologies. These risks include:

- delays in pre-clinical testing, product development, clinical testing or manufacturing;

- unplanned expenditures for product development, clinical testing or manufacturing;

2

- failure of the technologies and products being developed to have the desired effect or an acceptable safety profile;

- failure to receive regulatory approvals;

- emergence of equivalent or superior products;

- inability to manufacture (directly or through third parties) product candidates on a commercial scale;

- inability to market products due to third party proprietary rights;

- inability to find collaborative partners to pursue product development; and

- failure by future collaborative partners to successfully develop products.

If these risks materialize, our research and development efforts may not result in any commercially viable products.

WE HAVE A HISTORY OF OPERATING LOSSES AND WE EXPECT TO GENERATE OPERATING LOSSES FOR THE FORESEEABLE FUTURE.

We currently are engaged in research and development activities, and do not have any commercially marketed products. The product research and development process requires significant capital expenditures, and we do not have any other sources of revenue to off-set such expenditures. Accordingly, we expect to generate additional operating losses at least until such time as we are able to generate significant revenues.

WE MAY NEED TO RAISE ADDITIONAL CAPITAL TO FUND OUR RESEARCH EFFORTS AND TO FULLY DEVELOP COMMERCIALLY VIABLE PRODUCTS. WE CANNOT ASSURE YOU THAT WE WILL BE ABLE TO OBTAIN ADDITIONAL CAPITAL WHEN NEEDED OR THAT SUCH CAPITAL WILL BE AVAILABLE ON FAVORABLE TERMS, IF AT ALL. OUR BUSINESS WILL BE ADVERSELY AFFECTED IF WE CANNOT RAISE ADDITIONAL CAPITAL WHEN NEEDED.

The costs for us to continue our research and to develop our intellectual property will be substantial. We expect that our existing capital resources will satisfy our capital requirements through approximately June 2003. However, given the fact that we do not have any current sources of revenue, substantial additional capital will likely be needed to continue the development and commercialization of our intellectual property. Currently there are no commitments for any additional financing. Any additional equity financing may be dilutive to stockholders, and debt financing, if available, may include restrictive covenants and there can be no assurance that additional financing will be available. While the amount of capital required cannot be estimated with precision, we estimate it will require approximately 2 million Euros just to move our business forward into a position of being prepared to initiate clinical trials.

The availability of and the need for future capital will depend on many factors, including:

- continued scientific progress in our research and development program;

- results of pre-clinical tests;

- results of any clinical trials;

- the time and cost involved in obtaining regulatory approvals;

- future collaborative relationships; and

- the cost of manufacturing.

If adequate funds are not available, we may be required to curtail or cease operations.

3

COMMERCIALIZATION OF OUR INTELLECTUAL PROPERTY AND CREATION OF VIABLE PRODUCTS DEPEND ON COLLABORATIONS WITH OTHERS. IF WE ARE UNABLE TO FIND COLLABORATORS IN THE FUTURE, WE MAY NOT BE ABLE TO DEVELOP PROFITABLE PRODUCTS.

Our strategy for the research, development and commercialization of products requires us to enter into contractual arrangements with corporate collaborators, licensors, licensees and others. We do not have the funds to develop products on our own, and intend to depend on collaborators to develop products on our behalf. If collaborative relationships cannot be found, we may not be able to continue our development programs.

Moreover, we could become involved in disputes with collaborative partners, which could lead to delays or termination of development programs and time-consuming, expensive and distracting litigation or arbitration. Even if we fulfill our obligations under a collaborative agreement, a partner may terminate the agreement. If any collaborative partner terminates or breaches an agreement with us, or otherwise fails to complete its obligations in a timely manner, our ability to successfully commercialize our intellectual property will be adversely affected.

IF WE ARE NOT ABLE TO DEMONSTRATE THE RESULTS OF OUR RESEARCH IN CLINICAL TRIALS, OR IF CLINICAL TRIALS ARE DELAYED, WE MAY NOT BE ABLE TO OBTAIN REGULATORY CLEARANCE TO MARKET OUR PRODUCTS IN THE UNITED STATES OR IN FOREIGN COUNTRIES ON A TIMELY BASIS, OR AT ALL.

Assuming we are able to successfully develop our research into potential products, such products will require regulatory approval. Before obtaining regulatory approvals for the commercial sale of any of the products under development, pre-clinical studies and clinical trials must demonstrate that the product is safe and effective for use in each target indication. If any of the products fail in clinical trials, the approval of the United States Food and Drug Administration (the "FDA") and similar agencies operating in foreign countries will not be obtained for such products, and we will not be able to generate revenues from such products.

Clinical testing is a long, expensive and uncertain process. One cannot be certain that the data collected from the clinical trials will be sufficient to support approval by the FDA or any foreign regulatory authorities, that the clinical trials will be completed on schedule or, even if the clinical trials are successfully completed and on schedule, that the FDA or any foreign regulatory authorities will ultimately approve the product for commercial use.

Clinical trials could be delayed for a variety of reasons, including:

- delays in enrolling volunteers;

- lower than anticipated retention rate of volunteers in the trials; and

- serious adverse events related to the products being developed.

Our research is presently focused on developing vaccines and therapeutics to prevent and treat HIV. Trials will be conducted on animals prior to humans. Results of animal trials, even if successful, may not be relevant for determining the preventive or therapeutic effect of any potential product designed to prevent or treat HIV infection in humans. In addition, results from early clinical trials are not necessarily indicative of future results. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in late stage clinical trials even after promising results in early stage development. Furthermore, pre-clinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approvals. Negative or inconclusive results or interpretations could cause the trials to be unacceptable for submission to regulatory authorities.

4

IF WE ARE UNABLE TO ATTRACT AND RETAIN KEY EMPLOYEES AND CONSULTANTS, WE WILL BE UNABLE TO DEVELOP AND COMMERCIALIZE PRODUCTS.

We are dependent on the principal members of our management and scientific staff. In order to successfully complete our research and development activities and our commercialization plans, we will need to hire personnel with experience in clinical testing, drug discovery, government regulation, manufacturing, marketing and finance. We may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among high technology enterprises, including biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions.

IF WE FAIL TO ENTER INTO SUCCESSFUL MARKETING ARRANGEMENTS WITH THIRD PARTIES, WE WILL NOT BE ABLE TO COMMERCIALIZE PRODUCTS.

We do not currently have any sales or marketing infrastructure, and we do not have significant experience in marketing, sales and distribution. Future profitability will depend in part on plans to enter into successful marketing arrangements with third parties. To the extent that we enter into marketing and sales arrangements with other companies, revenues will depend on the efforts of others. These efforts may not be successful. If we are unable to enter into successful third-party arrangements, we may not be able to commercialize our products.

IF WE DO NOT SUCCESSFULLY COMPETE IN THE DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS AND KEEP PACE WITH RAPID TECHNOLOGICAL CHANGE, WE WILL BE UNABLE TO CAPTURE AND SUSTAIN A MEANINGFUL MARKET POSITION.

The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. We are aware of several companies that are actively engaged in research and development in areas related to our research focus. Many of these companies are addressing the same diseases and disease indications that we are addressing. As a result of this intense competition, any products that we develop may become obsolete before we are able to recover the expenses incurred in their development. Moreover, many of these companies, either alone or together with their collaborative partners, have substantially greater financial resources and larger research and development staffs. These competitors, either alone or together with their collaborative partners, also have significantly greater experience in:

- developing products;

- undertaking pre-clinical testing and human clinical trials;

- obtaining FDA and other regulatory approvals of products; and

- manufacturing and marketing products.

IF OUR INTELLECTUAL PROPERTY DOES NOT ADEQUATELY PROTECT PRODUCT CANDIDATES, WE COULD ENCOUNTER MORE DIRECT COMPETITION, WHICH COULD ADVERSELY IMPACT REVENUES.

Our success depends, in part, on our ability to:

- obtain and maintain patents or rights to patents;

- protect trade secrets;

- operate without infringing upon the proprietary rights of others; and

- prevent others from infringing on our proprietary rights.

We will be able to protect proprietary rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biotechnology companies involves complex legal and factual questions and, therefore, enforceability cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. Thus, any patents that are owned or licensed from third parties may not provide adequate protection

5

against competitors. Pending patent applications, those applications that we may file in the future, or those applications that may be licensed from third parties, may not result in patents being issued. Also, patent rights may not provide adequate proprietary protection or competitive advantages against competitors with similar technologies. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States.

In addition to patents, we rely on trade secrets and proprietary know-how. Protection of trade secrets and know-how is sought, in part, through confidentiality and proprietary information agreements and customary principles of "work-for-hire." These agreements may not provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. Failure to protect proprietary rights could seriously impair our competitive position.

IF THIRD PARTIES CLAIM WE ARE INFRINGING THEIR INTELLECTUAL PROPERTY RIGHTS, WE COULD BECOME SUBJECT TO SIGNIFICANT LITIGATION OR LICENSING EXPENSES OR BE PREVENTED FROM MARKETING OUR PRODUCTS.

The areas in which we have focused our research and development have a number of competitors. This has resulted in a number of issued patents and still-pending patent applications. Patent applications in the United States are, in most cases, maintained in secrecy until the patents issue. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made. Commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. In the event of such infringement, we may be prevented from pursuing certain product development or commercialization and may be required to obtain a license for the use of the proprietary rights or patents. We may also be required to pay damages for past infringement.

The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual property rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings and related legal and administrative proceedings in the United States and in foreign countries involve complex legal and factual questions. As a result, such proceedings are costly and time consuming to pursue and their outcome is uncertain.

Litigation may be necessary in the future to:

- enforce patents that we own or license;

- protect trade secrets or know-how that we own or license; or

- determine the enforceability, scope and validity of the proprietary rights of others.

We believe that our technology has been independently developed and does not infringe upon the proprietary or intellectual property rights of others. We cannot, however, guarantee that our technology does not, and will not in the future, infringe upon the rights of third parties. We may be a party to legal proceedings and claims relating to the proprietary information of others from time to time in the ordinary course of our business. If we become involved in any litigation, interference or other administrative proceedings, we will incur substantial expense and the efforts of technical and management personnel will be significantly diverted. An adverse determination may subject us to loss of proprietary position or to significant liabilities, or require licenses that may not be available from third parties. We may be restricted or prevented from manufacturing and selling products, if any, in the event of an adverse determination in a judicial or administrative proceeding or if we fail to obtain necessary licenses. Costs associated with these arrangements may be substantial and may include ongoing royalties. Furthermore, the necessary licenses may not be available on satisfactory terms, if at all.

WE CAN NOT BE SURE THAT ANY FUTURE OR CURRENTLY PENDING PATENT APPLICATIONS RELATING TO OUR PRODUCTS WILL ISSUE ON A TIMELY BASIS, IF EVER.

Since patent applications in the United States are maintained in secrecy until 18 months from the priority date, and since publication of discoveries in the scientific or patent literature often lag behind actual discoveries, we

6

cannot be certain that we were the first to develop the inventions covered by each of our pending patent applications or that we were the first to file patent applications for such inventions. Even if patents are issued, the degree of protection afforded by such patents will depend upon the:

- scope of the patent claims;

- validity and enforceability of the claims obtained in such patents; and

- our willingness and financial ability to enforce and/or defend them.

EVEN IF WE OBTAIN REGULATORY APPROVAL TO MARKET AND SELL OUR PRODUCTS, WE WILL BE SUBJECT TO ONGOING REGULATORY REVIEW, WHICH WILL BE EXPENSIVE AND MAY AFFECT OUR ABILITY TO SUCCESSFULLY COMMERCIALIZE OUR PRODUCTS.

Even if regulatory approval for a product is secured, such approval may be subject to limitations on the indicated uses for which the product may be marketed. Such limitations may restrict the size of the available market for the product or contain requirements for costly post-marketing surveillance studies. Manufacturers of medical products are subject to continued review and periodic inspections by the FDA and other regulatory authorities. The subsequent discovery of previously unknown problems with the product, clinical trial subjects, or with the manufacturer or its manufacturing facility may result in the imposition of restrictions on the product or manufacturer, including withdrawal of the product from the market. If we or any of our collaborative partners fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

IF OUR PRODUCTS ARE NOT ACCEPTED BY THE MARKET, WE ARE NOT LIKELY TO GENERATE SIGNIFICANT REVENUES OR BECOME PROFITABLE.

Even if we are able to successfully develop a viable product and obtain regulatory approval of such product, such product may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any medical product depends on a number of factors, including:

- demonstration of clinical efficacy and safety;

- cost-effectiveness;

- potential advantages over alternative therapies;

- reimbursement policies of government and third party payors;

- effectiveness of marketing and distribution capabilities; and

- the success of physician education programs.

Physicians will not recommend therapies using products until clinical data or other factors demonstrate their safety and efficacy as compared to other drugs or treatments. Even if the clinical safety and efficacy of therapies using the products is established, physicians may elect not to recommend the therapies for other reasons, including whether the mode of administration of products is effective for certain indications.

RAW MATERIALS NECESSARY TO MANUFACTURE OUR PRODUCTS MAY NOT BE AVAILABLE, WHICH MAY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

We believe we will have access to sufficient quantities of raw materials to conduct and advance our research. We utilize third party collaborators, licensors, licensees and others to conduct research on our behalf, and we rely on these third parties to provide the necessary materials to conduct such research. If we or our third-party

7

collaborators are unable to obtain the necessary materials to conduct such research, our business, financial condition and results of operations will be adversely affected.

OUR STOCK PRICE MAY EXPERIENCE SIGNIFICANT VOLATILITY, WHICH COULD ADVERSELY AFFECT THE VALUE OF YOUR INVESTMENT.

The market price of our common stock, like that of the common stock of many other development stage biotechnology companies, may be highly volatile. In addition, the stock market has experienced extreme price and volume fluctuations. This volatility has significantly affected the market prices of securities of many biotechnology and pharmaceutical companies for reasons frequently unrelated to, or disproportionate to, the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock.

THE MARKET FOR OUR COMMON STOCK IS VERY LIMITED

Our common stock is currently traded only on the OTC Bulletin Board. Accordingly, we cannot provide assurances as to the future liquidity of our common stock or the price at which you would be able to sell your shares in any available market.

THE ISSUANCE OF ADDITIONAL EQUITY SECURITIES MAY DILUTE YOUR INVESTMENT.

We currently have 50,944,505 shares of common stock outstanding (assuming the conversion of all the outstanding Class B Exchangeable Preferential Non-Voting Stock, or Preferential Shares, of our subsidiary, 6543 Luxembourg S.A., into 16,393,616 shares of our common stock), 1 share of Special Voting Preferred Stock, options to purchase an aggregate of 381,250 shares of common stock and warrants to purchase an aggregate of 80,166 shares of common stock. We are authorized to issue up to 80 million shares of common stock and 5 million shares of preferred stock without additional stockholder approval. The issuance of additional common stock or preferred stock will dilute our stockholders' percentage ownership, and, depending on the offering price of such stock, may also serve to dilute the value of such ownership interest.

WE CURRENTLY DO NOT INTEND TO PAY CASH DIVIDENDS ON OUR SHARES.

We have never declared or paid any cash dividends on our common stock, nor do we intend on doing so in the foreseeable future. The payment of dividends, if any, in the future is within the discretion of our board of directors and will depend upon our earnings, capital requirements and financial condition as well as other relevant factors. We currently intend to retain all earnings, if any, to finance our continued growth and the development of our business. Furthermore, our ability to declare or pay dividends may be limited in the future by the terms of any then-existing credit facilities, which may contain covenants that restrict the payment of cash dividends.

POLITICAL OR SOCIAL FACTORS MAY ADVERSELY IMPACT REVENUES BY DELAYING OR IMPAIRING THE CORPORATION'S ABILITY TO MARKET ITS PRODUCTS.

We are focused on developing vaccines and products for the treatment and prevention of HIV. Products developed to address the HIV/AIDS epidemic have been, and may continue to be, subject to competing and changing political and social pressures. The political and social response to the HIV/AIDS epidemic has been emotionally charged and unpredictable. Such political and social forces may serve to delay or prevent introduction of our products into the marketplace or to place restrictions upon the pricing, availability and marketing of such products.

8

TABLE OF CONTENTS

                                                                                            PAGE

                                                 PART I

ITEM 1.           BUSINESS..............................................................      10

ITEM 2.           PROPERTIES ...........................................................      20

ITEM 3.           LEGAL PROCEEDINGS ....................................................      20

ITEM 4.           SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS ..................      20

                                                 PART II

ITEM 5.           MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED
                  STOCKHOLDER MATTERS...................................................      21

ITEM 6.           SELECTED FINANCIAL DATA ..............................................      23

ITEM 7.           MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                  CONDITION AND RESULTS OF OPERATIONS...................................      23

ITEM 7A.          QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
                  MARKET RISK...........................................................      25

ITEM 8.           FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ..........................      25

ITEM 9.           CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
                  ACCOUNTING AND FINANCIAL DISCLOSURE...................................      25

                                                  PART III

ITEM 10.          DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT ...................      26

ITEM 11.          EXECUTIVE COMPENSATION ...............................................      26

ITEM 12.          SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
                  AND MANAGEMENT........................................................      26

ITEM 13.          CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS .......................      26

ITEM 14.          CONTROLS AND PROCEDURES...............................................      26

                                                   PART IV

ITEM 15.          EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS
                  ON FORM 8-K...........................................................      27

SIGNATURES..............................................................................      46

9

PART I

ITEM 1. BUSINESS

THE CORPORATION

We are a holding company conducting business through our subsidiaries 6543 Luxembourg S.A., a joint stock company organized in 2001 under the laws of Luxembourg ("LuxCo"), Mymetics S.A. (formerly Hippocampe S.A.), a company organized in 1990 under the laws of France ("Mymetics S.A.") and Mymetics Deutschland GmbH, a company organized in 2002 under the laws of Germany. We were incorporated in July 1994 pursuant to the laws of the Commonwealth of Pennsylvania under the name "PDG Remediation, Inc." In November 1996, we reincorporated under the laws of the State of Delaware and changed our name to "ICHOR Corporation." In July 2001, we changed our name to "Mymetics Corporation." We own all of the outstanding voting stock of LuxCo and Mymetics GmbH, and Mymetics S.A. is a wholly-owned subsidiary of LuxCo. In this document, unless the context otherwise requires, "Mymetics" and the "Corporation" refer to Mymetics Corporation and its subsidiaries.

We currently do not make, market or sell any products or services, and thus, we have no revenues. We believe that our research and development activities, and the resulting intellectual property, will lead to the creation of commercially viable products, which can generate revenues for us in the future. If financially favorable terms are available, we may license or sell our intellectual property to third parties. If we fail to develop our intellectual property, we are unlikely to generate significant revenues.

DEVELOPMENT OF THE CORPORATION

From our inception in 1994 to December 1997, we operated in the environmental services industry, focusing on thermal treatment (in Florida), remediation services (in Florida and Pennsylvania) and waste oil recycling (in Illinois). In February 1995, we completed an initial public offering. In 1998 and 1999, after disposing of our thermal treatment, remediation services and waste oil recycling businesses, we provided consulting services to an industrial customer in Europe. In June 1999, we acquired a majority interest in Nazca Holdings Ltd., whose business involved the exploration for and development of groundwater resources in Chile. Following the disposal of our interest in Nazca in July 2000, we did not have an operating business.

In March 2001, we acquired 99.9% of the outstanding shares of Mymetics S.A. in consideration for shares of our common stock and shares of Class B Exchangeable Preferential Non-Voting Stock of LuxCo, or Preferential Shares, which are convertible into shares of our common stock. In 2002, we acquired the remaining 0.1% of the outstanding common stock of Mymetics S.A. pursuant to share exchanges with the remaining stockholders of Mymetics S.A. The terms of these recent share exchanges were substantially similar to the terms of the share exchange that occurred in March 2001. Mymetics S.A. was, and continues to be, a biotechnology research and development company.

On June 30, 2001, we closed on a private offering of 1,333,333 shares of our common stock, at E1.77 (U.S. $1.50) per share, for an aggregate price of E2,355,600 (U.S. $2,000,000). This private placement was exempt from registration pursuant to Regulation S of the Securities Act of 1933, and the shares were sold to foreign investors meeting the requirements of Regulation S. In August, 2002 the Company formed Mymetics Deutschland GmbH for the purpose of applying for German government support of research activities to be conducted in Germany.

We own all the outstanding voting stock of LuxCo. There are also 15,372 Preferential Shares of LuxCo currently outstanding, which are convertible into 16,393,316 shares of our common stock. Holders of the Preferential Shares do not have any voting rights with respect to LuxCo. However, pursuant to a Voting and Exchange Trust Agreement dated March 28, 2001, the holders of the Preferential Shares are entitled to vote on all matters to be voted on by the holders of our common stock to the same extent as if they had converted the Preferential Shares into shares of our common stock.

10

MYMETICS CORPORATION

Prior to 2002, our activities were primarily conducted in Europe. During the second quarter of 2002, through our operations in the United States, we launched programs in the United States in an attempt to reinforce our intellectual property portfolio and to accelerate the commercialization of our technology. This was done, in part, by attempting to target products and business development in the United States. Again, prior to this time, activities such as design of the prototype molecules, synthesis, and in vitro testing had been conducted exclusively in Europe. We believed that expanding our operating activities in the United States offered numerous advantages, including greater access to expertise, grants, subsidies, intellectual property and public and private research teams. Due to financial constraints, we were forced to limit these activities in January 2003.

MYMETICS S.A.

Our subsidiary, Mymetics S.A., is a biotechnology research and development company devoted to fundamental and applied research in the area of human and veterinary biology and medicine. Mymetics S.A.'s primary objective is to develop therapies to treat certain retroviruses, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Additional applications of Mymetics S.A.'s research include potential treatments and/or vaccines for animal AIDS, human and animal oncoviral leukemias, multiple sclerosis and organ transplantation. To date, Mymetics S.A. has conducted its fundamental research in Europe.

Mymetics S.A.'s research strategy is to structure and manage a network of public and private best-in-class research teams, each with a clearly delineated focus. Mymetics S.A. has segmented its primary research into modules, which are then out-sourced, under its direct supervision, to high-level, specialized and complementary public and private research teams. Mymetics S.A. retains all intellectual property rights in the combined research and applies for domestic and international patents whenever justified. As agreed and coordinated by Mymetics S.A., the research teams are authorized to co-publish their results.

MYMETICS GMBH

Mymetics Deutschland GmbH was formed in 2002 for the purpose of applying for German government support of research activities to be conducted in Germany. The German government offers subsidy programs as a means of attracting business investment into parts of eastern Germany. In particular, Mymetics Deutschland GmbH was organized to take advantage of (i) an investment matching program offered by the German government, whereby the German government matches the amount of certain investments made by companies in eastern Germany and (ii) a broader program, whereby the German government offers significant amounts of grant money to companies in eastern Germany that satisfy certain conditions. Mymetics Deutschland GmbH solicited interest from existing research teams in eastern Germany, formulated four distinct research programs and applied for German government grants. In December 2002, Mymetics Deutschland GmbH was informed that two of its programs would be eligible for matching grants. However, the broader program described above, which may have served as a source of substantial working capital, was suspended by the German government for biotechnology companies. Consequently, we elected to suspend our planned expansion of research activities into Germany.

RECENT INDUSTRY DEVELOPMENTS

In late 2002, it became apparent that one of our major competitors would be receiving approval from the United States Food and Drug Administration of its fusion inhibitor candidate drug in the first quarter of 2003. This development, combined with advances in our research activities, served to validate our basic technology in the area of fusion inhibitors and, in particular, the efficacy of gp41-derived peptide product. Given this validation, as well as (i) advances in the our research and development efforts, (ii) poor worldwide capital market conditions and (iii) lack of sufficient long term working capital, we have decided to re-direct our business development strategy:
rather than independently funding the completion of research and development programs prior to the sale or licensing of our technology to a major international pharmaceutical or biotechnology firm, we have opted to accelerate the exploration of potential partnerships with major international pharmaceutical and biotechnology firms. We have also accelerated the development of our patent portfolio.

11

SCIENCE OVERVIEW

Virus. A virus is a noncellular organism consisting of deoxyribonucleic acid ("DNA") or ribonucleic acid ("RNA") and a protein coat. During the free and infectious stage of their life cycle, viruses do not perform the usual functions of living cells, such as respiration and growth. Rather, when viruses enter a living plant, animal or bacterial cell, they utilize the host cell's chemical energy and synthesizing ability to replicate. After the replication of the viral components by the infected host cell, virus particles are released and the host cell is often destroyed. The approximately 2,450 viral species identified to date are divided into about 75 groups. HIV belongs to the group of retroviruses, so called because they contain a reverse transcriptase that copies viral RNA back into DNA (the reverse of what usually occurs when DNA is copied into RNA). Retroviruses include spumaviruses, oncoviruses (causing cancers) and lentiviruses (viruses with a slow pathogenic action, e.g. AIDS-associated lentiviruses).

HIV. HIV is a type of retrovirus, a virus of the family Retroviridae that has RNA as its nucleic acid and uses the enzyme reverse transcriptase to copy its genome into the DNA of the host cells chromosomes. Once inside the T cell, HIV uses the cell's machinery to copy its RNA into DNA by means of the reverse transcriptase. HIV is characterized by an inability to mount a normal immune response and is the cause of the fatal illness known as AIDS. AIDS is the late stage of infection caused by HIV.

Two strains of HIV have been identified, HIV-1 and HIV-2. The genetic material of these two strains is approximately 60% identical. Each strain contains a number of subtypes, which are slight genetic variations of the virus. At least 32 sub-types have been identified to date. These variations result from the high mutation rate of HIV's genetic material. Most variations occur in the gene encoding the GP120 protein, and these mutations can alter the protein's structure. HIV-1 or Type 1 classified as a lentivirus is a subgroup of retroviruses that have been isolated and recognized as the cause of a disease that induces AIDS. HIV-1, like most viruses and all bacteria, plants and animals, has genetic codes made up of DNA, which uses RNA to build specific proteins. HIV's genetic material is the RNA itself. HIV inserts its own RNA into the host cell's DNA, preventing the host cell from performing its natural functions and transforming it into an HIV virus factory.

AIDS. AIDS is a fatal epidemic disease caused by an infection by HIV (HIV-1 or HIV-2). In most cases, HIV slowly attacks and destroys the immune system, the body's defense against disease, leaving the infected individual vulnerable to malignancies and infections that eventually cause death. Propagation of HIV results from the invasion of the host cell and its use of the host cell's protein synthesis capability. The immune system's response (antibodies and cellular immune response) is usually sufficient to temporarily arrest progress of the infection and reduce levels of the virus in the blood. Virus replication continues, however, and gradually destroys the immune system by infecting and destroying critical white blood cells known as CD4 cells. The main cellular target of HIV is a special class of white blood cells critical to the immune system, known as helper T lymphocytes, or T4 helper cells. These cells play a principal role in normal immune responses by stimulating or activating virtually all of the other cells involved in immune protection. These cells include B lymphocytes, the cells that produce antibodies needed to fight infection; cytotoxic T lymphocytes, which destroy cells infected with virus; and macrophages and other effector cells, which attack invading pathogens. Once HIV has entered the helper T cell, it can impair the functioning of or destroy the cell. A hallmark of the onset of AIDS is a drastic reduction in the number of helper T cells in the body. HIV also can infect other cells, including certain monocytes and macrophages, as well as brain cells. Among those cells are CD4, HIV's preferred target cells due to a docking molecule called cluster designation 4 on their surfaces. Cells with this molecule are known as CD4+ cells. These cells normally orchestrate the immune response, signaling other cells in the immune system to perform their special functions. Destruction of CD4+ lymphocytes is the major cause of the immunodeficiency observed in AIDS, and decreasing CD4+ lymphocyte levels appear to be the best indicator of morbidity in these patients. As the infection progresses, the immune system's control of HIV levels weakens, the level of the virus in the blood rises and the level of critical T cells declines to a fraction of their normal level.

Viral Envelope of HIV. The viral envelope of HIV is covered with mushroom-shaped spikes that enable the virus to attach itself to the target cell. The cap of each "mushroom" is comprised of GP120 molecules and its stem is comprised of GP41 molecules. GP120 is a glycoprotein that protrudes from the surface of HIV and binds to the CD4 receptor of the CD4+ T-cells. In a two-step process that allows HIV to breach the membrane of T-cells, the GP120-CD4 complex refolds to reveal a second structure that binds to CCR5 or CXCR4, one of several chemokine co-receptors used by the virus to gain entry into T cells. GP41 is a glycoprotein embedded in the outer envelope of HIV and plays a key role in HIV's infection of cells by carrying out the fusion of the viral and cell membranes. GP160 is a glycoprotein, which is the precursor of HIV envelope proteins GP120 and GP41.

12

Immune System. The immune system functions to protect the body against infection and foreign substances, including viruses and bacteria. This defensive function is performed by the body's white blood cells (leukocytes) and by a number of accessory cells, including B lymphocytes, the cells that produce the antibodies needed to fight infection, and cytotoxic T lymphocytes, which destroy cells infected with viruses. When an immunocompetent cell recognizes foreign material or a biological invader presented by the macrophages, it normally induces a response. This recognition function relies on the immune system's ability to recognize specific foreign molecular configurations, generically referred to as antigens. T4 lymphocytes, as the central cells of the immune system, specifically recognize foreign invaders presented by macrophages. After specific recognition of a presented antigen, T4 lymphocytes play a major role in the immune response, producing interleukine-2 ("IL-2"), a central interleukine that activates all of the accessory cells previously described and the overall immune response.

BUSINESS STRATEGY

Our current objective is to develop a platform of both therapeutic compounds and vaccines. We have made a series of discoveries about how the body's immune system responds to retroviruses, specifically HIV. The foundation of our platform technology and product pipeline is our discovery of a subtle mimicry between the virus and the host cells. By understanding the precise dynamics of the virus's GP41 and the host-cell's IL-2, we believe we have the potential to design and develop specific therapeutic molecules and antibodies to disrupt or even prevent the disease. In addition to targeting HIV and AIDS, we plan to apply these findings to the potential treatment or even prevention of a range of additional diseases, including certain oncoviruses like leukemia.

Some biotechnology companies are focusing on slowing or impeding the progress of the virus once it has infected the body's host cells. Other biotechnology firms are attempting to develop therapies that prevent the virus from fusing with host cells. If the virus cannot fuse, it cannot reproduce, and the body's immune system then succeeds in arresting the invasion. Our approach is also based on the concept of preventing viral fusion. Our scientific strategy is unique in that its design is based on a series of discoveries involving mimicry, and, in particular, on the inter-reaction between the viral envelope glycoprotein GP41 and the host cell's IL-2. We have discovered that a piece of the virus closely resembles or "mimics" the host cell's IL-2. By exploiting this mimicry, we believe the virus unlocks the host cell and gains access to the cell's machinery. The body's immune system responds to the invasion, but fails to differentiate between the viral GP41 and the host cell's IL-2. As a result, we believe that the immune system attacks both of them with equal vigor. The unfortunate consequence is that the body, in turning on itself, undercuts its own defenses. By better understanding these precise dynamics, we believe we will be able to design and develop specific therapeutic molecules, vaccines and antibodies to disrupt the mimicry, prevent HIV from entering the host cell and enable the body's immune system to recognize HIV. Our current scientific strategy is to create therapeutic peptides and antibodies to disrupt the mimicry, block the fusion, and condition the body's immune system to recognize GP41 as separate and distinct from IL-2. If this can be accomplished, the body's immune system should be able to identify and attack the virus instead of the healthy cells.

The Discovered Molecular Mimicry Between Trimeric GP41 AND IL-2. We have discovered a molecular mimicry between the trimeric ectodomain of the transmembrane protein of immunosuppressive lentiviruses (HIV-SIV-FIV) and IL-2. Our initial results were published with the French Academy of Sciences in November 2000.

Autoimmune Consequences for HIV Infected Subjects. We have found some of the expected autoimmune consequences of the described virus-host molecular mimicry in HIV infected subjects. As expected, HIV positive sera recognize human IL-2, and cross-reactivity was found between the structurally and physically antigenic analogous sites of GP41 (HIV-1) and human IL-2. The tests included 2,352 HIV+ and HIV-sera, and the results demonstrated that 100% of HIV+ patients (stages II, III and IV) were positive for the anti IL-2 response. The first results were presented in the Journal of Autoimmunity in 2001 and were also presented in a poster session at the Cold Springs Harbor, New York meeting on infectious disease in December 2001.

13

THERAPEUTIC AND VACCINAL USE OF THE MIMICRY DISCOVERY

Our current research modules focus on the following four fields:

- FUNDAMENTAL RESEARCH. We believe that our insight into the GP41/IL-2 mimicry can help explain, in large part, the main AIDS-associated disorders: drop of peripheral IL-2, decrease of non-infected T helper lymphocytes, lymphoproliferation disorders and a2 microglobulin increase and hypergammaglobulinemia. Some of the possible effects of the tridimensional GP41 (HIV-1)/human IL-2 molecular mimicry on the AIDS-associated disorders are being evaluated by our research teams. These teams are also studying molecular mimicry in FIV, between the viral envelope protein gp36 and feline IL-2.

- THERAPEUTIC MOLECULES. Based on insights into mimicry, we have developed a series of synthetic peptides that potently inhibit the fusion between HIV and its target cell in an infected subject. These synthetic peptides have been effective in both HIV and FIV contexts. These therapeutic molecules would prevent the virus from binding to the target cell, inhibiting its attempts to reproduce. Having demonstrated that the transmission of HIV depends on the viral load, and that no transmission has been observed below 1500 viral copies/ml., treatment with therapeutic agents may provide a strategy to control AIDS epidemicity. This application would complement available antiretroviral drugs, or may even provide a substitute for the available antiretroviral drugs. In a series of independent in vitro experiments, our rationally-designed peptide compounds were proven to effectively block viral fusion. These compounds also showed a potency that is equivalent to the gp41 compound recently approved by the United States Food and Drug Administration, or FDA. A poster presentation given at Interscience Conference on Antimicrobal Agents and Chemotherapy in San Diego CA in September 2002 communicated the relative potency of our compounds. An additional poster presentation at the International Feline Retrovirus Research Symposium conference in December 2002 showed the potency of a series of OUR FIV gp36-derived peptides, and in particular highlighted the surprising potency of a short compound (consisting of 8 amino acids). Results were also recently published in the Journal of Virology (March 2003) in an article entitled "Antiviral Activity and Conformational Features of an Octapeptide Derived from the membrane-Proximal Ectodomain of the Feline Immunodefeciency Virus Transmembrane Glycoprotein." An additional poster presentation at the annual International Retrovirus Conference in Boston in February 2003 communicated the results of a series of benchmarking in vitro assays, highlighting the potency of our peptide compounds across a wide array of clades or strains of the virus. These data appear to validate our strategy of creating compounds from well-conserved, IL-2-homologous regions, for the greatest possible application for patients worldwide. Based on the success of in vitro compounds, we launched our first in vivo tests in the feline model, collaborating with research partners at the Retroviral Center at the University of Pisa, Italy. These tests are expected to provide valuable insight into the actual efficacy of the potential peptides, in particular the shorter peptides, which would offer a number of practical advantages in terms of commercialization, including less complexity, lower cost to manufacture, less immunogenicity, and potential greater bio-availability.

- THERAPEUTIC AND PREVENTIVE VACCINES. We believe that our discovery of the host-virus autoimmune mimicry opens the door to novel therapeutic and preventive vaccine strategies for both humans and animals. We believe that properly mutated trimeric gp41 and gp36 represent an excellent candidate for vaccines, because of their well-conserved and immunogenic properties. Our specific preventive vaccine would be "universal" in that it would train the body's immune system to recognize and defeat a broad array of strains of the virus. Recent advances in designing and producing soluble, trimeric gp41 and gp36, have accelerated the vaccine program, and we expect to initiate in vivo and in vitro testing later this year.

- AIDS CARTRIDGE. We have developed a number of therapeutic immunocartridges that would help patients infected with AIDS by reducing the viral load. These immunocartridges have been tested and approved by the Ethics Committee for the Treatment of Systemic Lupus Erythematosus and Hemophilia A. Our research has demonstrated that the anti IL-2 antibodies in HIV infected subjects recognize some sites of IL-2 that are crucial for its bioactivity. Therefore, we believe that the development of an "AIDS cartridge" could be efficient in the restoration of the immune system (CD4/CD8-viral load) of HIV infected subjects.

14

We currently have several compound prototypes potentially capable of commercialization, including:

- Therapeutic molecules (pharmacological agents) - administered to infected subjects to prevent cell infection by HIV and FIV.

- Therapeutic vaccines (immunotherapeutic agents) - administered to infected subjects to orient the immune system into recognizing the transmembrane glycoprotein of the virus and not the host cell's IL-2.

- Preventive vaccines - administered to healthy subjects to prevent infection by HIV or FIV.

- AIDS cartridge - administered to infected subjects to selectively remove the identified immunosuppressive antibodies present in the serum of AIDS patients, using some peptides that have been tested for activity.

The Company is exploring both HIV and FIV in parallel, and gaining insight into product design through the synergies between these two programs.

KEY STAFF

Our management team has changed over the past few months. Peter P. McCann, Ph.D., resigned as our Chief Executive Officer, President and Director on February 14, 2003. Michael K. Allio, our Chairman, has assumed the responsibilities of day-to-day operations until a replacement Chief Executive Officer and President is named. On December 25, 2000, Patrice Pactol resigned from our board of directors. In addition, as of January 31, 2003, Joseph D. Mosca, Ph.D. is no longer employed as our Vice President of Development. At this time, we do not anticipate hiring a new Vice President of Development.

Research and Development activities continue to be spearheaded by Dr. Pierre-Francois Serres, our Chief Scientific Officer. Dr. Serres is an experienced research and development scientist in the field of immunology and AIDS. Dr. Serres became our Chief Scientific Officer on February 7, 2002, and has been a member of our board of directors since March 28, 2001. He has previously served as our Chief Executive Officer and President, and was the founder, President and Chief Executive Officer of our subsidiary, Mymetics S.A.

Dr. Serres has over 25 years experience in laboratory research and development. He began his career as a professor and researcher at the medical faculty of the University of Lyon in France. His professional experience includes positions at institutions such as the Institut Pasteur, and the Jules Courmont Hospital (Faculty of Medicine). He has published numerous articles in scientific journals including the French "Academie des Sciences" and has authored a number of patents in the fields of biology and medicine. These include applications in clinical diagnostic-therapeutic treatments and vaccines. Dr. Serres holds qualifications in Medical Psychology, Pathology, Biological Engineering and Human Biology from the Institut National des Sciences Appliquees (INSA) in France. His research over the past 20 years has addressed immunology and organ transplantation, metabolic diseases, hemophilia, and AIDS.

RESEARCH AND DEVELOPMENT EXPENSES

For the year ended December 31, 2002, we focused on research and development and, as a result, did not generate any revenues or engage in any marketing activities. For the years ended December 31, 2002, December 31, 2001 and December 31, 2000, we spent E 1,878,000, E 482,000 and E 101,000, respectively, on research and development activities.

INTELLECTUAL PROPERTY

We are the exclusive owner of intellectual property relating to our core research, which is focused on the development of novel HIV and FIV therapeutics and vaccines. Particularly, we own one issued European patent and corresponding granted patents in Austria, Belgium, Denmark, Germany, France, Italy, Luxembourg, the Netherlands, Sweden, Switzerland, and the United Kingdom. We own six pending French patent applications. We

15

also filed four Patent Cooperation Treaty, or PCT, applications, which claim priority to four of our six pending French applications, and two national phase United States patent applications based on the PCT applications. Recently, one of our United States applications was allowed by the United States Patent and Trademark Office. We have seven pending United States provisional applications, and a continuation application which we recently filed based on our allowed United States application. Additionally, we filed regional national applications based on one of our PCT applications in the European, Eurasian, OAPI, and ARIPO regional systems and in Canada and South Africa.

We rely primarily on a combination of patent, copyright, trademark and trade secret laws, as well as contractual restrictions, to protect our intellectual property. These legal protections afford limited protection. We generally require employees, strategic research partners and consultants with access to our intellectual property to execute confidentiality agreements. Despite our efforts to protect our intellectual property, unauthorized parties may attempt to copy the research and research methods that form the basis of our intellectual property. The laws of many countries do not afford the same level of protection as those provided by United States intellectual property laws. Litigation may be necessary to protect and enforce our rights in our intellectual property.

COMPETITION

We have not yet developed an actual product or generated any revenues. Our future competitive position depends on our ability to successfully develop our intellectual property, and to either use such intellectual property to produce one or more products capable of generating significant revenues or to license or sell such intellectual property to third parties on financially favorable terms. Although we believe that the results of our research and development activities have been favorable, there are numerous entities and individuals conducting research and development activities in the area of human and veterinary biology and medicine all of which could be considered competitors. While many of these individuals and entities have greater financial, manufacturing, technical, human resource, marketing and distribution capabilities, and greater experience in conducting pre-clinical and clinical trials and in obtaining regulatory and FDA approvals, we believe that our technologies nonetheless provide us with a competitive advantage.

Further, we may face significant competition in the design and development of some of our therapeutic compounds and preventive vaccines.

Therapeutic Molecules (pharmacological agents). The biopharmaceutical industry is intensely competitive, especially in the field of HIV. If we are successful in developing and proving our therapeutic agents, we will compete with existing developed and approved therapies. The FDA has approved 16 antiviral drugs to treat HIV and AIDS, which fall into two categories depending on whether they target one or two viral enzymes: either HIV protease or reverse transcriptase ("RT"). RT drugs aim to block reverse transcriptases and prevent transcription of the virus' generic material from RNA to DNA. There are two classes of RT drugs: nucleoside analogues inhibitors and non-nucleoside inhibitors. The approved nucleoside analogues inhibitors include drugs such as Retrovir (ziduvodine; AZT), Videx (didanosine; ddl), Hivid (zalcitabine; ddc), Zerit (stavudine; d4T), Epivir (larnivudine; 3TC), Combivir (ziduvodine + lamivudine), Ziagen (abacavir; ABC). These drugs are manufactured by companies such as Glaxo Wellcome Plc, Bristol-Myers Squibb Company, Roche Holding AG and BioChem Pharma Inc. The approved non-nucleoside inhibitors include drugs such as Viramuno (nevlrapine), Rescriptor (delavirdine), Sustiva (efavirenz; EFV) which are produced by Boehringer Ingelhelm Gmbh, Pharmacia & Upjohn Inc. and E. I. Du Pont de Nemours and Company. The objective of approved protease inhibitor drugs is to prevent the assembly of new virus particles. The approved protease inhibitors include drugs such as Invirase (saquinavir), Fortovase (saquinavir), Norvir (ritonavir), Crixivan (indinavir), Viracept (nellinavir) and Agenerase (amprenavir), which are manufactured by companies including Roche Holding AG, Abbot Laboratories, Merck & Co. Inc., Agouron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated and Glaxo Wellcome Plc.

Both HIV protease and RT drugs have demonstrated their efficacy in terms of HIV blood concentration and HIV-positive period and are used to slow the progression of the disease. Furthermore, efficacy has been higher with drug combinations. None of these drugs are, however, a cure, and mutations of HIV's envelope produce viral strains resistant to both classes of drugs. These drugs also produce toxic side effects on the peripheral nervous system and gastrointestinal tract. Non-compliance on combination therapies and interruptions in dosing could have an effect on, and trigger, accelerated viral replication.

16

If successful in developing and validating our therapeutic molecules, we believe that there are significant existing and future markets for the treatment of HIV and AIDS. There can be no assurance that currently approved drugs or products developed in the future for the treatment of HIV/AIDS by our competitors (which may include Roche Holding AG, Abbot Laboratories, Merck & Co. Inc., Agouron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Glaxo Wellcome Plc, Bristol-Myers Squibb Company, Trimeris, Inc., Progenics, Inc., and BioChem Pharma Inc.) will not be effectively marketed and sold. We believe, however, that our unique approach and fundamental understanding of molecular mimicry will provide an advantage over existing and future competitors.

The recent progress of Trimeris Inc. in securing FDA approval for its fusion inhibitor product, "Fuzeon", a gp41-derived peptide comprised of 36 amino acids, represents excellent proof-of-concept for us by demonstrating, through human trials, that such a compound is safe and effective in lowering viral load. Industry experts estimate that the annual revenue generated from this drug may reach U.S. $500,000,000 - U.S. $750,000,000, which confirms the significant demand for fusion inhibitor drugs. The media has also, however, published that Trimeris and its partner Roche face significant challenges and limitations, including prohibitive cost of goods, a complex manufacturing process involving 106 separate steps in chemical synthesis, an elevated retail price (recent estimates exceed $20,000 per patient per annum, more than double the cost of current therapies), significant supply shortages (year one capacity will likely not exceed 15,000 patients, less than 7.5% market share in the United States alone), and difficult delivery of the drug (requiring subcutaneous injection twice/day of 90 mg. of the drug). These challenges suggest that a drug that can be made less expensively, and delivered more easily, will have significant competitive advantages.

Therapeutic Molecules (immunotherapeutic agent). We believe that our targeted immunotherapeutic vaccines may be innovative within the field of therapeutic research related to AIDS.

Preventive Vaccines. We are conducting research aimed at developing a preventive vaccine for the HIV-1 virus, which vaccine will provide protection against a broad array of viral strains.

In the field of HIV vaccines, the recent failure of the VAXGEN product in Phase III clinical trials underscores the need for an effective solution to the global challenge posed by HIV. As this particular candidate was based on technology unrelated to our technology, we do not feel that the cessation of clinical trials with respect to VAXGEN negatively impacts our prospects for developing a viable preventive vaccine.

In the field of FIV vaccines, Ft. Dodge, a division of Wyeth Pharmaceuticals, launch the industry's first FIV preventive vaccine in late 2002. We consider this development as further validation of the demand and viability of this product category. Press releases issued by Ft. Dodge cite a significant potential market for this drug. Like the Trimeris product, the Ft. Dodge feline vaccine appears to suffer from a range of drawbacks, so we consider the competitive threat of Ft. Dodge's FIV preventive vaccine to be moderate.

The worldwide vaccine market is dominated by four large multinational companies: Merck & Co., SmithKline Beecham Plc, Wyeth Lederle Vaccines & Pediatrics (a division of American Home Products Corporation), and Aventis S.A. Pasteur. Companies such as The Immune Response Corporation, VaxGen Inc., Trimeris, Inc., and Progenics Pharmaceuticals, Inc. are also developing preventive vaccines.

We believe that while these companies have greater financial, manufacturing, technical, human resource, marketing and distribution capabilities, and greater experience in conducting pre-clinical and clinical trials and in obtaining regulatory and FDA approvals, our technologies, nonetheless, provide us with a competitive advantage. Our innovative approach to vaccine development is based on the observed immunological cross-reactivity (or mimicry) between the well preserved, antigenic and immunodominant domain of GP41 and IL-2, and relies on the observation of expected autoimmune consequences in HIV infected subjects.

17

We believe that our approach is most promising in comparison with the approaches that have been pursued so far, including:

- Sub-unit vaccine: a technology addressing a piece of the outer surface of HIV, such as GP160 or GP120, produced by genetic engineering.

- Live vector vaccine: a live bacterium or virus such as vaccinia (used in the smallpox vaccine) modified so it cannot cause disease, but can transport into the body one or more genes that makes one or more HIV proteins.

- Vaccine combination: an example includes a "prime-boost strategy", use of a recombinant vector vaccine to induce cellular immune responses followed by booster shots of a sub-unit vaccine to stimulate antibody production.

- Peptide vaccine: chemically synthesized pieces of HIV proteins (peptides) known to stimulate HIV-specific immunity.

- Virus-like particle vaccine (pseudovirion vaccine): a non-infectious HIV look-alike that has one or more, but not all, HIV proteins.

- DNA vaccine: direct injection of genes coding for HIV proteins.

- Whole-killed virus vaccine: HIV that has been inactivated by chemicals, irradiation or other means rendering it non-infectious.

- Live-attenuated virus vaccine: live HIV from which one or more apparent disease-promoting genes of the virus have been deleted.

Cartridge. We believe that our cartridge or therapeutic plasmapheresis is significantly different from the cartridges being developed and provided by competitors. The more specific technique for antibody removal is known as immunoadsorption, yet all existing systems are non-specific in removal of antibodies, which limits their effectiveness and may have serious side effects. Current immunoadsorption systems selectively remove antibodies by the interposition of affinity columns in the devices. These cartridges are expensive, large, require trained technicians and are not protein specific. In addition, the cartridge is based on a biocompatible membrane based on a discovery of antibody binding, which perform a highly specific extra-corporeal immunoadsorption. When specific (as compared with selective) there is the definitive advantage of removing only the targeted pathogenic antibodies while leaving the other antibodies essential to the patients normal immune systems, and defense against infection. The main competitor with respect to cartridges appears to be Aethlon Medical with its HIV Hemopurifier.

GOVERNMENTAL REGULATION

We contract with third parties to perform research projects related to our business. These third parties are located in various countries and are subject to the applicable laws and regulations of their respective countries. Accordingly, regulation by government authorities in the United States and foreign countries is a significant factor in the development, manufacture and marketing of our proposed products and in our ongoing research and product development activities. Any products that we develop will require regulatory approval by government agencies prior to commercialization. In particular, human therapeutic products are subject to rigorous pre-clinical studies and clinical trials and other approval procedures of the FDA and similar regulatory authorities in foreign countries. In addition, various federal and state statutes and regulations will also govern or influence testing, manufacturing, safety, labeling, storage and record keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent substantial compliance with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources. The success of our business will depend on our ability to obtain and maintain the necessary regulatory approvals.

Pre-clinical studies generally are conducted on laboratory animals to evaluate the potential safety and the efficacy of a product. In the United States, we must submit the results of pre-clinical studies to the FDA as a part of an investigational new drug application, or IND, which application must become effective before we can begin clinical trials in the United States. An IND becomes effective 30 days after receipt by the FDA unless the FDA objects to it. Typically, clinical evaluation involves a time-consuming and costly three-phase process.

18

Phase I. Refers typically to closely monitored clinical trials and includes the initial introduction of an investigational new drug into human patients or normal volunteer subjects. Phase I clinical trials are designed to determine the metabolism and pharmacologic actions of a drug in humans, the side effects associated with increasing drug doses and, if possible, to gain early evidence on effectiveness. Phase I trials also include the study of structure-activity relationships and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. During Phase I clinical trials, sufficient information about a drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase II studies. The total number of subjects and patients included in Phase I clinical trials varies, but is generally in the range of 20 to 80 people.

Phase II. Refers to controlled clinical trials conducted to evaluate the effectiveness of a drug for a particular indication or indications in patients with a disease or condition under study and to determine the common short-term side effects and risks associated with the drug. These clinical trials are typically well-controlled, closely monitored and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.

Phase III. Refers to expanded controlled clinical trials, which many times are designated as "pivotal trials" designed to reach end points that the FDA has agreed in advance, if met, would allow approval for marketing. These clinical trials are performed after preliminary evidence suggesting effectiveness of a drug has been obtained. They are intended to gather additional information about the effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase III trials can include from several hundred to several thousand subjects depending on the specific indication being treated.

The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the United States and may, at its discretion, reevaluate, alter, suspend or terminate the testing based upon the data accumulated to that point and the FDA's assessment of the risk/benefit ratio to the patient. We have not yet conducted any clinical trials and are currently focused on research.

Once Phase III trials are completed, drug developers submit the results of pre-clinical studies and clinical trials to the FDA, in the form of an new drug application, or NDA, for approval to commence commercial sales. In response, the FDA may grant marketing approval, request additional information or deny the application if the FDA determines that the application does not meet the predetermined study end points and other regulatory approval criteria. Furthermore, the FDA may prevent a drug developer from marketing a product under a label for its desired indications, which may impair commercialization of the product.

If the FDA approves the new drug application, the drug becomes available for physicians to prescribe in the United States. After approval, the drug developer must submit periodic reports to the FDA, including descriptions of any adverse reactions reported. The FDA may request additional studies, known as Phase IV trials, to evaluate long-term effects. We will be required to comply with similar regulatory procedures in countries other than the United States.

In addition to studies requested by the FDA after approval, a drug developer may conduct other trials and studies to explore use of the approved compound for treatment of new indications. The purpose of these trials and studies and related publications is to broaden the application and use of the drug and its acceptance in the medical community.

We will have to complete an approval process, similar to the one required in the United States, in virtually every foreign target market in order to commercialize our product candidates in those countries. The approval procedure and the time required for approval vary from country to country and may involve additional testing. Approvals (both foreign and in the United States) may not be granted on a timely basis, or at all. In addition, regulatory approval of prices is required in most countries other than the United States. We face the risk that the resulting prices would be insufficient to generate an acceptable return to us or our collaborators. A failure to obtain or maintain the necessary regulatory approvals will have an materially adverse effect on our business.

19

EMPLOYEES

As of December 31, 2002, Mymetics S.A. had seven full-time employees and Mymetics Corporation had two full-time employees.

WWW.MYMETICS.COM

News and information about Mymetics Corporation and its subsidiaries are available on our web site, www.mymetics.com. In addition to news and other information about the Corporation, we provide access (free of charge) through this site to our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after we file or furnish them electronically with the United States Securities and Exchange Commission.

ITEM 2. PROPERTIES

Mymetics S.A. currently leases approximately 170 square meters of office space in Saint-Genis Laval, France, in which the Corporation's European administrative activities are conducted. The current all inclusive rent is approximately E 1,641 per month, and the lease expires on January 31, 2006. Up until January 31, 2003, we leased approximately 250 square feet of space in Annapolis, Maryland. The rent under our Annapolis lease was $1,000 per month prior to its termination. We are temporarily using a small amount of space at the office of our Chairman, Michael K. Allio, for our principal executive office. This space is being provided by Mr. Allio at no charge. All of the Corporation's research activities are conducted at the properties of third parties with whom the Corporation contracts to perform research projects.

ITEM 3. LEGAL PROCEEDINGS

We are subject to routine litigation incidental to our business. We do not believe that the outcome of such litigation will have a material adverse effect on our business or financial condition.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

20

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS

(a) Market Information. The Corporation's common stock is quoted on the OTC Bulletin Board under the trading symbol "MYMX". The Corporation's trading symbol changed from ICHR to MYMX in July 2001, pursuant to a corporate name change from ICHOR Corporation to Mymetics Corporation. The following table sets forth the quarterly high and low sale price per share of the Corporation's common stock for the periods indicated. The prices represent inter-dealer quotations, which do not include retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

FISCAL QUARTER ENDED                                    HIGH          LOW

2001
March 31.........................................    $    3.25    $    1.88
June 30..........................................         3.50         2.35
September 30.....................................         4.10         2.50
December 31......................................         3.95         2.00

2002
March 31.........................................    $    3.85    $    2.15
June 30..........................................         3.70         2.70
September 30.....................................         3.45         0.06
December 31......................................         0.36         0.09

(b) Stockholders. At March 24, 2003, the Corporation had approximately 646 holders of record of its common stock, some of which are securities clearing agencies and intermediaries.

(c) Dividends. The Corporation has not paid any dividends on its common stock and does not anticipate that it will pay any dividends in the foreseeable future.

(d) Securities Authorized for Issuance Under Equity Compensation Plans.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides information about the common stock that may be issued upon the exercise of options, warrants and rights under all of our existing equity compensation plans as of December 31, 2002.

----------------------------------------------------------------------------------------------------------------------
                                                                                          Number of Securities
                                                                                          remaining available for
                                Number of Securities to be   Weighted Average Exercise    issuance under equity
                                issued upon exercise of      Price of Outstanding         compensation plans
                                Outstanding Options,         Options, Warrants and        (excluding securities
                                Warrants and Rights          Rights                       reflected in column (a))
Plan Category                               (a)                          (b)                          (c)
----------------------------------------------------------------------------------------------------------------------
Equity Compensation Plans
Approved by Security
Holders (1)                              381,250(2)                   U.S. $1.38                    4,782,500
----------------------------------------------------------------------------------------------------------------------

Equity Compensation Plans not
Approved by Security Holders
(3)                                       80,166                     U.S. $1.725                      N/A(4)
----------------------------------------------------------------------------------------------------------------------

         Total                            461,416                    U.S.  $1.44                    4,782,500
----------------------------------------------------------------------------------------------------------------------

21

(1) Equity compensation plans approved by our security holders include (i) our 1994 Amended and Restated Stock Option Plan, (ii) our 1995 Qualified Incentive Stock Option Plan and (iii) our 2001 Stock Option Plan. Our 1994 Amended and Restated Stock Option Plan and our 1995 Qualified Incentive Stock Option Plan were both terminated in March 2001, but some options granted under these plans prior to such termination remain outstanding and are included in this table.

(2) Includes (i) 217,500 shares of common stock underlying options granted under our 2001 Stock Option Plan, (ii) 100,000 shares of common stock underlying options granted under our 1995 Qualified Incentive Stock Option Plan and (iii) 63,750 shares of common stock underlying options granted under our 1994 Amended and Restated Stock Option Plan.

(3) From time to time we have granted our lender, MFC Merchant Bank S.A., warrants to purchase shares of our common stock. These warrants are granted in connection with certain credit facilities provided to us by MFC Merchant Bank S.A., and placement services provided by MFC Merchant Bank S.A. in connection with a private placement of our securities in June 2001. These warrants were not granted pursuant to any formal equity compensation plan approved by our board of directors, but rather, each grant was an individual equity compensation arrangement, authorized by our board of directors and granted as compensation for services provided. All of the outstanding warrants were granted pursuant to similar forms of warrants, and each has an exercise price of U.S. $1.725.

(4) We do not have any formal equity compensation plan that has not been authorized by our stockholders. These grants are made on an individual basis and are approved by our board of directors. Accordingly, there are no shares of common stock reserved for issuance under these arrangements.

ISSUANCES OF UNREGISTERED SECURITIES

Set forth below is information regarding our sales of unregistered securities during the period commencing on January 1, 2002 and ending on December 31, 2002. These issuances were made in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as transactions by an issuer not involving any public offering.

- In June 2002, we granted Peter P. McCann options to purchase 10,000 shares of common stock at $3.50 per share. These options were granted under our 2001 Stock Option Plan.

- In August 2002, we issued 46,925 shares of our common stock to Gilles Rossi, Marianne Rossi, Jean-Loup Rossi and Alessandro Zuccato in connection with the Share Exchange Agreement dated July 30, 2002 among the Corporation, Michele Rossi, Gilles Rossi, Marianne Rossi, Jean-Loup Rossi and Alessandro Zuccato.

- In July 2002, we granted each of John M. Musacchio, Robert Demers, Pierre-Francois Serres, Patrice Pactol, Peter P. McCann and Michael K. Allio options to purchase 1,250 shares of common stock at $3.50 per share. These options were granted under our 2001 Stock Option Plan.

- In June 2002, we granted MFC Merchant Bank S.A. warrants to purchase 26,775 shares of our common stock at an exercise price of E 0.23 per share.

- In July 2002, we issued MFC Merchant Bank S.A. (i) 1,602,174 shares of our common stock for E 0.23 per share and (ii) 23,393 shares of our common stock for U.S. $1.725 per share, all in connection with the exercise of warrants by MFC Merchant Bank S.A. The aggregate amount to be paid by MFC Merchant Bank S.A. in connection with these exercises was not paid in cash, but, rather, was used to reduce our revolving credit debt to MFC Merchant Bank in an amount of E 412,000.

- On August 21, 2002, we granted Michael K. Allio options to purchase 100,000 shares of our common stock at $0.55 per share in connection with a Consulting Agreement we entered into with Mr. Allio.

22

ITEM 6. SELECTED FINANCIAL DATA

The following table reflects selected consolidated financial data for the Corporation for the fiscal years ended December 31, 2002, 2001, 2000, 1999 and 1998, respectively.

                                                  FOR THE          FOR THE           FOR THE           FOR THE         FOR THE
                                                    YEAR             YEAR              YEAR              YEAR            YEAR
                                                    ENDED            ENDED             ENDED             ENDED           ENDED
                                                 DECEMBER 31      DECEMBER 31,      DECEMBER 31,      DECEMBER 31,     DECEMBER 31,
                                                    2002              2001              2000              1999            1998
                                                    ----              ----              ----              ----            ----
                                                                  (EUROS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

OPERATING DATA
Operating revenues .....................                8                26                13                47              42
Research & Development Expenses ........            1,878               482               101                94              70
General & Administrative Expenses ......            1,293             1,034               351                37              38
Loss from continuing operations ........           (3,622)          (15,701)           (1,314)              (99)            (68)

COMMON SHARE DATA(1)
Loss from continuing operations per
   common share ........................            (0.07)            (0.37)            (0.04)            (0.00)          (0.00)
Weighted average common shares
   outstanding (in thousands) ..........           50,046            42,460            33,311            33,311          33,311


BALANCE SHEET DATA
Working capital ........................           (2,306)              565              (652)              (24)            (40)
Total assets ...........................              477             1,692               625               146              77
Long-term obligations ..................              242               242               242               242             138
Total stockholders' equity .............           (2,349)              693              (765)             (257)           (158)


(1) Basic and diluted common share data is the same.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the years ended December 31, 2002, 2001 and 2000 should be read in conjunction with the Corporation's audited consolidated financial statements and related notes included elsewhere herein.

RESULTS OF OPERATIONS - YEAR ENDED DECEMBER 31, 2002 COMPARED TO YEAR ENDED
DECEMBER 31, 2001

Revenues of the year ended December 31, 2002 were E8,000 compared to E26,000 for the year ended December 31, 2001.

Costs and expenses decreased to E3,630,000 for the year ended December 31, 2002 compared to E15,727,000 for year ended December 31, 2001 as a result of a decrease in bank fees to E63,000 for the year ended December 31, 2002 from E14,063,000 in the comparative period in 2001, primarily as a result of reverse purchase transaction in 2001. Research and development expenses increased to E1,878,000 in the current year from E482,000 in the

23

comparative period of 2001 as a result of an increase in research activities. General and administrative expenses increased to E1,293,000 in the year ended December 31, 2002 from E1,034,000 in the comparative period of 2001. The Corporation reported a net loss of E3,622,000 or E0.07 per share, for the year ended December 31, 2002, compared to E15,701,000 or E0.37, for the year ended December 31, 2001.

RESULTS OF OPERATIONS - YEAR ENDED DECEMBER 31, 2001 COMPARED TO YEAR ENDED
DECEMBER 31, 2000

Revenues of the year ended December 31, 2001 were E26,000 compared to E13,000 for the year ended December 31, 2000. Sales for the year ended December 31, 2001 were nil compared to E13,000 for the comparative period in last year, primarily as a result of decreased contract research activity. Interest income was E26,000 and nil for the years ended December 31, 2001 and 2000, respectively.

Costs and expenses increased to E15,727,000 for the year ended December 31, 2001 compared to E1,326,000 for year ended December 31, 2000. Research and development expenses increased to E482,000 in the current year from E101,000 in the comparative period of 2000 as a result of an increase in research activities. General and administrative expenses increased to E1,034,000 in the year ended December 31, 2001 from E351,000 in the comparative period of 2000, primarily as a result of the expenses related to the reverse purchase transaction in current year. Bank fees increased to E14,063,000 for the year ended December 31, 2001 from E806,000 in the comparative period in 2000, primarily as a result of reverse purchase transaction.

The Corporation reported a net loss of E15,701,000 or E0.37 per share, for the year ended December 31, 2001, compared to E1,314,000 or E0.04, for the year ended December 31, 2000.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation had cash E183,000 at December 31, 2002, compared to E888,000 at December 31, 2001.

Net cash used by operating activities was E3,235,000 for the year ended December 31, 2002, compared to E2,000,000 for the year ended December 31, 2001. An increase in accounts payable provided cash of E16,000 for the year ended December 31, 2002 compared to a decrease of the same used cash of E508,000 for the year ended December 31, 2001.

Investing activities provided cash E252,000 for the year ended December 31, 2002 compared to used cash of E237,000 for the same period last year. Short term investment provided cash of E354,000 for the year ended December 31, 2002 compared to used cash of E205,000 for the year ended December 31, 2001.

Financing activities provided cash of E2,181,000 for the year ended December 31, 2002 compared to E2,840,000 in the same period last year. Proceeds from issuance of common stock provided cash of E8,000 for the year ended December 31, 2002 compared to E2,724,000 in the same period last year. Increases in borrowing pursuant to a non-revolving term facility and other short term advances provided cash of E2,173,000 in current year and E116,000 in the comparative period last year. The non-revolving term facility is in the principal amount of up to E2.8 million and matures on August 31, 2003. At December 31, 2002, Mymetics had borrowed an aggregate of E1,989,000 pursuant to this non-revolving term facility.

The Corporation expects that it will require substantial additional capital to continue its research and development, clinical studies and regulatory activities necessary to bring its potential products to market and to establish production, marketing and sales capabilities. The Corporation anticipates its operations will require approximately E2.0 million in the year ending December 31, 2003. The Corporation will seek to raise the required capital from lenders, equity or debt issuances and/or potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that the Corporation will be able to raise additional capital on terms satisfactory to the Corporation, or at all, to finance its operations. In the event that the Corporation is not able to obtain such additional capital, it would be required to restrict or even halt its operations.

24

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk.

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have debt obligations which are sensitive to interest rate fluctuations. The following tables provide information about our exposure to interest rate fluctuations for the carrying amount of such debt obligations as of December 31, 2002 and 2001 and expected cash flows from these debt obligations.

                                                               EXPECTED FUTURE CASH FLOW
                                                               -------------------------
                                                             YEAR ENDING DECEMBER 31, 2002
                                                                    (IN THOUSANDS)
                                                                    --------------
                           CARRYING     FAIR
                             VALUE      VALUE      2003       2004       2005       2006       2007    THEREAFTER
                             -----      -----      ----       ----       ----       ----       ----    ----------

Debt obligations......      E1,989     E1,989     E2,082      E--         E--        E--        E--        E--

                                                             YEAR ENDING DECEMBER 31, 2001
                                                                    (IN THOUSANDS)
                                                                    --------------
                           CARRYING     FAIR
                             VALUE      VALUE      2002       2003       2004       2005       2006    THEREAFTER
                             -----      -----      ----       ----       ----       ----       ----    ----------

Debt obligations......       E228       E228       E244       E--         E--        E--        E--        E--

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The consolidated financial statements and supplementary data required with respect to this Item 8, and as identified in Item 14 of this annual report, are included in this annual report commencing on page 31.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE

None.

25

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Incorporated by reference from the Corporation's definitive proxy statement to be filed within 120 days of the end of the Corporation's 2002 fiscal year.

ITEM 11. EXECUTIVE COMPENSATION

Incorporated by reference from the Corporation's definitive proxy statement to be filed within 120 days of the end of the Corporation's 2002 fiscal year.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Incorporated by reference from the Corporation's definitive proxy statement to be filed within 120 days of the end of the Corporation's 2002 fiscal year.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Incorporated by reference from the Corporation's definitive proxy statement to be filed within 120 days of the end of the Corporation's 2002 fiscal year.

ITEM 14. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Within 90 days prior to the filing date of this report, the Corporation's principal executive officer and principal financial officer, carried out an evaluation of the effectiveness and design of the Corporation's disclosure controls and procedures (as defined in Exchange Act Rules 13a-14(c) and 15d-14(c)) and have concluded that, based on such evaluation, the Corporation's disclosure controls and procedures were adequate and effective to ensure that material information relating to the Corporation, including its consolidated subsidiaries, was made known to them by others within those entities, particularly during the period in which this annual report on Form 10-K was being prepared.

(b) Changes in Internal Controls. There were no significant changes in the Corporation's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, nor were there any significant deficiencies or material weaknesses in the Corporation's internal controls. Accordingly, no corrective actions were required or undertaken.

26

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

(a)(1) Index to Financial Statements

Independent Auditors' Report Consolidated Balance Sheets Consolidated Statements of Operations and Comprehensive Loss Consolidated Statements of Changes in Shareholders' Equity Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements

(a)(2) ALL OTHER SCHEDULES HAVE BEEN OMITTED BECAUSE THEY ARE NOT APPLICABLE OR THE REQUIRED INFORMATION IS SHOWN IN THE FINANCIAL STATEMENTS OR NOTES THERETO.

(3) List of Exhibits

2.1 Share Exchange Agreement dated December 13, 2001 between the Corporation and the stockholders of Mymetics S.A. listed on the signature page thereto (1)

2.2 Share Exchange Agreement dated December 13, 2001 between the Corporation and the stockholders of Mymetics S.A. listed on the signature page thereto (1)

2.3 Purchase Agreement dated October 17, 1998 between the Corporation and the majority stockholders of Nazca Holdings Ltd.

(2)

2.4 Amendment to the Purchase Agreement dated October 17, 1998 between the Corporation and the majority stockholders of Nazca Holdings Ltd. (3)

2.5 Revised Purchase Agreement dated July 28, 1999 between the Corporation and the majority stockholders of Nazca Holdings Ltd.

(4)

2.6    Share Exchange Agreement dated July 30, 2002 between the
       Corporation and the stockholders of Mymetics S.A. listed on the
       signature page therto (5)

3(i)   Articles of Incorporation of the Corporation (as amended through
       May 10, 2002) (6)

3(ii)  Bylaws (7)

4      Form of Specimen Stock Certificate (8)

9      Voting and Exchange Trust Agreement dated March 28, 2001, among
       the Corporation, 6543 Luxembourg S.A. and MFC Merchant Bank S.A.
       (8)

10.1   Services Agreement dated May 31, 2001, between the Corporation
       and MFC Merchant Bank, S.A.(7)

10.2   Employment Agreement dated May 3, 2001, between Pierre-Francois
       Serres and the Corporation (7)

10.3   Indemnification Agreement dated March 28, 2001, between the
       Corporation and MFC Bancorp Ltd. (7)

10.4   Agreement dated for reference May 15, 2000, between the
       Corporation and Maarten Reidel (7)

27

10.5   Preferred Stock Redemption and Conversion Agreement dated for
       reference December 21, 2000, between the Corporation and Sutton
       Park International Ltd. (10)

10.6   Preferred Stock Conversion Agreement dated for reference
       December 21, 2000, between the Corporation and Med Net
       International Ltd. (11)

10.7   Preferred Stock Conversion Agreement dated December 21, 2000,
       between the Corporation and Dresden Papier GmbH (11)

10.8   Assignment Agreement dated December 29, 2000, among the
       Corporation, Mymetics S.A. and MFC Merchant Bank S.A. (1)

10.9   Credit Facility Agreement dated July 27, 2000, between MFC
       Merchant Bank, S.A. and the Corporation (1)

10.10  Amended Credit Facility Agreement dated for reference August 13,
       2001, between MFC Merchant Bank, S.A. and the Corporation

10.11  Second Amended Credit Facility Agreement dated for reference
       February 27, 2002, between MFC Merchant Bank, S.A. and the
       Corporation

10.12  Amended and Restated Credit Facility Agreement dated for
       reference February 28, 2003, among MFC Merchant Bank, S.A., MFC
       Bancorp Ltd., and the Corporation

10.13  Guarantee dated for reference February 28, 2003, by MFC Bancorp
       Ltd. to MFC Merchant Bank S.A.

10.14  Shareholder Agreement dated March 28, 2001, among the
       Corporation, the Holders of Class B Exchangeable Preferential
       Non-Voting Shares of 6543 Luxembourg S.A. signatory thereto and
       6543 Luxembourg S.A.(8)

10.15  Support Agreement dated March 28, 2001, between the Corporation
       and 6543 Luxembourg S.A. (8)

10.16  1995 Qualified Incentive Stock Option Plan (12)

10.17  Amended 1994 Stock Option Plan (13)

10.18  2001 ICHOR Corporation Stock Option Plan (7)

10.19  Employment Agreement dated March 18, 2002, between the
       Corporation and Peter P. McCann (14)

10.20  Consulting Agreement dated August 31, 2001, between the
       Corporation and Michael K. Allio (8)

10.21  Amendment to Consulting Agreement dated August 21, 2002, between
       the Corporation and Michael K. Allio

10.22  Employment Agreement dated March 18, 2002, between the
       Corporation and Dr. Joseph D. Mosca (15)

10.23  Separation Agreement and Release dated January 31, 2003, between
       the Corporation and Peter P. McCann

28

         10.24  Director and Non-Employee Stock Option Agreement dated July 19,
                2001, between the Corporation and Robert Demers (8)

         10.25  Director and Non-Employee Stock Option Agreement dated July 19,
                2001, between the Corporation and Michael K. Allio (8)

         10.26  Director and Non-Employee Stock Option Agreement dated July 19,
                2001, between the Corporation and John M. Musacchio (8)

         10.27  Director and Non-Employee Stock Option Agreement dated July 19,
                2001, between the Corporation and Patrice Pactol (8)

         10.28  Director and Non-Employee Stock Option Agreement dated July 19,
                2001, between the Corporation and Pierre-Francois Serres (8)

         10.29  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and Pierre-Francois Serres

         10.30  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and Patrice Pactol

         10.31  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and Robert Demers

         10.32  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and John M. Musacchio

         10.33  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and Michael K. Allio

         10.34  Director and Non-Employee Stock Option Agreement dated August
                21, 2002, between the Corporation and Michael K. Allio

         10.35  Director and Non-Employee Stock Option Agreement dated June 20,
                2002, between the Corporation and Peter P. McCann

         10.36  Director and Non-Employee Stock Option Agreement dated July 23,
                2002, between the Corporation and Peter P. McCann

         10.37  Director and Non-Employee Stock Option Agreement dated February
                6, 2003, between the Corporation and Peter P. McCann

         10.38  Patent Pledge Agreement dated November __, 2002 among Mymetics
                S.A., Mymetics Deutschland GmbH, the Corporation and MFC
                Merchant Bank S.A.

         11     Statement Regarding Calculation of Per Share Earnings.

         21     List of Subsidiaries

         24.1   Power of Attorney for Pierre-Francois Serres

         24.2   Power of Attorney for Robert Demers

         24.3   Power of Attorney for Michael K. Allio

         99.1   Certification Pursuant to Section 906 of the Sarbanes-Oxley
                Act of 2002

                                       29

----------------

(1) Incorporated by reference to the Corporation's Schedule 14C filed with the Securities and Exchange Commission on April 26, 2001.

(2) Incorporated by reference to the Corporation's report on Form 8-K filed with the Securities and Exchange Commission on October 22, 1998.

(3) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on April 15, 1999.

(4) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on August 13, 1999.

(5) Incorporated by reference to the Corporation's Amendment No. 1 to Form S-1 filed with the Securities and Exchange Commission on August 8, 2002.

(6) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002.

(7) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended June 30, 2001, filed with the Securities and Exchange Commission on August 14, 2001.

(8) Incorporated by reference to the Corporations Registration Statement on Form S-1, File No. 333-88782, filed with the Securities and Exchange Commission on May 22, 2002.

(9) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on August 9, 2000.

(10) Incorporated by reference to Schedule 13D/A filed by MFC Bancorp Ltd.
with the Securities and Exchange Commission on dated January 2, 2001.

(11) Incorporated by reference to the Corporation's report on Form 10-K for the fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission on March 14, 2001.

(12) Incorporate by reference to the Corporation's Registration Statement on Form S-8, File No. 333-15831, filed with the Securities and Exchange Commission on November 8, 1996.

(13) Incorporated by reference to the Corporation's Registration Statement on Form S-8, File No. 333-15829, filed with the Securities and Exchange Commission on November 8, 1996.

(14) Incorporated by reference to the Corporation's report on Form 10-K for the fiscal year ended December 31, 2001, and filed with the Securities and Exchange Commission on March 14, 2001.

(15) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002.

(b) Reports on Form 8-K

None.

30

PETERSON SULLIVAN PLLC
601 UNION STREET SUITE 2300 SEATTLE WA 98101 (206) 382-7777 FAX 382-7700

CERTIFIED PUBLIC ACCOUNTANTS

INDEPENDENT AUDITORS' REPORT

To the Shareholders
Mymetics Corporation and Subsidiaries

We have audited the accompanying consolidated balance sheets of Mymetics Corporation (a development stage company) and Subsidiaries as of December 31, 2002 and 2001, and the related consolidated statements of operations and comprehensive loss, changes in shareholders' equity, and cash flows for the years ended December 31, 2002, 2001 and 2000, and for the period from May 2, 1990 (inception) to December 31, 2002. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Mymetics Corporation (a development stage company) and Subsidiaries as of December 31, 2002 and 2001, and the results of their operations and their cash flows for the years ended December 31, 2002, 2001 and 2000, and for the period from May 2, 1990 (inception) to December 31, 2002, in conformity with accounting principles generally accepted in the United States.

The accompanying 2002 consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has not developed a commercially viable product and has not been able to generate revenues and as a result has experienced significant losses. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Peterson Sullivan PLLC

Peterson Sullivan PLLC
Seattle, Washington
March 12, 2003

31

MYMETICS CORPORATION AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS
December 31, 2002 and 2001
(In Thousands of Euros)

              ASSETS                                                       2002                 2001
                                                                         ---------           ---------
Current Assets
     Cash                                                                E     183           E     888
     Short-term investments                                                      -                 354
     Receivables                                                                59                  49
     Prepaid expenses                                                           36                  31
                                                                         ---------           ---------
              Total current assets                                             278               1,322
Patents                                                                        199                 161
Goodwill                                                                         -                 209
                                                                         ---------           ---------
                                                                         E     477           E   1,692
                                                                         =========           =========
              LIABILITIES AND SHAREHOLDERS' EQUITY


Current Liabilities
     Accounts payable                                                    E     452           E     436
     Taxes and social costs payable                                            119                  83
     Note payable                                                            1,989                 228
     Other                                                                      24                  10
                                                                         ---------           ---------
              Total current liabilities                                      2,584                 757
Payable to Shareholders                                                        242                 242
                                                                         ---------           ---------
              Total liabilities                                              2,826                 999
Shareholders' Equity
     Common stock, U.S. $.01 par value; 80,000,000 shares
        authorized; issued and outstanding 50,944,505
        at December 31, 2002 and 49,261,962 at
        December 31, 2001                                                      579                 562
     Additional paid-in capital                                             17,888              17,422
     Deficit accumulated during the development stage                      (21,013)            (17,391)
     Accumulated other comprehensive income                                    197                 100
                                                                         ---------           ---------
                                                                            (2,349)                693
                                                                         ---------           ---------
                                                                         E     477           E   1,692
                                                                         =========           =========

The accompanying notes are an integral part of these financial statements.

32

MYMETICS CORPORATION AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the

Years Ended December 31, 2002, 2001 and 2000, and the Period from May 2, 1990 (Inception) to December 31, 2002


(In Thousands of Euros, Except Per Share Data)

                                                                                                             Total
                                                                                                          Accumulated
                                                                                                             During
                                                                                                          Development
                                                                                                             Stage
                                                                                                        (May 2, 1990 to
                                                                                                          December 31,
                                                 2002              2001                2000                  2002)
                                             -------------     -------------       -------------      --------------------
Revenues
     Sales                                   E           -     E           -       E          13       E               224
     Interest                                            8                26                   -                        34
                                             -------------     -------------       -------------      --------------------
                                                         8                26                  13                       258
Expenses
     Research and development                        1,878               482                 101                     2,722
     General and administrative                      1,293             1,034                 351                     2,908
     Bank fee                                           63            14,063                 806                    14,932
     Interest                                           60                79                  16                       155
     Goodwill impairment                               209                 -                   -                       209
     Amortization                                       64                51                  52                       258
     Directors' fees                                    63                18                   -                        81
                                             -------------     -------------       -------------      --------------------
                                                     3,630            15,727               1,326                    21,265
                                             -------------     -------------       -------------      --------------------
Loss before income tax provision                    (3,622)          (15,701)             (1,313)                  (21,007)
Income tax provision                                     -                 -                   1                         6
                                             -------------     -------------       -------------      --------------------
           Net loss                                 (3,622)          (15,701)             (1,314)                  (21,013)
Other comprehensive income
     Foreign currency translation
        adjustment                                      97               100                   -                       197
                                             -------------     -------------       -------------      --------------------
Comprehensive loss                           E      (3,525)    E     (15,601)      E      (1,314)     E            (20,816)
                                             =============     =============       =============      ====================
Basic and diluted loss per share             E       (0.07)    E       (0.37)      E       (0.04)     E              (0.59)
                                             =============     =============       =============      ====================

The accompanying notes are an integral part of these financial statements.

33

MYMETICS CORPORATION AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY For the
Period from May 2, 1990 (Inception) to December 31, 2002
(In Thousands of Euros)

                                                                                 Date of             Number of
                                                                               Transaction             Shares      Par Value
                                                                           ---------------------    ------------   ----------
Balance at May 2, 1990                                                                                             E        -
     Shares issued for cash                                                     June 1990             33,311,361          119
     Net losses to December 31, 1999                                                                           -            -
                                                                                                    ------------   ----------
Balance at December 31, 1999                                                                          33,311,361          119
     Bank fee                                                                                                  -            -
     Net loss for the year                                                                                     -            -
                                                                                                    ------------   ----------
Balance at December 31, 2000                                                                          33,311,361          119
     Effect on capital structure resulting from a business combination          March 2001             8,165,830          354
     Issuance of stock purchase warrants for bank fee                           March 2001                     -            -
     Issuance of shares for bank fee                                            March 2001             1,800,000           21
     Issuance of shares for bank fee                                            June 2001                225,144            3
     Issuance of shares for cash                                                June 2001              1,333,333           15
     Exercise of stock purchase warrants in repayment of debt                   June 2001              1,176,294           13
     Exercise of stock purchase warrants for cash                             December 2001            3,250,000           37
     Net loss for the year                                                                                     -            -
     Translation adjustment                                                                                    -            -
                                                                                                    ------------   ----------
Balance at December 31, 2001                                                                          49,261,962          562
     Exercise of stock options                                                  March 2002                10,000            -
     Issuance of stock purchase warrants for bank fee                           June 2002                      -            -
     Exercise of stock purchase warrants in repayment of debt and
        for cash                                                                July 2002              1,625,567           16
     Issuance of remaining shares from 2001 business combination               August 2002                46,976            1
     Net loss for the year                                                                                     -            -
     Translation adjustment                                                                                    -            -
                                                                                                    ------------   ----------
Balance at December 31, 2002                                                                          50,944,505   E      579
                                                                                                    ============   ==========



                                                                                                              Accumulated
                                                                                                                 Other
                                                                                              Deficit         Comprehensive
                                                                                            Accumulated     Income - Foreign
                                                                            Additional      During the          Currency
                                                                              Paid-in       Development       Translation
                                                                              Capital          Stage           Adjustment
                                                                            -----------   ---------------   ----------------
Balance at May 2, 1990                                                      E         -    E            -     E            -
     Shares issued for cash                                                           -                 -                  -
     Net losses to December 31, 1999                                                  -              (376)                 -
                                                                            -----------   ---------------   ----------------
Balance at December 31, 1999                                                          -              (376)                 -
     Bank fee                                                                       806                 -                  -
     Net loss for the year                                                            -            (1,314)                 -
                                                                            -----------   ---------------   ----------------
Balance at December 31, 2000                                                        806            (1,690)                 -
     Effect on capital structure resulting from a business combination             (354)                -                  -
     Issuance of stock purchase warrants for bank fee                            14,063                 -                  -
     Issuance of shares for bank fee                                                (21)                -                  -
     Issuance of shares for bank fee                                                 (3)                -                  -
     Issuance of shares for cash                                                  2,109                 -                  -
     Exercise of stock purchase warrants in repayment of debt                       259                 -                  -
     Exercise of stock purchase warrants for cash                                   563                 -                  -
     Net loss for the year                                                            -           (15,701)                 -
     Translation adjustment                                                           -                 -                100
                                                                            -----------   ---------------   ----------------
Balance at December 31, 2001                                                     17,422           (17,391)               100
     Exercise of stock options                                                        8                 -                  -
     Issuance of stock purchase warrants for bank fee                                63                 -                  -
     Exercise of stock purchase warrants in repayment of debt                       396                 -                  -
     Issuance of remaining shares from 2001 business combination                     (1)                -                  -
     Net loss for the year                                                            -            (3,622)                 -
     Translation adjustment                                                           -                 -                 97
                                                                            -----------   ---------------   ----------------
Balance at December 31, 2002                                                E    17,888    E      (21,013)   E           197
                                                                            ===========   ===============   ================









                                                                                 Total
                                                                              ------------
Balance at May 2, 1990                                                         E         -
     Shares issued for cash                                                            119
     Net losses to December 31, 1999                                                  (376)
                                                                              ------------
Balance at December 31, 1999                                                          (257)
     Bank fee                                                                          806
     Net loss for the year                                                          (1,314)
                                                                              ------------
Balance at December 31, 2000                                                          (765)
     Effect on capital structure resulting from a business combination                   -
     Issuance of stock purchase warrants for bank fee                               14,063
     Issuance of shares for bank fee                                                     -
     Issuance of shares for bank fee                                                     -
     Issuance of shares for cash                                                     2,124
     Exercise of stock purchase warrants in repayment of debt                          272
     Exercise of stock purchase warrants for cash                                      600
     Net loss for the year                                                         (15,701)
     Translation adjustment                                                            100
                                                                              ------------
Balance at December 31, 2001                                                           693
     Exercise of stock options                                                           8
     Issuance of stock purchase warrants for bank fee                                   63
     Exercise of stock purchase warrants in repayment of debt                          412
     Issuance of remaining shares from 2001 business combination                         -
     Net loss for the year                                                          (3,622)
     Translation adjustment                                                             97
                                                                              ------------
Balance at December 31, 2002                                                   E    (2,349)
                                                                              ============

The accompanying notes are an integral part of these financial statements.

34

MYMETICS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2002, 2001 and 2000 and the Period from May 2, 1990 (Inception) to December 31, 2002


(In Thousands of Euros)

                                                                                                              Total
                                                                                                           Accumulated
                                                                                                             During
                                                                                                           Development
                                                                                                              Stage
                                                                                                         (May 2, 1990 to
                                                                                                          December 31,
                                                                  2002          2001          2000            2002)
                                                               ----------   ------------   ----------    ---------------

Cash Flows from Operating Activities
     Net loss                                                  E   (3,622)  E    (15,701)  E   (1,314)    E      (21,013)
     Adjustments to reconcile net loss to net cash
        provided by (used in) operating activities
        Amortization                                                   64             51           52                258
        Goodwill impairment                                           209              -            -                209
        Fees paid in warrants                                          63         14,063            -             14,126
        Fee paid in common stock                                        -              -          806                806
        Changes in current assets and liabilities
           net of effects from reverse purchase
           Receivables                                                (10)            53            7                (21)
           Accounts payable                                            16           (508)         546                154
           Taxes and social costs payable                              36            (26)          55                119
           Other                                                        9             68           (7)                36
                                                               ----------   ------------   ----------    ---------------
              Net cash provided by (used in)
                  operating activities                             (3,235)        (2,000)         145             (5,326)
Cash Flows from Investing Activities
     Patents and other                                               (102)           (45)        (128)              (337)
     Short-term investments                                           354           (205)        (122)                 -
     Cash acquired in reverse purchase                                  -             13            -                 13
                                                               ----------   ------------   ----------    ---------------
              Net cash provided by (used in)
                  investing activities                                252           (237)        (250)              (324)
Cash Flows from Financing Activities
     Proceeds from the issuance of common stock                         8          2,724            -              2,851
     Borrowings from shareholders                                       -              -            -                242
     Increase in note payable and other
        short-term advances                                         2,173            116          384              2,673
     Loan fees                                                          -              -         (130)              (130)
                                                               ----------   ------------   ----------    ---------------
              Net cash provided by financing activities             2,181          2,840          254              5,636
Effect of exchange rate changes on cash                                97            100            -                197
                                                               ----------   ------------   ----------    ---------------
              Net increase (decrease) in cash                        (705)           703          149                183
Cash, beginning of period                                             888            185           36                  -
                                                               ----------   ------------   ----------    ---------------
Cash, end of period                                            E      183   E        888   E      185     E          183
                                                               ==========   ============   ==========    ===============

The accompanying notes are an integral part of these financial statements.

35

MYMETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1. The Company and Summary of Significant Accounting Policies

Basis of Presentation

The amounts in the notes are rounded to the nearest thousand except for per share amounts.

Mymetics Corporation ("the Company") was created for the purpose of engaging in research and development of human health products. Its main research efforts have been concentrated in the prevention and treatment of the AIDS virus. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies.

These financial statements have been prepared treating the Company as a development stage company. As of December 31, 2002, the Company had not performed any clinical testing and a commercially viable product is not expected for several more years. As such, the Company has not generated significant revenues. Revenues reported by the Company consist of incidental serum by-products of the Company's research and development activities and interest income. For the purpose of these financial statements, the development stage started May 2, 1990.

These financial statements have also been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in a deficit in shareholders' equity of E2,349 at December 31, 2002. Deficits in operating cash flows since inception have been financed through debt and equity funding sources. In order to remain a going concern and continue the Company's research and development activities, management intends to seek additional funding. But there can be no assurance that management will be successful in these efforts.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

36

Foreign Currency Translation

The Company translates non-Euro assets and liabilities of its subsidiary at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the year. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because a substantial portion of the Company's activities have been conducted in Europe.

Cash

Cash balances are occasionally in excess of insured amounts. Interest paid was E60 in 2002, E42 in 2001 and none in 2000. Income tax paid in 2002, 2001 and 2000 was nil.

Short-Term Investments

Short-term investments consisted of certificates of deposit stated at cost. The fair value approximates cost based on the length to maturity and interest rate.

Revenue Recognition

The Company records the sale of products when the products are delivered and the Company has only a security interest in the products should a customer default on payment.

Receivables

Receivables are stated at their outstanding principal balances. Management reviews the collectibility of receivables on a periodic basis and determines the appropriate amount of any allowance. Based on this review procedure, management has determined that the allowances at December 31, 2002 and 2001, are sufficient. The Company charges off receivables to the allowance when management determines that a receivable is not collectible.

Goodwill and Other Intangibles

As required, the Company adopted Statement of Financial Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets," beginning January 1, 2002. Under this standard, goodwill of a reporting unit and intangible assets that have indefinite useful lives are not amortized but are tested annually for impairment. Intangible assets with a finite life are amortized over their estimated useful lives.

Research and Development

Research and development costs are expensed as incurred.

37

Taxes on Income

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.

Earnings per Share

Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding in the period. The weighted average number of shares was 50,045,658 for the year ended December 31, 2002, 42,459,784 for the year ended December 31, 2001, and 33,311,361 for 2000. The weighted average number of shares for the period May 2, 1990 through December 31, 2002, was 35,354,881. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. Warrants and options were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred.

Stock-Based Compensation

The Company has a stock-based employee compensation plan, which is described more fully in Note 7. The Company accounts for the plan under the recognition and measurement principles of APB Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. No stock-based employee compensation cost is reflected in net income, as all options granted under the plan had an exercise price equal to or greater than the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123, "Accounting for Stock-Based Compensation," to stock-based employee compensation.

                                                                                             Total Accumulated
                                                                                            During Development
                                                                                            Stage (May 2, 1990
                                                    2002          2001          2000       to December 31, 2002)
                                                ----------     ---------    ----------     ---------------------

Net Income (Loss)
-----------------
    As reported                                 E   (3,622)    E (15,701)   E   (1,314)       E     (21,013)
    Deduct: Total stock-based employee
       compensation expense determined under
       fair value based methods for all
       awards, net of any related tax effects          (72)         (221)            -                 (293)
                                                ----------     ---------    ----------        -------------

    Pro forma                                   E   (3,694)    E (15,922)   E   (1,314)       E     (21,306)
                                                ==========     =========    ==========        =============
Basic and Diluted Earnings (Loss) Per Share
-------------------------------------------
    As reported                                 E     (.07)    E    (.37)   E     (.04)       E        (.59)
    Pro forma                                   E     (.07)    E    (.38)   E     (.04)       E        (.60)

38

Estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standards

SFAS No. 145 and 146 are generally modifications to previously adopted standards. A part of SFAS 145 is effective for years beginning after May 15, 2002, and SFAS 146 is effective for years beginning after December 31, 2002. These new standards do not have an effect on the Company's consolidated financial statements.

Note 2. Receivables

                                                        2002                 2001
                                                   ----------------     ---------------

Trade receivables (including E23 from a
    shareholder in 2002 and 2001)                  E            37      E            37
Refunds due from suppliers                                       -                    6
Value added tax                                                 41                   31
Other                                                           15                    9
                                                   ---------------      ---------------

                                                                93                   83
Allowance for doubtful accounts                                (34)                 (34)
                                                   ---------------      ---------------

                                                   E            59      E            49
                                                   ===============      ===============

Note 3. Goodwill and Other Intangible Assets

Prior to January 1, 2002, the Company was amortizing goodwill over a five-year period. In accordance with current accounting standards, goodwill is not to be amortized beginning January 1, 2002. Goodwill was acquired during 2001 at a cost of E247 and amortization amounted to E38 for the year ended December 31, 2001. Had goodwill not been amortized in 2001, net loss would have amounted to E(15,663) and basic and diluted loss per share would not have changed. No additional acquisitions have occurred. Based on a review of the fair value of the Company's only reporting unit at December 31, 2002, management has determined that the goodwill is fully impaired. Accordingly, an impairment loss is recorded in the 2002 statement of operations.

39

Other intangible assets consist of patents which are stated at cost of the fees paid to the French patent office. At December 31, 2002 and 2001, the carrying amount of patents was E199 and E161 net of accumulated amortization of E125 and E61, respectively. Amortization expense relating to patents was E64, E13 and E52 for 2002, 2001 and 2000, respectively. Amortization expense is expected to amount to E64 during each of the next three years and E7 during 2006, which will completely amortize this asset.

Note 4. Taxes and Social Costs Payable

                                                        2002                 2001
                                                   ---------------      ---------------

Social security and other social benefits          E           113      E            75
Value added tax                                                  -                    3
Other                                                            6                    5
                                                   ---------------      ---------------

                                                   E           119      E            83
                                                   ===============      ===============

Note 5. Transactions With Affiliates

During 2000, the Company agreed to pay a fee in common stock to MFC Merchant Bank SA ("MFC Bank") for services provided in a business combination transaction. The parent of MFC Bank was a shareholder of the Company. The common shares were not issued in 2000. The fair value of the shares at the measurement date, amounting to E806 (which may not be indicative of the value of the Company as a whole), was included in additional paid-in capital at December 31, 2000. In 2001, a total of 2,025,144 common shares were issued to MFC Bank which resulted in E24 being reclassified to common stock based on the par value of the shares.

The Company has a non-revolving term credit facility with MFC Bank which allowed the Company to borrow up to E2,800 at LIBOR plus 4% (approximately 7.0% at December 31, 2002) repayable on August 31, 2003, as extended, collateralized by all of the Company's assets plus any future patents. The Company owed E1,989 and E228 under this facility as of December 31, 2002 and 2001, respectively. The fair value of this note approximates carrying value because the note is short-term and has a market rate of interest. MFC Bank had also advanced E400 to the Company in a prior year which was paid in 2001.

In connection with the term credit facility, the Company agreed to pay MFC Bank an arrangement fee of E130 and E10 per month for nine months as a retainer fee. The arrangement fee was amortized over the original term of the loan and the retainer fee was expensed monthly beginning August 2000.

The Company incurred fees of E155 to MFC Bank in 2002 related to management services.

40

In March 2001, the Company granted warrants under the agreements with MFC Bank which entitle MFC Bank to purchase 6,001,693 of the Company's common shares. The warrants allow MFC Bank to convert to shares an amount equal to the maximum of the credit facility including unpaid interest plus the arrangement and retainer fees. The warrants are exercisable within a three-year period beginning August 2000 at approximately E.2319 per common share. The fair value of the beneficial conversion feature amounting to E14,063 (which may not be indicative of the value of the Company as a whole) was calculated on March 28, 2001, the grant date, using the Black-Scholes model. This amount was recorded as paid-in capital of E14,063 and allocated to bank fee expense in 2001. During 2001, MFC Bank exercised warrants to acquire 1,176,294 common shares in exchange for the arrangement fee and the retainer fee plus E52 in accrued interest. MFC also exercised warrants to acquire 3,250,000 common shares for cash in 2001. In 2002, the Company granted 26,775 additional warrants under the original agreements with MFC Bank. The fair value of the beneficial conversion feature on these warrants was calculated using the Black-Scholes model which amounted to E63. This amount was recorded as paid-in capital of E63 and allocated to bank fee expense in 2002. During 2002, MFC Bank exercised the remaining warrants to acquire 1,602,174 common shares. This resulted in a decrease of E372 due on the revolving term credit facility with MFC Bank. This is a non-cash transaction for purposes of the statement of cash flows.

In June 2001, the Company issued additional warrants to MFC Bank to purchase 103,559 common shares at U.S. $1.725 per share exercisable during a three-year period. These warrants were issued in connection with MFC Bank's placement of 1,333,333 of the Company's common shares. The warrants were valued at E118 based on the fair value of the placement fees rendered and was a cost of the placement. In 2002, MFC Bank exercised warrants to acquire 23,393 common shares. This resulted in a decrease of E40 due on the revolving term credit facility with MFC Bank. This is a non-cash transaction for purposes of the statement of cash flows.

The amounts payable to shareholders bear no interest, have no collateral, and are repayable upon the Company becoming profitable. Since the timing of the Company becoming profitable cannot be determined, the fair value of the amounts payable to shareholders cannot be determined. The Company is not expected to become profitable in the near-term, therefore, the amounts payable to shareholders have been classified as long-term.

During 2002 and 2001, the Company incurred fees to its Chairman of E275 and E82 for consulting from a company owned by him, and E27 in 2001 from a company owned by the former Chief Financial Officer of the Company. Accounts payable at December 31, 2002 and 2001, includes E23 and E14 of these fees, respectively.

41

Note 6. Income Taxes

The reconciliation of income tax on income computed at the federal statutory rates to income tax expense is as follows:

                                                         2002                2001                 2000
                                                   ---------------      ----------------     ---------------

U.S. Federal statutory rates on loss from
    operations                                     E        (1,231)     E        (5,338)     E          (446)

Nondeductible fee paid in warrants and common
    stock                                                       21                4,781                  275

Effect of U.S. tax on French losses                            378                  550                    -

Change in valuation allowance                                  890                   (6)                 172

Other                                                          (58)                  13                    -
                                                   ---------------      ---------------      ---------------

Income tax expense                                 E             -      E             -      E             1
                                                   ===============      ===============      ===============

Deferred tax asset is composed of the following:

                                                                              2002                 2001
                                                                        ---------------      ---------------

Difference in book and tax basis of amounts payable to shareholder      E            82      E            82

Net operating loss carryforward                                                   1,063                  173
                                                                        ---------------      ---------------

                                                                                  1,145                  255
Less valuation allowance for deferred tax asset                                  (1,145)                (255)
                                                                        ---------------      ---------------

Net deferred tax asset                                                  E             -      E             -
                                                                        ===============      ===============

The Company's provision for income taxes was derived from U.S. and French operations. The Company had no net operating loss carryforwards as of December 31, 2002, in France and E3,128 in the United States which expire beginning in year 2021.

42

Note 7. Stock Option Plans

1994 Amended Stock Option Plan

The Company's 1994 stock option plan provided for the issuance of up to 350,000 shares of the Company's common stock to employees and non-employee directors. The plan was terminated during 2002. The following table summarizes information with respect to this plan:

                                                                                                Weighted
                                                                                                 Average
                                                                    Number of Shares         Exercise Price
                                                                    -----------------        ----------------
Outstanding and exercisable at December 31, 2001 and 2000                    73,750    U.S.  $          .82
                                                                                             ==============

Exercised in 2002                                                           (10,000)
                                                                    ---------------
Outstanding and exercisable at December 31, 2002                             63,750    U.S.  $          .83
                                                                    ===============          ==============
Reserved for future grants at December 31, 2002                                   -
                                                                    ===============

1995 Qualified Incentive Stock Option Plan

The Company's board of directors approved a stock option plan on August 15, 1996 which provided for the issuance of up to 150,000 shares of the Company's common stock to key employees. The plan was terminated during 2002. The following table summarizes information with respect to this plan:

                                                                                                Weighted
                                                                                                 Average
                                                                    Number of Shares         Exercise Price
                                                                    -----------------        ----------------

Outstanding and exercisable at December 31, 2002, 2001 and 2000             100,000    U.S.  $          .75
                                                                    ===============          ==============

Reserved for future grants at December 31, 2002                                   -
                                                                    ===============

43

2001 Qualified Incentive Stock Option Plan

The Company's board of directors approved a stock option plan on June 15, 2001, which provides for the issuance of up to 5,000,000 shares of the Company's common stock to employees and non-employee directors. The weighted average fair value of these options at the grant dates were E.62 and E2.24 per option in 2002 and 2001, respectively. The following table summarizes information with respect to this plan:

                                                                                                Weighted
                                                                                                 Average
                                                                    Number of Shares         Exercise Price
                                                                    -----------------        ----------------

Granted in 2001                                                             100,000   U.S.   $         2.86
                                                                    ---------------

Outstanding and exercisable at December 31, 2001                            100,000   U.S.   $         2.86
                                                                                             ==============

Granted in 2002                                                             117,500   U.S.   $          .99
                                                                    ---------------

Outstanding and exercisable at December 31, 2002                            217,500   U.S.   $         1.83
                                                                    ===============          ==============

Reserved for future grants at December 31, 2002                           4,782,500
                                                                    ===============

Almost all options have an expiration date ten and a half years after issuance.

The fair value of each option granted was estimated for proforma purposes on the grant date using the Black-Scholes Model (use of this Model for proforma purposes is not intended to indicate the value of the Company as a whole). The assumptions used in calculating fair value are as follows:

                                                                       2002                        2001
                                                              ------------------------    -----------------------
Risk-free interest rate                                                4.75%                       4.5%
Expected life of the options                                          7 years                    8 years
Expected volatility                                              71.10% - 243.12%            63.91% - 160.97%
Expected dividend yield                                                 0%                          0%

Note 8. Commitments and Contingencies

The Company leases property under noncancelable operating leases through January 2006. Future minimum lease payments under noncancelable operating leases are as follows:

2003                                                E          7
2004                                                           7
2005                                                           7
2006                                                           1
                                                    ------------

                                                    E         22
                                                    =============

44

Total rent expense per year was E30 for 2002 and E7 for 2001 and 2000.

The Company is involved in various matters of litigation arising in the ordinary course of business. In the opinion of management, the estimated outcome of such issues will not have a material effect on the Company's financial statements.

45

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 27, 2003                     MYMETICS CORPORATION

                                         By: /s/ MICHAEL K. ALLIO
                                             ----------------------------------
                                                 Michael K. Allio
                                                 Interim Chief Executive Officer
                                                 and Director
                                                 (Principal Executive Officer)

                                         By: /s/ JOHN M. MUSACCHIO
                                            ------------------------------------
                                                  John M. Musacchio
                                                  Chief Financial Officer,
                                                  Secretary and Director
                                                  (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

By:              /s/ JOHN M. MUSACCHIO                                          March 27, 2003
   ----------------------------------------------
         John M. Musacchio
         Chief Financial Officer,
         Secretary and Director

Pierre-Francois Serres
Chief Scientific Officer and
Director

By:              /s/ JOHN M. MUSACCHIO                                          March 27, 2003
   ----------------------------------------------
         Signing on behalf of
         Pierre-Francois Serres pursuant
         to a Power of Attorney

Robert Demers
Director

By:              /s/ JOHN M. MUSACCHIO                                          March 27, 2003
   ----------------------------------------------
         Signing on behalf of
         Robert Demers pursuant
         to a Power of Attorney

Michael K. Allio
Chairman, Interim Chief Executive Officer
and Director


By:              /s/ JOHN M. MUSACCHIO                                          March 27, 2003
   ----------------------------------------------
         Signing on behalf of
         Michael K. Allio pursuant
         to a Power of Attorney

46

INTERIM CHIEF EXECUTIVE OFFICER
I, Michael K. Allio, certify that:

1. I have reviewed this annual report on Form 10-K of Mymetics Corporation;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

                                               /s/ Michael K. Allio
                                               -----------------------------

Date: March 27, 2003                       By:
                                               Interim Chief Executive Officer

47

CHIEF FINANCIAL OFFICER
I, John M. Musacchio, certify that:

1. I have reviewed this annual report on Form 10-K of Mymetics Corporation;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

                                     /s/ John M. Musacchio
                                     ----------------------------

Date: March 27, 2003              By:
                                     Chief Financial Officer
                                     Principal financial and chief
                                        accounting officer

48

EXHIBIT INDEX

EXHIBIT
 NUMBER                       DESCRIPTION
 ------                       -----------
   2.1     Share Exchange Agreement dated December 13, 2001 between the Corporation and
           the stockholders of Mymetics S.A. listed on the signature page thereto (1)

   2.2     Share Exchange Agreement dated December 13, 2001 between the Corporation and
           the stockholders of Mymetics S.A. listed on the signature page thereto (1)

   2.3     Purchase Agreement dated October 17, 1998 between the Corporation and the
           majority stockholders of Nazca Holdings Ltd. (2)

   2.4     Amendment to the Agreement dated October 17, 1998 between the Corporation and
           the majority stockholders of Nazca Holdings Ltd. (3)

   2.5     Revised Purchase Agreement dated July 28, 1999 between the Corporation and the
           majority stockholders of Nazca Holdings Ltd. (4)

   2.6     Share Exchange Agreement dated July 30, 2002 between the Corporation and the
           stockholders of Mymetics S.A. listed on the signature page thereto (5)

   3(i)    Articles of Incorporation of the Corporation (as amended through May 10, 2002)
           (6)

   3(ii)   Bylaws (7)

   4       Form of Specimen Stock Certificate (8)

   9       Voting and Exchange Trust Agreement dated March 28, 2001, among the
           Corporation, 6543 Luxembourg S.A. and MFC Merchant Bank S.A. (8)

   10.1    Services Agreement dated May 31, 2001, between the Corporation and MFC Merchant
           Bank, S.A.(7)

   10.2    Employment Agreement dated May 3, 2001, between Pierre-Francois Serres and the
           Corporation (7)

   10.3    Indemnification Agreement dated March 28, 2001, between the Corporation and MFC
           Bancorp Ltd. (7)

   10.4    Agreement dated for reference May 15, 2000, between the Corporation and Maarten
           Reidel (7)

   10.5    Preferred Stock Redemption and Conversion Agreement dated for reference
           December 21, 2000, between the Corporation and Sutton Park International Ltd.
           (10)

   10.6    Preferred Stock Conversion Agreement dated for reference December 21, 2000,
           between the Corporation and Med Net International Ltd. (11)

   10.7    Preferred Stock Conversion Agreement dated December 21, 2000, between the
           Corporation and Dresden Papier GmbH (11)

   10.8    Assignment Agreement dated December 29, 2000, among the Corporation, Mymetics
           S.A. and MFC Merchant Bank S.A. (1)


10.9    Credit Facility Agreement dated July 27, 2000, between MFC Merchant Bank, S.A.
        and the Corporation (1)

10.10   Amended Credit Facility Agreement dated for reference August 13, 2001, between
        MFC Merchant Bank, S.A. and the Corporation

10.11   Second Amended Credit Facility Agreement dated for reference February 27, 2002,
        between MFC Merchant Bank, S.A. and the Corporation

10.12   Amended and Restated Credit Facility Agreement dated for reference February 28, 2003,
        among MFC Merchant Bank, S.A., MFC Bancorp Ltd., and the Corporation

10.13   Guarantee dated for reference February 28, 2003, by MFC Bancorp Ltd. to MFC
        Merchant Bank S.A.

10.14   Shareholder Agreement dated March 28, 2001, among the Corporation, the Holders
        of Class B Exchangeable Preferential Non-Voting Shares of 6543 Luxembourg S.A.
        signatory thereto and 6543 Luxembourg S.A.(8)

10.15   Support Agreement dated March 28, 2001, between the Corporation and 6543
        Luxembourg S.A. (8)

10.16   1995 Qualified Incentive Stock Option Plan (12)

10.17   Amended 1994 Stock Option Plan (13)

10.18   2001 ICHOR Corporation Stock Option Plan (7)

10.19   Employment Agreement dated March 18, 2002, between the Corporation and Peter P.
        McCann (14)

10.20   Consulting Agreement dated August 31, 2001, between the Corporation and Michael
        K. Allio (8)

10.21   Amendment to Consulting Agreement dated August 21, 2002, between the
        Corporation and Michael K. Allio

10.22   Employment Agreement dated March 18, 2002, between the Corporation and Dr.
        Joseph D. Mosca (15)

10.23   Separation Agreement and Release dated January 31, 2003, between the
        Corporation and Peter P. McCann

10.24   Director and Non-Employee Stock Option Agreement dated July 19, 2001, between
        the Corporation and Robert Demers (8)

10.25   Director and Non-Employee Stock Option Agreement dated July 19, 2001, between
        the Corporation and Michael K. Allio (8)

10.26   Director and Non-Employee Stock Option Agreement dated July 19, 2001, between
        the Corporation and John M. Musacchio (8)

10.27   Director and Non-Employee Stock Option Agreement dated July 19, 2001, between
        the Corporation and Patrice Pactol (8)

10.28   Director and Non-Employee Stock Option Agreement dated July 19, 2001, between
        the Corporation and Pierre-Francois Serres (8)


10.29   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and Pierre-Francois Serres

10.30   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and Patrice Pactol

10.31   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and Robert Demers

10.32   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and John M. Musacchio

10.33   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and Michael K. Allio

10.34   Director and Non-Employee Stock Option Agreement dated August 21, 2002, between
        the Corporation and Michael K. Allio

10.35   Director and Non-Employee Stock Option Agreement dated June 20, 2002, between
        the Corporation and Peter P. McCann

10.36   Director and Non-Employee Stock Option Agreement dated July 23, 2002, between
        the Corporation and Peter P. McCann

10.37   Director and Non-Employee Stock Option Agreement dated February 6, 2003,
        between the Corporation and Peter P. McCann

10.38   Patent Pledge Agreement dated November __, 2002 among Mymetics S.A., Mymetics
        Deutschland GmbH, the Corporation and MFC Merchant Bank S.A.

11      Statement Regarding Calculation of Per Share Earnings.

21      List of Subsidiaries

24.1    Power of Attorney for Pierre-Francois Serres

24.2    Power of Attorney for Robert Demers

24.3    Power of Attorney for Michael K. Allio

99.1    Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


(1) Incorporated by reference to the Corporation's Schedule 14C filed with the Securities and Exchange Commission on April 26, 2001.

(2) Incorporated by reference to the Corporation's report on Form 8-K filed with the Securities and Exchange Commission on October 22, 1998.

(3) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on April 15, 1999.

(4) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on August 13, 1999.


(5) Incorporated by reference to the Corporation's Amendment No. 1 to Form S-1 filed with the Securities and Exchange Commission on August 8, 2002.

(6) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002.

(7) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended June 30, 2001, filed with the Securities and Exchange Commission on August 14, 2001.

(8) Incorporated by reference to the Corporations Registration Statement on Form S-1, File No. 333-88782, filed with the Securities and Exchange Commission on May 22, 2002.

(9) Incorporated by reference to the Corporation's report on Form 8-K/A filed with the Securities and Exchange Commission on August 9, 2000.

(10) Incorporated by reference to Schedule 13D/A filed by MFC Bancorp Ltd.
with the Securities and Exchange Commission on dated January 2, 2001.

(11) Incorporated by reference to the Corporation's report on Form 10-K for the fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission on March 14, 2001.

(12) Incorporate by reference to the Corporation's Registration Statement on Form S-8, File No. 333-15831, filed with the Securities and Exchange Commission on November 8, 1996.

(13) Incorporated by reference to the Corporation's Registration Statement on Form S-8, File No. 333-15829, filed with the Securities and Exchange Commission on November 8, 1996.

(14) Incorporated by reference to the Corporation's report on Form 10-K for the fiscal year ended December 31, 2001, and filed with the Securities and Exchange Commission on March 14, 2001.

(15) Incorporated by reference to the Corporation's report on Form 10-Q for the quarter ended March 31, 2002, filed with the Securities and Exchange Commission on May 15, 2002.


Exhibit 10.10

AMENDED CREDIT FACILITY AGREEMENT

This Amended Credit Agreement is dated for reference August 13th, 2001, and made among MFC MERCHANT BANK S.A., a bank organized under the laws of Switzerland ("Merchant Bank" or "Lender") and MYMETICS CORPORATION (f/k/a/ Ichor Corporation, a corporation organized under the laws of the State of Delaware, as a successor in interest hereunder by assignment and assumption to Hippocampe) ("Borrower").

WHEREAS Merchant Bank and Hippocampe entered into that certain Credit Facility Agreement dated July 27, 2000 (the "Credit Agreement");

WHEREAS on December 29, 2000, all the rights and obligations under the Credit Agreement were assigned to and assumed by Ichor Corporation;

WHEREAS Ichor Corporation changed its name to Mymetics Corporation on July 23, 2001;

WHEREAS Merchant Bank and Lender have agreed to extend the Maturity date of the Credit Agreement between the parties dated July 27, 2000, with six months.

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, and intending to be legally bound, the parties hereto agree as follows:

1. Definitions. Defined terms not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement and the Assignment Agreement;

2. Extension of Maturity Date. Section 2.1 of the Credit Agreement shall be amended in its entirety as follows:

Section 2.1. The Lender shall make available to the Borrower in accordance with, and subject to the terms and the conditions of this Agreement, until February 28, 2002 (the "Maturity Date"), a revolving term facility in the principal amount of up to Euro 1,300,000 (the "Credit Facility") and made available to the Borrower by way of Advances in accordance with Section 2.2 hereof. The parties also have the intention to extend the Credit Agreement with subsequent six month terms, at the option of Merchant Bank.

All other provisions of the Credit Agreement and the Assignment Agreement shall continue in full force and effect and shall not be modified hereby.

3. Governing Law. This Amendment shall be construed, performed and enforced in accordance with, and governed by, the internal laws of Switzerland, without giving effect to the principles of conflict of law thereof.

4. Successors and Assigns. This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors, heirs, executors, administrators, legal representatives and assigns.


5. Counterparts. This Amendment may be executed in counterparts, each of which will be an original and all of which will constitute the same document.

IN WITNESS HEREOF, the parties have caused this Amendment to be executed and delivered by their duly authorized officers as of the date first written above.

THE BORROWER

MYMETICS CORPORATION

per:  /s/ [illegible]
      ----------------------------------
         Authorized Signing Officer

per:  /s/ [illegible]
      ----------------------------------
         Authorized Signing Officer

THE LENDER

MFC MERCHANT BANK S.A.

per:  /s/ [illegible]
      ----------------------------------
         Authorized Signing Officer

per:  /s/ [illegible]
      ----------------------------------
         Authorized Signing Officer


Exhibit 10.11

SECOND AMENDED CREDIT FACILITY AGREEMENT

This second Amended Credit Agreement is dated for reference February 27, 2002 and made among MFC MERCHANT BANK S.A., a bank organized under the laws of Switzerland ("Merchant Bank" or the "Lender") and MYMETICS CORPORATION (f/k/a Ichor Corporation, a corporation organized under the laws of the State of Delaware, as a successor in interest hereunder by assignment and assumption to Hippocampe) (the "Borrower").

WHEREAS Merchant Bank and the Borrower entered into that certain Credit Facility Agreement dated July 27, 2000 (the "Credit Agreement");

WHEREAS on December 29, 2000, all the rights and obligations under the Credit Agreement were assigned to and assumed by Ichor Corporation;

WHEREAS Ichor Corporation changed its name to Mymetics Corporation on July 23, 2001;

WHEREAS Merchant Bank and the Borrower entered into an Amended Credit Facility Agreement dated August 13, 2001 (the "First Amended Credit Agreement") in order to extend the Maturity Date of the Credit Agreement to February 28, 2002;

WHEREAS on December 27, 2001 the Borrower prepaid Euro 747,300 of the outstanding aggregate principal amount of the Advances made to the Borrower under the Credit Agreement; and

WHEREAS Merchant Bank and the Borrower have agreed to further extend the Maturity Date of the Credit Agreement to August 31 2002 and the Borrower has agreed to provide additional security to Merchant Bank in consideration therefor.

NOW THEREFORE, in consideration of the premises and the covenants contained herein the parties hereto agree as follows:

1. DEFINITIONS. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Credit Agreement.

2. EXTENSION OF MATURITY DATE. Section 2.1 of the Credit Agreement shall be amendment in its entirety by deleting such section and replacing the same with the following:

SECTION 2.1. CREDIT FACILITY. The Lender shall make available to the Borrower in accordance with, and subject to the terms and the conditions of this Agreement, until August 31, 2002 (the "Maturity Date"), a revolving term facility in the principal amount of up to Euro 1,300,000 (the "Credit Facility") and made available to the Borrower by way of Advances in accordance with Section 2.2 hereof. The Maturity Date may be extended for an additional term of up to six months at the option of the Lender, which option is exercisable in the Lender's sole discretion.


3. REPLACEMENT OF SCHEDULE A. Schedule A to the Credit Agreement shall be amended in its entirety by deleting such schedule and replacing the same with Schedule A attached hereto.

4. CONTINUED PERFECTION AND AGREED RELEASE OF SECURITY. The Borrower shall take such action and execute and deliver to the Lender such agreements, conveyances, deeds and other documents and instruments as the Lender shall reasonably request for the purpose of establishing, perfecting, preserving and protecting the Security and any additional security given to the Lender to secure the Obligations, in each case forthwith upon request therefor by the Lender and in form and substance reasonably satisfactory to the Lender.

5. FULL FORCE AND EFFECT. All the other provisions of the Credit Agreement shall continue in full force and effect and shall not be modified hereby.

6. GOVERNING LAW. This Second Amended Credit Agreement shall be construed, performed and enforced in accordance with, and governed by, the internal laws of Switzerland, without giving effect to the principles of conflict of law thereof.

7. CONSENT TO JURISDICTION.

(1) Each of the parties hereby irrevocably affords to the non-exclusive jurisdiction of the Courts of Geneva (Switzerland) in any action or proceeding arising out of ore relating to this Second Amended Credit Agreement. The Borrower agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

(2) Nothing in this Section 7 shall affect the right of the Lender to serve legal process in any other manner permitted by Law or affect the right of the Lender to bring any action or proceeding against the Borrower or its property in the courts or other jurisdictions.

8. ENGLISH VERSION. The parties hereby represent, warrant, acknowledge and agree that: (i) they have agreed that this Second Amended Credit Agreement be drawn upon in the English language; and (ii) the English version of this Second Amended Credit Agreement shall govern for all purposes.

9. SEVERABILITY. If one or more provisions of this Second Amended Credit Agreement be or become invalid, or unenforceable in whole or in part in any jurisdiction, the validity of the remaining provisions of this Second Amended Credit Agreement shall not be affected. The parties hereto undertake to replace any such invalid provision without delay with a valid provision which as nearly as possible duplicates the corporate intent of the invalid provision.

-2-

10. SUCCESSORS AND ASSIGNS. This Second Amended Credit Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors, heirs, executors, administrators, legal representatives and assigns.

11. COUNTERPARTS. This Second Amended Credit Agreement may be executed in counterparts, each of which will be an original and all of which will continue the same document.

12. FACSIMILE. The parties hereto agree that this Second Amended Credit Agreement may be transmitted by facsimile or such similar device and that the reproduction of signatures by facsimile or such similar device will be treated as binding as if originals and each party hereto undertakes to provide each and every other party hereto with a copy of the Second Amended Credit Agreement bearing original signatures forthwith upon demand.

THE BORROWER:

MYMETICS CORPORATION

Per: /s/ [illegible]
     -----------------------------
         Authorized Signatory



Per: /s/ [illegible]
     -----------------------------
         Authorized Signatory

THE LENDER:

MFC MERCHANT BANK S.A.

Per: /s/ [illegible]
     -----------------------------
         Authorized Signatory



Per: /s/ [illegible]
     -----------------------------
         Authorized Signatory

-3-

A-1

SCHEDULE A

LIST OF PATENTS OF BORROWER

APPLICATION NO.         APPLICATION DATE                 PUBLICATION NO.
---------------         ----------------                 ---------------

97/74587                November 17, 1997                2711011

PCT/FR9X02447           November 17, 1998                WO99/25377

99/06528                May 21, 1999                     N/A

PCT/FR00/01399          May 22, 2000                     N/A

01/10910                August 17, 2001                  N/A

01/15423                November 23, 2001                N/A

01/15424                November 29, 2001                N/A

01/36290                December 17, 2001                N/A

US 60/340492            December 18, 2001                N/A

A-1

Exhibit 10.12

CREDIT FACILITY AGREEMENT

THIS AMENDED AND RESTATED CREDIT FACILITY AGREEMENT dated for reference the 28th day of February, 2003,

AMONG:

MFC MERCHANT BANK S.A., a bank organized under the laws of Switzerland (hereinafter, the "LENDER")

AND:

MYMETICS CORPORATION, a corporation organized under the laws of the State of Delaware (hereinafter, the "BORROWER")

AND:

MFC BANCORP LTD., a corporation organized under the laws of the Yukon Territory (hereinafter, the "GUARANTOR")

WHEREAS:

A. The Lender agreed to make the Credit Facility available to the Borrower pursuant to and in accordance with the terms of a credit facility agreement entered into between the Lender, the Borrower and the Guarantor dated for reference the 27th day of July, 2000, as amended by amendment agreements dated for reference August 13, 2001, February 27, 2002 and February 28, 2003 (as amended, the "ORIGINAL CREDIT AGREEMENT"); and

B. The Lender, the Borrower and the Guarantor have agreed to execute and deliver this amended and restated credit facility agreement in the place and stead of the Original Credit Agreement,

NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree as follows:

I. ARTICLE 1 - INTERPRETATION

SECTION 1.1. DEFINITIONS. When used in this agreement (including the recitals and


schedules hereto) (this "AGREEMENT") or in any amendment hereto, the terms listed in Schedule B hereto shall, unless otherwise expressly provided, have the meanings assigned to them therein.

ARTICLE 2 - THE CREDIT FACILITY

SECTION 2.1. CREDIT FACILITY. The Lender shall make available to the Borrower in accordance with, and subject to the terms and conditions of, this Agreement, until August 31, 2003 (the "MATURITY DATE"), a non-revolving term facility in the principal amount of up to Euro 2,800,000 (the "CREDIT FACILITY") and made available to the Borrower by way of Advances in accordance with Section 2.2 hereof. The Maturity Date may be extended for an additional term of up to six months at the option of the Lender, which option is exercisable in the Lender's sole discretion.

SECTION 2.2. THE ADVANCES. On the terms and conditions set forth herein the Lender, from time to time, on any banking day, prior to the Maturity Date, agrees to make advances to the Borrower ("ADVANCES"). Each Advance shall be in an aggregate amount of not less than Euro 50,000 and in integral multiples of Euro 10,000.

SECTION 2.3. MAKING THE ADVANCES. Each Advance shall be made on three banking days' notice. Each such notice shall be given by a borrowing notice in form satisfactory to the Lender (the "BORROWING NOTICE") which shall specify therein (i) the requested date of such Advance; (ii) the aggregate amount of such Advance; and (iii) the Outstanding Amount having given effect to such Advance.

SECTION 2.4. USE OF PROCEEDS. The Borrower shall use all Advances to fund: (i) fees associated with registering and maintaining the registration of the Patents; (ii) operating and research activities until December 31, 2000; and
(iii) working capital and general corporate activities.

ARTICLE 3 - REPAYMENT

SECTION 3.1. PAYMENTS. The Borrower shall pay or repay to the Lender on the Maturity Date all amounts owing under the Credit Facility and not previously paid or repaid hereunder, without set-off, counterclaim or deduction, unless, in the case of set-off, such set-off is specifically acknowledged in writing by the Lender.

SECTION 3.2. INTEREST ON ADVANCES. The Borrower shall pay to the Lender on the first banking day of each calendar month (the "INTEREST PAYMENT DATES"), the first such date falling on October 1, 2000, Interest on the unpaid principal amount of each Advance made to it from the date of such Advance in Euros, until such principal amount shall be repaid in full, at the Interest Rate. Interest shall accrue from day to day and shall be compounded monthly in arrears.

SECTION 3.3. FEES. Provided the Lender is prepared to make Advances to the Borrower up to the amount set forth in Section 2.1 hereof, the Borrower shall pay the Lender on the Closing Date an arrangement fee equal to Euro 130,000 (the "ARRANGEMENT FEE"), whether or not any Advances

2

are made under this Agreement; provided that the parties hereto may agree in writing to include the Arrangement Fee as an Outstanding Amount, with Interest to be paid thereon in accordance with Section 3.2 hereof and to be repaid in accordance with Section 3.1 hereof.

SECTION 3.4. BORROWER'S RIGHT TO PREPAY THE LOAN. The Borrower may, on ten banking days' prior notice given to the Lender, prepay the outstanding aggregate principal amount of the Advances made to the Borrower under the Credit Facility, in whole or in part, together with accrued Interest to the date of such prepayment on the amount prepaid. Each prepayment shall be in a principal amount of not less than Euro 50,000 and in integral multiples of Euro 10,000 thereafter.

ARTICLE 4 - SECURITY

SECTION 4.1. SECURITY. As general and continuing security for the performance of all Obligations of the Borrower under the Credit Facility Documents, the Borrower shall deliver to the Lender, in form and substance satisfactory to the Lender:

(a) on or prior to the Closing Date, a pledge agreement in the aggregate principal amount of Euro 1,300,000, which agreement shall pledge all existing and future pecuniary claims of the Borrower against third parties;

(b) on or prior to the Closing Date, a pledge agreement in the aggregate principal amount of Euro 1,300,000, which agreement shall pledge the Patents (now existing and hereafter acquired or registered); and

(c) at or prior to the time of completion of the Reorganization, a demand debenture in the aggregate principal amount of Euro 1,300,000 duly created by the Borrower in favour of the Lender, which debenture shall contain a first fixed and specific charge and security interest on the interest of the Borrower in and to all of its property, assets and undertakings and a floating charge on the interest of the Borrower in and to all of its other property, assets and undertakings not otherwise specifically mortgaged and charged under the debenture,

and the Guarantor shall deliver to the Lender, in form and substance satisfactory to the Lender:

(d) on or prior to the Lender making its first Guaranteed Advance, the Guarantee.

On or before the date of the first Guaranteed Advance, the Borrower shall deliver to the Lender amended Security Documents securing an aggregate principal amount of Euro 2,800,000 and from such date forward all references to Euro 1,300,000 in Section 4.1 hereof shall be read as Euro 2,800,000 mutatis mutandis. In addition, as general and continuing security for the performance of all Obligations of the Borrower under the Credit Facility Documents, the Borrower undertakes to pledge to the Lender, until the debenture contemplated in
Section 4.1(c) above is delivered to the Lender, any of its future patents derived from the Patents, in and restricted to the field of human and animal AIDS, each time and as soon as such future patent comes into existence, and to deliver to the Lender a patent pledge agreement in form and substance satisfactory to the Lender; provided that the Lender at the time of entering into each future patent pledge agreement simultaneously

3

undertakes in writing to the Borrower and any other party designated by the Borrower not to hinder the applications of such future patents in fields other than human and animal AIDS.

SECTION 4.2. CONTINUED PERFECTION AND AGREED RELEASES OF SECURITY. Each of the Borrower and the Guarantor shall take such action and execute and deliver to the Lender such agreements, conveyances, deeds and other documents and instruments as the Lender shall reasonably request for the purpose of establishing, perfecting, preserving and protecting the Security, in each case forthwith upon request therefor by the Lender and in form and substance reasonably satisfactory to the Lender.

ARTICLE 5 - CONDITIONS PRECEDENT TO THE ADVANCES

SECTION 5.1. CONDITIONS PRECEDENT TO THE INITIAL ADVANCE. The obligation of the Lender to make its initial Advance was subject to the fulfillment of: (i) the conditions precedent set forth in Section 5.2; and (ii) the following conditions precedent:

(a) the Lender shall have received, in a form satisfactory to it: (i) copies certified by a senior officer of the Borrower of its Charter Documents, the resolutions of its board of directors approving the Credit Facility Documents to which it is a party and all documents evidencing any necessary corporate action of the Borrower with respect to the Credit Facility Documents to which it is a party; (ii) a certificate of good standing for the Borrower; and (iii) a favourable opinion of Borrower's counsel as to such matters as the Lender may require;

(b) the Credit Facility Documents other than the Guarantee shall have been executed and delivered to the Lender, the Security other than the Security described in Section 4.1(d) hereof shall have been created, and all registrations, filings or recordings necessary or desirable to preserve, protect or perfect the enforceability and priority of such Security shall have been completed, all in such form, content and manner as is satisfactory to the Lender;

(c) all of the representations and warranties of the Borrower contained in Article 6 hereof shall be correct on and as of the Closing Date as though made on and as of such date; and

(d) the Lender shall have received such other documents as it may reasonably request.

SECTION 5.2. CONDITIONS PRECEDENT TO ALL ADVANCES. The obligation of the Lender to make an Advance and the right of the Borrower to deliver a Borrowing Notice shall be subject to the condition precedent that on the date of such Advance and after giving effect thereto and to the application of proceeds therefrom: (i) the representations and warranties of the Borrower contained in Article 6 hereof are true and correct in every material respect on the date of the Advance as if made on and as at such date; (ii) no event has occurred and is continuing, or would result from such Advance, which constitutes or would, with the giving of notice or the passage of time, constitute an Event of Default;
(iii) such Advance will not violate any applicable Law; (iv) there have been no amendments to the Charter Documents or authorizing resolutions of the Borrower, subsequent to those delivered to the Lender pursuant to Section 5.1(a), which are material to the ability of the

4

Borrower to enter into this Agreement and any of the other Credit Facility Documents to which the Borrower is a party and to perform its obligations hereunder and thereunder; and (v) the Lender shall have received, if requested, such other certificates and documentation as it may reasonably request with respect to the foregoing and opinions from Borrower's counsel updating opinions previously delivered.

SECTION 5.3. CONDITIONS PRECEDENT TO THE INITIAL GUARANTEED ADVANCE. The obligation of the Lender to make its initial Guaranteed Advance shall be subject to the fulfilment of: (i) the conditions precedent set forth in Sections 5.2 and 5.4; and (ii) the following conditions precedent:

(a) the Lender shall have received, in a form satisfactory to it: (i) copies certified by a senior officer of the Guarantor of its Charter Documents, the resolutions of its board of directors approving the Credit Facility Documents to which it is a party and all documents evidencing any necessary corporate action of the Guarantor with respect to the Credit Facility Documents to which it is a party; (ii) a certificate of good standing for the Guarantor; and (iii) a favourable opinion of Guarantor's counsel as to such matters as the Lender may require;

(b) the Guarantee shall have been executed and delivered to the Lender, the Security to be granted pursuant to the Guarantee shall have been created, and all registrations, filings or recordings necessary or desirable to preserve, protect or perfect the enforceability and priority of such Security shall have been completed, all in such form, content and manner as is satisfactory to the Lender;

(c) all of the representations and warranties of the Guarantor contained in Article 6 hereof shall be correct on and as of the date of the initial Guaranteed Advance as though made on and as of such date; and

(d) the Lender shall have received such other documents as it may reasonably request.

SECTION 5.4. CONDITIONS PRECEDENT TO ALL GUARANTEED ADVANCES. The obligation of the Lender to make a Guaranteed Advance and the right of the Borrower to deliver a Borrowing Notice in respect of a Guaranteed Advance shall be subject to the condition precedent that on the date of such Guaranteed Advance and after giving effect thereto and to the application of proceeds therefrom: (i) the representations and warranties of the Guarantor contained in Article 6 hereof are true and correct in every material respect on the date of the Guaranteed Advance as if made on and as at such date; (ii) no event has occurred and is continuing, or would result from such Guaranteed Advance, which constitutes or would, with the giving of notice or the passage of time, constitute an Event of Default; (iii) such Guaranteed Advance will not violate any applicable Law; (iv) there have been no amendments to the Charter Documents or authorizing resolutions of the Guarantor, subsequent to those delivered to the Lender pursuant to Section 5.3(a) which are material to the ability of the Guarantor to enter into this Agreement and any of the other Credit Facility Documents to which the Guarantor is a party and to perform its obligations hereunder and thereunder; and (v) the Lender shall have received, if requested, such other certificates and documentation as it may reasonably request with respect to the foregoing and opinions from Guarantor's counsel updating opinions previously delivered.

5

ARTICLE 6 - REPRESENTATIONS AND WARRANTIES

SECTION 6.1. REPRESENTATIONS AND WARRANTIES. The Borrower represents and warrants to the Lender as outlined in Schedule C hereto and the Guarantor represents and warrants to the Lender as outlined in Schedule D hereto.

ARTICLE 7 - COVENANTS OF THE BORROWER

SECTION 7.1. AFFIRMATIVE COVENANTS. Until the Obligations are paid and satisfied in full and this Agreement has been terminated, the Borrower shall (or, if applicable, shall cause the relevant action to take place):

(a) FINANCIAL REPORTING. Deliver to the Lender as soon as available and in any case within 45 days or 90 days after the end of each financial quarter or year, respectively, quarterly and audited annual financial statements of the Borrower,, prepared in accordance with generally accepted accounting principles and certified by a senior officer of the Borrower as being true and correct in all material respects;

(b) CORPORATE EXISTENCE. Preserve and maintain in full force and effect its corporate existence and all qualifications to carry on the Borrower's business;

(c) COMPLIANCE WITH LAWS, ETC. Comply with all applicable Laws, non-compliance with which could have a Material Adverse Effect;

(d) PAYMENT OF TAXES AND CLAIMS. Pay and discharge before the same shall become delinquent: (i) all Taxes, assessments and Official Body charges or levies; and (ii) all lawful claims which, if unpaid, might become a Lien upon or in respect of its business or the Borrower's assets or properties;

(e) VISITATION, INSPECTION, ETC. Permit the Lender or any representative thereof on reasonable notice to visit and inspect the Borrower's business, to examine the Borrower's records and make copies and take extracts therefrom, and to discuss the Borrower's affairs, finances and accounts with the officers of the Borrower at such reasonable times during normal office hours and as often as may be reasonably requested;

(f) NOTICE OF DEFAULT. Promptly notify the Lender in writing of any Default or Event of Default or any default, or event, condition or occurrence which with notice or lapse of time, or both, would constitute a default, under any agreement;

(g) MAINTAIN REGISTRATION OF PATENTS. File all such materials, documents and applications, and take all such actions, as are necessary to maintain the validity and proper registration of the Patents;

(h) MAINTAIN TITLE. Maintain and, as soon as reasonably practicable, defend and take, all action necessary or advisable at any time, and from time to time, to maintain, defend, exercise or renew its right, title and interest in and to all of its property and assets;

6

(i) PAY OBLIGATIONS TO LENDER AND PERFORM OTHER COVENANTS. Make full and timely payment of its obligations hereunder and duly comply with the terms and covenants contained in each of the Credit Facility Documents, all at the times and places and in the manner set forth therein, and at all times take all action necessary to maintain the Liens provided for under or pursuant to this Agreement and the Security Documents as valid and perfected first Liens on the property intended to be covered thereby (subject only to Permitted Encumbrances);

(j) NOTICES OF OFFICIAL BODY ACTION. Promptly notify the Lender in writing of any notice of any action by any Official Body or any action, suit, proceeding or investigation (or any basis therefor) pending, or to the knowledge of the Borrower threatened, against or affecting the Borrower before any Official Body, where the amount involved exceeds Euro 50,000 or the equivalent amount in another currency;

(k) DEBENTURE. Execute and deliver to the Lender the debenture contemplated in Section 4.1(c) hereof at or prior to the time of completion of the Reorganization;

(l) REORGANIZATION. Complete the Reorganization on or before February 1, 2001 on terms satisfactory to the Lender and furnish the Lender with such evidence of such completion as the Lender may require; and

(m) FURTHER ASSURANCES. At its cost and expense, upon request by the Lender, duly execute and deliver, or cause to be duly executed and delivered, to the Lender, such further instruments and do and cause to be done such other acts as may be necessary or proper in the reasonable opinion of the Lender to carry out more effectually the provisions and purposes of this Agreement and the other Credit Facility Documents.

SECTION 7.2. NEGATIVE COVENANTS. Until the Obligations are paid and satisfied in full and this Agreement has been terminated, the Borrower shall not (or, if applicable, shall not permit the relevant action to take place), unless the Lender otherwise consents in accordance with the provisions of this Agreement:

(a) LIENS. Create, incur, assume or suffer to exist any Lien on any of its property or assets now owned or hereafter acquired other than the Liens created prior to the entering into of this Agreement or Liens created by the Security and any Permitted Encumbrances;

(b) DEBT. Create, incur, assume or suffer to exist, contingently or otherwise, any Debt other than Debt created prior to the entering into of this Agreement or Debt created by this Agreement;

(c) CHANGE IN NATURE OF BUSINESS. Make or permit to exist any change, condition, event or occurrence in or with respect to the nature of its business which when taken individually with all other changes, conditions, events or occurrences could reasonably be expected to have a Material Adverse Effect;

(d) MERGERS, ETC. Enter into or agree to enter into any transaction or series of related transactions (whether by way of reconstruction, reorganization, consolidation, combination, amalgamation, merger, transfer, sale, lease, modification or otherwise),

7

other than in connection with the Reorganization, whereby: (i) all or substantially all of the Borrower's undertaking, property or assets will become the property of any other person or the continuing corporation resulting therefrom; (ii) all or substantially all of the AIDS Related Intellectual Property Rights will become the property of any other person; (iii) there would be permitted any change in the direct or indirect Control of the Borrower; or (iv) the corporate structure of the Borrower would be modified, changed, altered or amended in any manner;

(e) REORGANIZATION. Complete the Reorganization without taking such action and without executing and delivering to the Lender such agreements, conveyances, deeds and other documents and instruments as the Lender shall request in connection therewith for the purpose of preserving and protecting the Security, in each case forthwith upon request therefor by the Lender and in form and substance satisfactory to the Lender;

(f) DISTRIBUTIONS. Prior to payment in full of all Obligations hereunder, make any payment on account of a redemption or a distribution or return of capital (including, without limitation, cash dividends or any repayment of shareholder loans or distributions) to any shareholder or holder of securities;

(g) USE OF PROCEEDS. Other than repayments of advances to the Borrower by Aralis S.A. in the aggregate amount of FFr. 600,000 used by the Borrower for patent fees and registration and PCT extensions, use the proceeds of any Advance made available to the Borrower hereunder for repayment of any shareholder loans or short-term loans or redemption of any shareholder capital without the prior written consent of the Lender;

(h) SUBSIDIARIES. Create any Subsidiaries or transfer and/or assign any assets or operations to any Subsidiaries; and

(i) AGREEMENTS WITH RELATED PARTIES. Enter into any agreement or arrangement with any person with whom the Borrower does not deal at arm's-length, including any affiliate thereof.

SECTION 7.3. WARRANTS. As part of the Lender's compensation for the services to be performed by it under this Agreement, the Borrower agrees to issue and deliver to the Lender the following share purchase warrants and to execute and deliver warrant certificate(s) setting forth the terms and conditions of the share purchase warrants, which shall be substantially in the form of the warrant certificate attached as Schedule A to the underwriting agreement made between the Borrower and the Lender dated for reference July 24, 2000 (the "UNDERWRITING AGREEMENT"):

(a) WARRANTS TO BE ISSUED ON THE CLOSING DATE ENTITLING THE LENDER TO CONVERT AN AMOUNT EQUAL TO THE MAXIMUM AMOUNT OF EURO 1,300,000 INTO 10% OF THE COMMON SHARES OF THE BORROWER (THE "Common Shares"), CALCULATED ON A POST-REORGANIZATION AND FULLY DILUTED BASIS AND DETERMINED ON THE DATE OF THE COMPLETION OF THE REORGANIZATION (THE "Conversion Rate"), EXERCISABLE AT ANY TIME UP TO AND INCLUDING THE DATE THREE YEARS AFTER THE CLOSING DATE AT A PRICE EQUAL TO EURO 1,170,000/0.10N, WHERE "N" EQUALS THE NUMBER OF COMMON SHARES OUTSTANDING ON THE APPLICABLE CALCULATION DATE, CALCULATED ON THE DATE OF

8

THE COMPLETION OF THE REORGANIZATION ON A POST-REORGANIZATION AND
FULLY DILUTED BASIS (THE "Conversion Price"); AND

A.

(b) WARRANTS TO BE ISSUED ON THE CLOSING DATE ENTITLING THE LENDER TO CONVERT AN AMOUNT EQUAL TO THE RETAINER FEE OF EURO 90,000 UNDER THE UNDERWRITING AGREEMENT AND THE ARRANGEMENT FEE OF EURO 130,000 AND THE INTEREST UNDER THIS AGREEMENT INTO COMMON SHARES AT THE CONVERSION RATE, EXERCISABLE AT ANY TIME UP TO AND INCLUDING THE DATE THREE YEARS AFTER THE CLOSING DATE AT A PRICE EQUAL TO THE CONVERSION PRICE.

B.

It is understood by the Lender and the Borrower that the issuance and delivery of the share purchase warrants pursuant to Section 5.7 of the Underwriting Agreement satisfies the obligations of the Borrower to issue and deliver the warrants described in this Section 7.3.

ARTICLE 8 - EVENTS OF DEFAULT

SECTION 8.1. EVENTS OF DEFAULT. An event of default ("EVENT OF DEFAULT") shall have occurred and be continuing in respect of the Borrower if:

(a) FAILURE TO MAKE PAYMENTS. The Borrower shall fail to pay any principal, Interest, fees or other amounts hereunder when the same becomes due and payable and in the case of Interest, fees and other amounts, the failure shall remain unremedied for a period of three banking days following notice from the Lender to the Borrower;

(b) REPRESENTATIONS AND WARRANTIES INCORRECT. Any representation or warranty made by the Borrower or the Guarantor herein or in any other Credit Facility Document or any representation, warranty or certification made by the Borrower or the Guarantor (or any of their officers) in any certificate or other writing delivered in connection with any of the Credit Facility Documents, or any representation or warranty deemed to be made by the Borrower or the Guarantor provided herein or therein, shall prove to have been incorrect in any material respect when made or deemed to be made;

(c) FAILURE TO PERFORM NEGATIVE COVENANTS. The Borrower shall fail to observe any of the negative covenants or financial covenants contained in the Credit Facility Documents including, without limitation, in Section 7.2;

(d) FAILURE TO PERFORM OTHER COVENANTS. The Borrower shall fail to perform or observe any other term, covenant or agreement contained in any of the Credit Facility Documents and such failure shall remain unremedied for 15 days;

(e) FAILURE TO PAY DEBTS TO THIRD PARTIES. The Borrower shall fail to pay the principal of or premium or interest on any Debt which is outstanding in an aggregate principal amount in excess of Euro 50,000 (or the equivalent amount in any other currency)

9

when the same becomes due and payable and such failure shall remain unremedied for a period of five banking days;

(f) EVENT OF BANKRUPTCY. The Borrower shall commit or permit to exist any Event of Bankruptcy in respect of the Borrower;

(g) JUDGMENTS. Any judgment or order for the payment of money in excess of Euro 50,000 (or the equivalent amount in any other currency) in respect of the Borrower shall be rendered against the Borrower and enforcement proceedings shall have been commenced by any creditor upon such judgment or order and not stayed within 10 days;

(h) UNENFORCEABILITY. This Agreement or any Credit Facility Document shall, at any time after execution and delivery, and for any reason (other than in accordance with the respective terms), cease to be in full force and effect or shall be declared to be null and void, or the validity or enforceability of any thereof shall be contested by the Borrower or any other party thereto, or the Borrower or any other such party shall deny that it has any further liability or obligation thereunder;

(i) CHALLENGE TO SECURITY. Any of the Security shall at any time after the execution and delivery of the relevant Security Document and for any reason cease to constitute a valid and subsisting Lien (subject only to Permitted Encumbrances) in respect of the assets and properties referred to therein or cease to rank in priority or in the matter contemplated herein other than by reason of the act or omission of the Lender;

(j) MATERIAL ADVERSE EFFECT. There occurs any change, condition, event or occurrence which, when considered individually or together with all other changes, conditions, events or occurrences could reasonably be expected to have a Material Adverse Effect;

(k) FAILURE TO COMPLETE REORGANIZATION. The Borrower shall terminate, cancel or otherwise not complete the Reorganization on or before February 1, 2001; or

(l) FAILURE TO DELIVER DEBENTURE. The Borrower shall fail to execute and deliver to the Lender the debenture contemplated in Section 4.1(c) hereof at or prior to the time of completion of the Reorganization,

then in any such event, the Lender may by notice to the Borrower: (i) cancel all the obligations of the Lender in respect of the Credit Facility, whereupon no further Advances may be made; (ii) declare the Obligations under this Agreement to be forthwith due and payable, whereupon the same shall become and be forthwith due and payable; and (iii) take all steps and proceedings as, in the opinion of the Lender is necessary or desirable to preserve, protect or enforce the Security.

ARTICLE 9 - MISCELLANEOUS

SECTION 9.1. NOTICES, ETC. Except as otherwise expressly provided herein, all notices, requests, demands, directions and communications by one party to the other shall be sent by hand

10

delivery or registered mail, and shall be effective when hand delivered or when delivered by the relevant postal service, as the case may be. All such notices shall be addressed to the President of the notified party at its address given on the signature page of this Agreement, or in accordance with any unrevoked written direction from such party to the other party in accordance with this
Section 9.1.

SECTION 9.2. REIMBURSEMENT FOR CERTAIN EXPENSES. (1) The Borrower shall pay or cause to be paid and shall indemnify and save the Lender harmless against liability for the payment of all reasonable out-of-pocket expenses, including without limitation counsel or compliance review fees and expenses and disbursements incurred by the Lender in connection with, among other things, the preparation or review of documentation pursuant to this Agreement, on-site inspections by the Lender or the enforcement or preservation of rights under this Agreement or the other Credit Facility Documents or any agreement or instrument contemplated hereby or thereby, including such expenses as may be incurred by the Lender in the collection of the Obligations or any litigation, proceeding or dispute in any way relating to the Obligations or the Credit Facility Documents.

(2) The parties hereto may agree in writing to include any expenses as an Outstanding Amount, with Interest to be paid thereon in accordance with
Section 3.2 hereof and to be repaid in accordance with Section 3.1 hereof.

SECTION 9.3. NO WAIVER; REMEDIES. No failure on the part of the Lender or the Borrower to exercise, and no delay in exercising, any right under any of the Credit Facility Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any right under any of the Credit Facility Documents preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law.

SECTION 9.4. TAXES, COSTS, ETC. All payments by the Borrower under this Agreement and the other Credit Facility Documents shall be made free and clear of, and without deduction or withholding for, Taxes unless such Taxes are required by Law to be deducted or withheld. If the Borrower shall be required by Law to deduct or withhold any Taxes from or in respect of any sum payable under this Agreement or the other Credit Facility Documents: (i) the sum payable shall be increased as may be necessary so that after making all required deductions or withholdings applicable to additional amounts paid under this Section 9.4, the Lender receives an amount equal to the sum it would have received if no deduction or withholding had been made; (ii) the Borrower shall make such deductions or withholdings; and (iii) the Borrower shall pay the full amount deducted or withheld to the relevant taxation authority or other authority in accordance with applicable Law.

SECTION 9.5. RIGHT OF SET-OFF. Upon the occurrence and during the continuance of any Event of Default, the Lender shall have the right, to the fullest extent permitted by Law, to set off and apply any and all deposits at any time held and other indebtedness at any time owing by the Lender to or for the credit or the account of the Borrower, against any and all of the obligations of the Borrower now or hereafter existing under any of the Credit Facility Documents.

SECTION 9.6. JUDGMENT CURRENCY. If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder to the Lender from Euros (the "ORIGINAL CURRENCY") into the Judgment Currency, the parties hereto agree that the rate of exchange used shall be that at which in accordance with normal banking procedures the Lender could purchase the

11

Original Currency with the Judgment Currency on the banking day preceding that on which final judgment is paid or satisfied.

SECTION 9.7. GOVERNING LAW. The Credit Facility Documents shall be governed by, and construed in accordance with, the laws of Switzerland and shall be treated in all respects as Swiss contracts without giving effect to applicable principles of conflicts of law to the extent that the application of the laws of another jurisdiction would be required thereby.

SECTION 9.8. CONSENT TO JURISDICTION. (1) Each of the parties hereby irrevocably attorns to the non-exclusive jurisdiction of the Courts of Geneva (Switzerland) in any action or proceeding arising out of or relating to this Agreement, or any other Credit Facility Document. The Borrower agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

(2) Nothing in this Section 9.8 shall affect the right of the Lender to serve legal process in any other manner permitted by Law or affect the right of the Lender to bring any action or proceeding against the Borrower or its property in the courts of other jurisdictions.

SECTION 9.9. ENGLISH VERSION. The parties hereby represent, warrant, acknowledge and agree that: (i) they have agreed that this Agreement be drawn up in the English language; and (ii) the English version of this Agreement shall govern for all purposes.

SECTION 9.10. SUCCESSORS AND ASSIGNS. The Borrower shall not have the right to assign its rights hereunder or any interest herein without the prior written consent of the Lender, which consent may be arbitrarily withheld.

SECTION 9.11. SEVERABILITY. If one or more provisions of this Agreement and/or a Security Document be or become invalid, or unenforceable in whole or in part in any jurisdiction, the validity of the remaining provisions of this Agreement and/or a Security Document shall not be affected. The parties hereto undertake to replace any such invalid provision without delay with a valid provision which as nearly as possible duplicates the economic intent of the invalid provision.

SECTION 9.12. COUNTERPARTS. This Agreement may be executed in counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.

THE LENDER

MFC MERCHANT BANK S.A.

Kasernenstrasse 1
9100 Herisau AR

Switzerland                            Per: /s/ Claudio Morandi
                                            ----------------------------------
                                             Authorized Signing Officer

                                       Per: /s/ Peter Hediger
                                            ----------------------------------
                                             Authorized Signing Officer

12

THE BORROWER

MYMETICS CORPORATION

50 - 52 Avenue Chanoine Cartellier
69230 Saint-Genis

Laval, France                           Per: /s/ Michael K. Allio
                                            ----------------------------------
                                              Authorized Signing Officer

THE GUARANTOR

MFC BANCORP LTD.

Floor 21, Millennium Tower
Handelskai 94-96

A-1200 Vienna, Austria                  Per: /s/ [illegible]
                                            ----------------------------------
                                              Authorized Signing Officer

13

SCHEDULE A

LIST OF PATENTS OF BORROWER

APPLICATION NO.                             APPLICATION DATE                          PUBLICATION NO.
---------------                             ----------------                          ---------------

97/14387                                    November 17, 1997                         2711011

PCT/FR98/02447                              November 17, 1998                         W099/25377

99/06528                                    May 21, 1999                              N/A

PCT/FR00/01399                              May 22, 2000                              W099/25377

01/10910                                    August 17, 2001                           N/A

01/15423                                    November 29, 2001                         N/A

01/15424                                    November 29, 2001                         N/A

01/16290                                    December 17, 2001                         N/A

US 60/340492                                December 18, 2001                         N/A

N/A                                         N/A                                       EP0453473 B1

US 09/570921                                May 15, 2000                              US 6,455,265

US 09/979271                                January 17, 2002                          N/A

US 60/386754                                June 10, 2002                             N/A

US 10/198938                                July 22, 2002                             N/A

US 60/413919                                July 27, 2002                             N/A

US 10/222976                                August 19, 2002                           N/A

US 60/421049                                September 27, 2002                        N/A

Re: Polypeptide inhibitors                  November 27, 2002                         N/A

Re: Short peptides as potent inhibitors     December 4, 2002                          N/A


SCHEDULE B

DEFINITIONS

"AIDS RELATED INTELLECTUAL PROPERTY RIGHTS" means the Patents and any existing or future related AIDS applications, interests, intellectual property rights, research, studies and technology deriving therefrom or from the AIDS related research of the Borrower;

"BBA" means the British Bankers' Association;

"BBA LIBOR" means the one month Euro London Inter-Bank Offered Rate fixed daily by the BBA;

"CHARTER DOCUMENTS" means constating documents and by-laws, and all amendments thereto;

"CLOSING DATE" means two banking days following satisfaction by the Borrower or waiver by the Lender of all conditions to Advance set out in the Credit Documents or such other date as may be agreed upon by the parties;

"CONSENT" means any permit, license, approval, consent, order, right, certificate, judgment, writ, injunction, award, determination, direction, decree, authorization, franchise, privilege, grant, waiver, exemption and other concession or by-law, rule or regulation;

"CONTROL" over a person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities or other equity interest, representation on its board of directors or body performing similar functions, by contract or otherwise. The terms "CONTROLLING" and "CONTROLLED" will have corollary meanings;

"CREDIT FACILITY DOCUMENTS" means this Agreement, the Security Documents and the Information Documents and all other documents to be executed and delivered to the Lender or by the Borrower or the Guarantor thereunder;

"DEBT" of any person means: (i) all indebtedness of such person for and in respect of borrowed money, including obligations with respect to bankers' acceptances, letters of credit and letters of guarantee; (ii) all indebtedness of such person for the deferred purchase price of property or services represented by a note or other evidence of indebtedness or other security; (iii) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired by such person (even though the rights or remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property); (iv) all obligations under leases which, in accordance with GAAP (or accounting principles generally accepted in the jurisdiction of incorporation or organization of such person), are recorded as capital leases in respect of which such person is liable as lessee; (v) the aggregate amount at which any shares in the capital of such person which are redeemable or retractable at the option of the holder thereof may be retracted or redeemed; and (vi) all Debt Guaranteed by such person; provided that


obligations related to any grant or subsidy which is to be reimbursed on a revenue or profit success basis are not considered Debt under this definition;

"DEBT GUARANTEED" by any person means the maximum amount which may be outstanding at any time of all Debt of the kind referred to in (i) through (v) or the definition of Debt which is directly or indirectly guaranteed by such person or such person agreed (contingently or otherwise) to purchase or otherwise acquire, or in respect of which such person is otherwise assured a creditor against loss by means of an indemnity, security or bond;

"EVENT OF BANKRUPTCY" means, in respect of any person, that such person shall generally not pay its Debts as such Debts become due, or shall admit in writing its inability to pay its Debts generally as they become due, or shall make a general assignment for the benefit of creditors; or any proceeding shall be instituted by or against any such person seeking to adjudicate it a bankrupt or insolvent or seeking liquidation, winding-up, a reorganization, arrangement, adjustment, protection, relief or a composition of it or its Debts under any law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking the entry of an order for relief or for the appointment of a receiver, trustee, custodian or other similar official for it or for any substantial part of its property and, in the case of any such proceeding instituted against such person (but not instituted by such person), either such proceeding shall remain undismissed or unstayed for a period of 30 days or any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against such person or for the appointment of a receiver, trustee, custodian or other similar official for such person or for any substantial part of its property) shall occur; or such person shall take any action to authorize any of the actions set forth above;

"GUARANTEE" means a guarantee to be provided by the Guarantor, in form and content satisfactory to the Lender, in respect of, inter alia, the Borrower's Obligations to the Lender pursuant to this Agreement;

"GUARANTEED ADVANCE" means any Advance the effect of which will be to cause the Outstanding Amount to exceed Euro 2,000,000;

"INFORMATION DOCUMENTS" means, collectively, at any time and in any form, information provided by the Borrower or on behalf of the Borrower, or by the Guarantor or on behalf of the Guarantor, to the Lender in writing in respect of the Borrower's business or the Guarantor's business, including, without limitation, all certificates, the financial statements of the Borrower or the Guarantor and all materials reasonably requested by the Lender for the purpose, inter alia, of providing such information to prospective assignees, all as from time to time amended, supplemented or replaced;

"INTEREST" means the interest accrued on Advances outstanding from time to time at the Interest Rate compounded monthly not in advance, and payable, in arrears, on the Interest Payment Dates;

"INTEREST PERIODS" means, collectively, periods of one month, each subsequent period commencing upon the expiry of the prior period, and "INTEREST PERIOD" means any one such period. Interest shall be calculated on the basis of a year of 360 days and the actual number of days (including the first day but excluding the last day) occurring in the period for which such Interest is payable;

"INTEREST RATE" means, at any time, Libor plus 4% per annum. With each successive Interest Period the Libor shall be reset on the second banking day prior to the commencement of the Interest

B-2

Period and there shall be a corresponding change in the rate of interest payable under this Agreement without the necessity of prior notice thereof to the Borrower or any other person;

"JUDGMENT CURRENCY" means the currency in which a court of competent jurisdiction may render judgment in connection with any litigation relating to the repayment of any amounts under this Agreement;

"LAW" means any law (including common law and equity), constitution, statute, order, treaty, regulation, rule, ordinance, order, injunction, writ, judgment, determination, decree or award of any Official Body;

"LIBOR" means BBA Libor or, if no such published rate is then available, the rate of interest calculated by the Lender, as being the arithmetic average
(rounded up, if necessary, to the nearest full multiple of 1/16 of one percent)
at which, in accordance with its normal practice, it would be prepared to offer to leading banks in the London interbank market for delivery on the first day of the particular Interest Period and for a period equal to such Interest Period based on the number of days comprised therein, deposits in Euros of amounts comparable to the Principal Sum or the balance outstanding thereof during such Interest Period, at or prior to 11:00 a.m. London, England, local time on the second banking day prior to an Advance and thereafter on the second banking day prior to the commencement of each subsequent Interest Period;

"LIEN" means any mortgage, pledge, lien, hypothecation, security interest or other encumbrance or charge (whether fixed, floating or otherwise) or title retention, any right of set-off (arising otherwise than by operation of Law) and any deposit of monies under any agreement or arrangement whereby such monies may be withdrawn only upon the fulfillment of any condition as to the discharge of any other indebtedness or other obligation to any creditor, or any right of or arrangement of any kind with any creditor to have its claim satisfied prior to other creditors with or from the proceeds of any properties, assets or revenues of any kind now owned or later acquired;

"MATERIAL ADVERSE EFFECT" means: (i) a material adverse effect on the property or assets of the Borrower and its Subsidiaries taken as a whole; (ii) a material adverse effect on the condition or prospects, financial or otherwise, of the Borrower and its Subsidiaries taken as a whole; (iii) a material adverse effect on the ability of the Borrower to perform and comply with this Agreement or to pay or perform any of the Obligations; (iv) a material adverse effect on the priority, effectiveness or enforceability of the Security; or (v) a material adverse effect on the condition or prospects, financial or otherwise, of the Borrower;

"OBLIGATIONS" means all obligations, liabilities and indebtedness of the Borrower to the Lender with respect to the principal of and Interest on Advances and the payment or performance of all other obligations, liabilities and indebtedness of the Borrower to the Lender under this Agreement or arising under and pursuant to any one or more of the Credit Facility Documents or with respect to the Advances and all fees, costs, expenses and indemnity obligations thereunder;

"OFFICIAL BODY" means any government or political subdivision or any agency (including, without limitation, any licensing or regulatory agency), body, office, authority, bureau, central bank, monetary authority, commission, department or instrumentality thereof, or any court, board, tribunal, grand jury or arbitrator, commission or instrumentality thereof, whether foreign or domestic and, when used in the context of a particular person having jurisdiction over such person;

B-3

"OUTSTANDING AMOUNT" means, in respect of the Credit Facility, on any day, an amount calculated and expressed in Euros equal to the aggregate principal amount of all Advances made by the Lender under the Credit Facility;

"PATENTS" means the patents set forth in Schedule A hereto and any existing or future related AIDS applications deriving therefrom or from the AIDS related research of the Borrower;

"PERMITTED ENCUMBRANCES" means, in respect of the Borrower, from time to time, any Lien not intentionally created by the Borrower and covering an asset which the Lender determines (acting reasonably) not to be required for or integral to the operation of the business of the Borrower or the effectiveness or value of the Security, and in respect of which Lien either (i) the same is discharged or
(ii) the Borrower provides the Lender such substituted security as the Lender shall consider satisfactory, in either (i) or (ii) above within 15 days of written notice from the Lender to the Borrower;

"REORGANIZATION" means a reorganization of the Borrower contemplated in the Underwriting Agreement pursuant to which the Borrower may directly or indirectly transfer and/or assign to a new company or an existing "shell" company, in one or a series of related transactions, among other things, the following: (i) the Borrower's rights and obligations under the Underwriting Agreement; (ii) the AIDS Related Intellectual Property Rights; and (iii) certain outsourcing contracts;

"SECURITY" means the security given to the Lender, at any time and from time to time to secure the Obligations, including, without limitation, the security referred to in Section 4.1 of this Agreement;

"SECURITY DOCUMENTS" means the documents referred to in Section 4.1 of this Agreement and the agreements, instruments and documents delivered from time to time to the Lender by the Borrower, the Guarantor or any other person, for the purpose of establishing, perfecting, preserving and protecting the Security; and "SECURITY DOCUMENT" means any one of them as the context prescribes or requires;

"SUBSIDIARY" means, at any time, as to any person, any corporation, partnership or other entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at such time directly or indirectly owned by such a person; and

"TAXES" means any and all present or future taxes (including, without limitation, all stamp, documentary, excise or property taxes), levies, imposts, deductions, charges or withholdings and liabilities with respect thereto.

B-4

SCHEDULE C

REPRESENTATIONS AND WARRANTIES OF THE BORROWER

(a) ORGANIZATION AND CORPORATE POWER. The Borrower has been duly incorporated and organized and is validly subsisting and in good standing under the laws of its jurisdiction and has full corporate right, power and authority to enter into and perform its obligations under each of the Credit Facility Documents to which it is or shall be a party and has full corporate right, power and authority to own and operate its properties and to carry on its business;

(b) CONFLICT WITH OTHER INSTRUMENTS. The execution and delivery by the Borrower of each of the Credit Facility Documents and the performance by the Borrower of its obligations thereunder, including, without limitation, the performance of the terms of the Security Documents, do not and will not: (i) conflict with or result in a breach of any of the terms, conditions or provisions of: (A) the Charter Documents of the Borrower; (B) any Law applicable to or binding on the Borrower; or (C) any contractual restriction binding on or affecting the Borrower or its properties the breach of which would have a Material Adverse Effect; or (ii) result in, or require or permit: (A) the imposition of any Lien on or with respect to the properties now owned or hereafter acquired by the Borrower; or (B) the acceleration of the maturity of any Debt of the Borrower, under any contractual provision binding on or affecting the Borrower;

(c) CONSENTS, OFFICIAL BODY APPROVALS. The execution and delivery of each of the Credit Facility Documents and the performance by the Borrower of its obligations thereunder have been duly authorized by all necessary action on the part of the Borrower, and no Consent under any applicable Law and no registration, qualification, designation, declaration or filing with any Official Body having jurisdiction over the Borrower is or was necessary therefor. The Borrower possesses all Consents, in full force and effect, under any applicable Law which are necessary in connection with the operation of its business, the non-possession of which could reasonably be expected to have a Material Adverse Effect;

(d) EXECUTION OF BINDING OBLIGATION. The Agreement has been duly executed and delivered by the Borrower, and the Agreement constitutes, and the remaining Credit Facility Documents when duly executed by the Borrower pursuant to the Agreement and delivered for value will constitute, legal, valid and binding obligations of the Borrower, enforceable against it in accordance with their respective terms; against it in accordance with their respective terms;

(e) NO LITIGATION. There are no actions, suits or proceedings pending or, to the knowledge of the Borrower, after due enquiry, threatened against or affecting the Borrower

C-2

(nor, to the knowledge of the Borrower, after due enquiry, any basis therefor) before any Official Body having jurisdiction over the Borrower which purport to or do challenge the validity or propriety of the transactions contemplated by the Credit Facility Documents or the documents, instruments or agreements executed and delivered in connection therewith or related thereto, which if adversely determined could reasonably be expected to have a Material Adverse Effect;

(f) NO DEFAULTS. The Borrower is not in breach of or in default under, in any respect: (i) its Charter Documents; (ii) any applicable Law; (iii) any contract or agreement binding on or affecting it or its property or assets (including, without limitation, the Credit Facility Documents); (iv) any material indenture, mortgage, deed of trust; or
(v) any writ, judgment, determination or award binding on it or affecting it where such breach or defect could, in the case of (ii),
(iii), (iv) or (v) above, have a Material Adverse Effect;

(g) INFORMATION DOCUMENTS. The information contained in the Information Documents is true and accurate in all material respects and does not contain any untrue statement of a material fact. The Information Documents do not omit to state any fact necessary in order to make any of the information contained in the Information Documents not misleading in all material respects;

(h) MATERIAL CHANGES. No changes occurred or are continuing in respect of the financial condition of the Borrower from that set out in the most recently delivered financial statements of the Borrower which could have a Material Adverse Effect; and no Law, regulation, rule or policy, or any change therein, has been enacted or proposed prior to the Closing Date which may have a Material Adverse Effect;

(i) PATENTS. To the best of the Corporation's knowledge, all necessary patent applications in respect of the Patents have been duly filed and the Corporation has good and valid title to the patents, and the Corporation did not disclose to the public the existence of the subject matter of any of the patents prior to the date of filing of each of the Patents;

(j) TITLE TO ASSETS. The Borrower has good and marketable title to all of its properties and assets, and the Security will constitute a first charge on the legal and beneficial interests of the Borrower in and to all such properties and assets, subject only to such Liens as are described in Section 7.2(a) of the Agreement and the Permitted Encumbrances;

(k) ABSENCE OF CHANGES. Since the date of the most recently delivered financial statements of the Borrower, the Borrower has carried on its business, operations and affairs only in the ordinary and normal course consistent with past practice; and

(l) SUBSIDIARIES. The Borrower has no Subsidiaries.

C-3

SCHEDULE D

REPRESENTATIONS AND WARRANTIES OF THE GUARANTOR

(a) ORGANIZATION AND CORPORATE POWER. The Guarantor has been duly incorporated and organized and is validly subsisting and in good standing under the laws of its jurisdiction and has full corporate right, power and authority to enter into and perform its obligations under each of the Credit Facility Documents to which it is or shall be a party and has full corporate right, power and authority to own and operate its properties and to carry on its business;

(b) CONFLICT WITH OTHER INSTRUMENTS. The execution and delivery by the Guarantor of the Credit Facility Documents to which it is a party and the performance by each of its obligations thereunder, including, without limitation, the performance of the terms of the Security Documents, do not and will not: (i) conflict with or result in a breach of any of the terms, conditions or provisions of: (A) its Charter Documents; (B) any Law applicable to or binding on the Guarantor; or
(C) any contractual restriction binding on or affecting the Guarantor or its property the breach of which would have a Material Adverse Effect; or (ii) result in, or require or permit: (A) the imposition of any Lien on or with respect to the properties now owned or hereafter acquired by the Guarantor; or (B) the acceleration of the maturity of any Debt of the Guarantor, under any contractual provision binding on or affecting the Guarantor which would have a Material Adverse Effect;

(c) CONSENTS, OFFICIAL BODY APPROVALS. The execution and delivery of each of the Credit Facility Documents to which it is a party and the performance by the Guarantor of its obligations thereunder have been duly authorized by all necessary action on the part of the Guarantor, and no Consent under any applicable Law and no registration, qualification, designation, declaration or filing with any Official Body having jurisdiction over the Guarantor is or was necessary therefor; and

(d) EXECUTION OF BINDING OBLIGATION. The Agreement has been duly executed and delivered by the Guarantor, and the Agreement constitutes, and the remaining Credit Facility Documents to which the Guarantor is a party when duly executed by the Guarantor pursuant to the Agreement and delivered for value will constitute, legal, valid and binding obligations of the Guarantor, enforceable against it in accordance with their respective terms.


Exhibit 10.13

GUARANTEE

THIS DEED OF GUARANTEE dated for reference the 28th day of February, 2003, by MFC BANCORP LTD., a corporation organized under the laws of the Yukon Territory (the "Guarantor"), having an office at Suite 300 - 204 Black Street, Whitehorse, Yukon, Canada Y1A 2M9, and delivered to MFC MERCHANT BANK S.A., a bank organized under the laws of Switzerland, having an office at Kasernenstrasse 1, 9100 Herisau AR, Switzerland (the "Lender"), witnesses that whereas:

A. Mymetics Corporation, a corporation organized under the laws of the State of Delaware, having an office at 50-52 Avenue Chanoine Cartellier, 69230 Saint-Genis-Laval, France (the "Borrower"), entered into a credit facility agreement with the Lender dated for reference the 27th day of July, 2000, as amended by amendment agreements dated for reference August 13, 2001 and February 27, 2002 (the "Original Credit Agreement");

B. The Guarantor, having a direct or indirect interest in the financial transactions between the Lender and the Borrower, wishes the Lender to carry on or continue to carry on business with the Borrower;

C. The Lender, the Borrower and the Guarantor entered into a third amendment agreement dated for reference February 28, 2003 (the "Third Amendment") and subsequently an amended and restated credit facility agreement dated for reference February 28, 2003, in the place and stead of the Original Credit Agreement as amended by the Third Amendment (as the same may be amended, extended, renewed or replaced from time to time, the "Credit Agreement");

D. The Guarantor has agreed, pursuant to the terms and conditions of this guarantee, to guarantee unconditionally a portion of the indebtedness of the Borrower to the Lender, which now exists or which from time to time hereafter exists under the Credit Agreement, limited to the principal amount of such indebtedness in excess of Euro 2,000,000 and all interest thereon (the "Guaranteed Indebtedness"); and

E. The Guarantor is a party to and acknowledges having received a copy of the Credit Agreement,

NOW THEREFORE in consideration of the premises hereinafter set forth and for other good and valuable consideration given by the Lender to the Guarantor, the receipt and sufficiency of which is hereby acknowledged by the Guarantor, the Guarantor agrees with the Lender as follows:

1. INTERPRETATION

Terms used as defined terms herein and not otherwise defined have the meanings given to them in the Credit Agreement.


2. REPRESENTATIONS AND WARRANTIES

The Guarantor makes the following representations and warranties which shall be continuing representations and warranties for so long as any Guaranteed Indebtedness shall remain unpaid:

2.1 RIGHTS

The Guarantor has full power and authority to make and carry out this guarantee.

2.2 GUARANTEE VALID

This guarantee is a legal, valid and binding obligation of the Guarantor enforceable in accordance with its terms. If the Guarantor is a corporation, the directors of the Guarantor have passed a resolution which is now in effect and which confirms that the directors of the Guarantor are of the opinion that the giving of this guarantee is in the best interests of the Guarantor.

2.3 NO CONFLICT

The execution and delivery of this guarantee does not, and the performance of this guarantee, and any indenture or undertaking to which the Guarantor is a party or by which it or any of its property is or may be bound or affected, does not, and will not, cause any security interest, lien or other encumbrance to be created or imposed upon any such property.

2.4 LITIGATION

There is no litigation or other proceeding pending or, to the knowledge of the Guarantor, threatened against, or affecting, it or its properties which, if determined adversely to the Guarantor, would have a materially adverse effect on the financial condition, properties or operations of the Guarantor, and the Guarantor is not in default with respect to any order, writ, injunction, decree or demand of any court or other governmental or regulatory authority.

2.5 ACCURACY OF RECITALS

Recital paragraphs A, B, C, D and E hereof are accurate, form part of this guarantee and are contractual in nature.

2.6 FINANCIAL BENEFIT

The Guarantor hereby acknowledges and warrants that it has derived or expects to derive a financial advantage from each and every loan, advance, other extension of credit or release of funds under the Credit Agreement, and from each and every renewal, extension, release of collateral or forbearance from pursuit or other relinquishment of legal rights, made or granted or to be made or granted by the Lender to the Borrower.


2.7 SOLVENCY

The Guarantor is not, and after the granting of this guarantee will not be, insolvent.

3. GUARANTEE

3.1 GUARANTEE

The Guarantor unconditionally guarantees and promises to pay or cause to be paid to or to the order of the Lender, on demand, the Guaranteed Indebtedness of the Borrower to the Lender in accordance with the provisions of this guarantee with interest thereon from the date of demand for payment until the date of payment at the rate of interest payable thereon by the Borrower pursuant to the Credit Agreement. The Guarantor covenants, agrees, represents and warrants as follows:

(a) the Guarantor acknowledges that the Lender may demand payment under this guarantee for and on behalf of the Lender and enter into renewals, compromises or extensions; and

(b) the Guarantor acknowledges that all sums due, accruing due or arising due under this guarantee shall be secured by the Credit Facility Documents granted by the Guarantor to and in favour of the Lender and the Guarantor shall not dispute the Lender's entitlement or authority to exercise its powers thereunder.

3.2 CONTINUING GUARANTEE

This is a continuing guarantee and this guarantee shall not be determined or affected by, and the Lender's rights hereunder shall not be prejudiced by, any of the death, the bankruptcy or reorganization, the loss or diminution of capacity or winding-up or dissolution of the Borrower, the Guarantor or any person or persons who is or are or shall become responsible in any way for payment of the Guaranteed Indebtedness or any part thereof, or by any change in the name, structure, memorandum, letters patent, articles, organization or management of the Borrower or the Guarantor. If the Borrower shall amalgamate or otherwise merge with one or more other corporations, this guarantee shall continue and apply to all Guaranteed Indebtedness owing to the Lender by the corporation continuing from amalgamation or merger.

3.3 NATURE OF GUARANTEE

The liability of the Guarantor hereunder is independent of the obligations of the Borrower and a separate action or separate actions may be brought and prosecuted against the Guarantor whether such action is brought or prosecuted against the Borrower or whether the Borrower is joined in any such action or actions. The liability of the Guarantor hereunder is independent of and not in consideration of or contingent upon the liability of any other person (including any other party comprising the Guarantor if more than one party executes this instrument as Guarantor) under this or any similar instrument and the


release of, or cancellation by, any signer of this or any similar instrument shall not act to release or otherwise affect the liability of the Guarantor hereunder. The Guarantor waives the benefit of any statute of limitations affecting its liability hereunder or the enforcement thereof to the fullest extent permitted by law. Any part payment by the Borrower or other circumstance which operates to toll any statute of limitations as to the Borrower shall operate to toll any statute of limitations as to the Guarantor.

3.4 GUARANTOR OBLIGATIONS

For greater certainty it is hereby declared and acknowledged by the Guarantor to be the intention of the Lender, the Borrower and the Guarantor that this guarantee shall be construed so as to impose the like obligation upon the Guarantor as if the Guarantor had covenanted as principal, jointly and severally with the Borrower, to be directly responsible for and to pay the Guaranteed Indebtedness; provided that nothing in this section 3.4 characterizing the liability of the Guarantor as that of a principal debtor is intended nor should be interpreted to confer on the Guarantor any right, benefit or advantage that the Guarantor would not otherwise have in the absence of this section 3.4.

3.5 TERMS OF PAYMENT

In implementation of the foregoing,

(a) the Guarantor guarantees that the Guaranteed Indebtedness will be paid to the Lender strictly in accordance with the terms and provisions of any agreement, express or implied, which has been made or may hereafter be made by the Borrower, regardless of any law, regulation or decree, now or hereafter in effect, which might in any manner affect any of the terms or provisions of any such agreement or rights of the Lender as against the Borrower with respect to any of the Guaranteed Indebtedness or cause or permit to be invoked, any alteration in the time, amount or manner of payment by the Borrower of any of the Guaranteed Indebtedness; and

(b) in each instance when the Borrower shall have agreed, relative to any of the Guaranteed Indebtedness hereby guaranteed, to pay or provide the Lender with any amount of money, if such amount is not actually paid or provided as and when agreed or within such time as the Lender deems reasonable, the Guarantor will, upon request, and as the Lender may elect, pay or provide the amount in the exact currency and place as agreed by the Borrower.

All such payments shall be made without set-off or counterclaim and free and clear of, and without deduction for or on account of, any present or future income, stamp or other taxes, levies, imposts, duties, charges, fees, deductions, withholdings or restrictions or conditions of any nature whatsoever now or hereafter imposed, levied, calculated, withheld or assessed by any country or any political subdivision or taxing authority thereof.


3.6 LENDER'S RECORDS CONCLUSIVE

The statement in writing of an officer of the Lender given from time to time of the amount of the Guaranteed Indebtedness existing at the relevant time shall be binding on and conclusive against the Guarantor.

3.7 AUTHORIZATION

The Guarantor authorizes the Lender without notice or demand and without affecting the liability of the Guarantor hereunder, from time to time, to do any one or more of the following:

(a) renew, compromise, extend, accelerate or otherwise change the time for payment of, or otherwise change the terms of, the Guaranteed Indebtedness or any part thereof, including increasing or decreasing the rate of interest payable thereon by the Borrower;

(b) take and hold security for the payment of this guarantee or the Guaranteed Indebtedness or any part thereof, and exchange, enforce, waive or release any such security and apply any such security and direct the order or manner of sale thereof, all as the Lender in its discretion may determine;

(c) release or substitute any one or more endorsers, guarantors and/or other obligors of this guarantee or the Guaranteed Indebtedness or any part thereof;

(d) grant any other indulgence to the Borrower, the Guarantor or any other person in respect of the Guaranteed Indebtedness or any other part thereof, or any instrument representing or relating thereto and to compromise and settle with all or any of such persons as the Lender shall see fit; and

(e) otherwise amend, supplement, modify, vary or otherwise change any of the terms or conditions of the Credit Agreement or any of the Credit Facility Documents in any manner whatsoever,

provided that any such action that would require the amendment of an agreement or document to which the Guarantor is a party will require the execution and delivery by the Guarantor of an instrument in writing providing for such amendment. None of the foregoing actions set out in subsections 3.7(a) through (e) hereof shall in any way lessen, limit or otherwise affect the obligations or liability of the Guarantor under this guarantee, regardless of whether any such action has the effect of increasing, expanding or otherwise affecting the nature, effect, term or scope of the Guaranteed Indebtedness hereunder.

3.8 SECURITY

This guarantee and the agreements of the Guarantor herein contained shall take effect and shall be and are hereby declared to be binding upon the Guarantor notwithstanding any defect in or omission from any securities instrument under which the Lender has taken or may hereafter take any security for the Guaranteed Indebtedness or any part thereof,

or


any non-registration or non-filing or defective registration or filing thereof and notwithstanding any failure or diminution of the security intended to be created thereby. The Guarantor hereby further agrees:

(a) that neither any amendment to, release of, nor any loss of or in respect of, any security received by the Lender from the Borrower or anyone else, whether occasioned through the fault of the Lender or otherwise shall discharge (pro tanto or otherwise), limit or diminish the liability of the Guarantor under this guarantee; and

(b) that the Lender may take securities from and give the same up to, may abstain from taking securities from or from perfecting securities of, may accept compositions from, and may otherwise deal with, the Borrower and all other persons (including the Guarantor) as the Lender may see fit.

3.9 WAIVERS

         The Guarantor waives the right to require the Lender to proceed against
         the Borrower or any other person, to proceed against or to endeavour to
         enforce or exhaust any security held from the Borrower or anyone else,
         or to pursue any other remedy in the Lender's power whatsoever and the
         Guarantor waives any right the Guarantor may have to require the
         property of the Borrower to be applied to the discharge of the
         Guaranteed Indebtedness before being entitled to payment of the
         Guaranteed Indebtedness from the Guarantor. The Lender may, at its
         election, exercise any right or remedy it may have against the Borrower
         or any security held by the Lender, including, without limitation, the
         right to foreclosure upon any such security or to exercise any power of
         sale without affecting or impairing in any way the liability of the
         Guarantor hereunder, and the Guarantor waives any defence arising out
         of absence, impairment or loss of any right of reimbursement,
         contribution or subrogation or any other right or remedy of the
         Guarantor against the Borrower, or any such security, whether resulting
         from such election or exercise of rights or remedies by the Lender, or
         otherwise. The Guarantor waives any defence arising by reason of the
         cessation from any cause whatsoever of the liability, either in whole
         or in part, of the Borrower to the Lender for the Guaranteed
         Indebtedness or any part thereof. Without limiting any of the foregoing
         or section 3.10, the Guarantor also waives all right to question in any
         way the Lender's present or future method of dealing with the Borrower
         or any person or persons now or hereafter liable to the Lender for the
         Guaranteed Indebtedness or any part thereof, or with any security now
         or hereafter held by the Lender or with any property covered by such
         security, including any rights under so-called "seize or sue"
         legislation.

3.10     ADDITIONAL WAIVERS AND DEFERRAL OF SUBROGATION

         Until all of the Guaranteed Indebtedness has been paid in full,
         including such part thereof as shall exceed the limit, if any, of
         liability of the Guarantor hereunder:

         (a) the Guarantor shall have no right of subrogation to, and waives any
         right to enforce, any remedy which the Lender now has or may hereafter
         have against the Borrower in respect of the Guaranteed Indebtedness;
         and

         (b) the Guarantor waives any benefit of, and any right to participate
         in, any security, whether over real or personal property or otherwise,
         now or hereafter held by the Lender for the Guaranteed Indebtedness, or
         any part thereof.

         The Guarantor waives all presentments, demands for performance, notices
         of non-performance, protests, notices of protest, notices of dishonour
         and notices of acceptance of this guarantee and of the existence,
         creation or incurring of new or additional Guaranteed Indebtedness of
         the Borrower to the Lender. The Guarantor also waives the benefit of
         any rights to receive a copy of any financing statement or financing
         change statement registered by the Lender. The Guarantor also waives
         the benefit of any rights of division. The Guarantor assumes the
         responsibility for being informed and keeping itself informed of the
         financial condition of the Borrower, the level of the Guaranteed
         Indebtedness which diligent inquiry would reveal and of all other
         circumstances bearing upon the risk of non-payment of the Guaranteed
         Indebtedness and agrees that the Lender shall have no duty to advise
         the Guarantor of information now or hereafter known to it regarding
         such financial condition or any such circumstances.

3.11     POWERS OF BORROWER

         Where the Borrower is a corporation, partnership or other organization,
         it is not necessary for the Lender to inquire into the powers of the
         Borrower or the officers, directors, partners, trustees or agents
         acting or purporting to act on behalf of the Borrower and any
         Guaranteed Indebtedness made or created in reliance upon the
         professional exercise of such powers shall form part of the Guaranteed
         Indebtedness even though such indebtedness is or was irregularly,
         fraudulently, defectively or informally made or created by or in excess
         of the powers of the Borrower or of any of its officers, directors,
         partners, trustees or agents and notwithstanding that the Lender has
         specific notice of any limitation on any of the powers of the Borrower
         or any of its officers, directors, partners, trustees or agents.

3.12     BANKRUPTCY AND DISSOLUTION

         Upon the bankruptcy of the Borrower, or where the Borrower is a
         corporation, upon the dissolution, winding up or other distribution of
         assets of the Borrower or of any surety or guarantor for any of the
         Guaranteed Indebtedness or any part thereof, the Lender's rights shall
         not be affected or impaired by any omission by the Lender to prove its
         claim or to prove its full claim and the Lender may prove or not prove
         such claim as it sees fit and may refrain from valuing any security
         held by the Lender without in any way releasing, reducing, or otherwise
         affecting the liability to the Lender of the Guarantor and until all of
         the Guaranteed Indebtedness has been fully paid, the Lender shall have
         the right to include in its claim the amount of all sums paid by the
         Guarantor under this guarantee and to prove and rank for and receive
         dividends in respect of such claim, any and all right of the Guarantor
         to prove and rank for such sums paid by the Guarantor and to receive
         the full amount of all dividends in respect thereof being hereby
         assigned and transferred to the Lender. All dividends, compositions,
         and money received by the Lender from the Borrower, the Guarantor or
         any other person or estate that is capable of being applied by the
         Lender in reduction of the Guaranteed Indebtedness shall be regarded
         for all purposes

         as payments in gross, and the Lender shall be entitled to prove in
         respect of the whole of the Guaranteed Indebtedness against the
         Borrower or the estate of the Borrower, as the case may be, upon the
         bankruptcy, dissolution, winding up or other distribution of assets of
         the Borrower.

3.13     INDEMNITY

         The Guarantor hereby covenants and agrees, as a separate obligation to
         the guarantee provided herein, to indemnify and save harmless the
         Lender from and against that portion of all losses, damages, costs and
         expenses in excess of Euro 2,000,000 which the Lender may sustain,
         incur or become liable for by reason of:

         (a)      the failure, for any reason whatsoever, of the Borrower to pay
                  any amounts expressed to be payable pursuant to the provisions
                  of the Credit Agreement in excess of Euro 2,000,000,
                  regardless of whether the Borrower's obligation to pay such
                  amounts is valid or enforceable against the Borrower;

         (b)      the failure, for any reason whatsoever, of the Borrower to
                  perform any other obligation under the Credit Agreement, the
                  Credit Facility Documents or any other security for the Credit
                  Facility; or

         (c)      any act, action or proceeding of or by the Borrower for or in
                  connection with the recovery of such amounts or the
                  performance of such obligations.


4.       MISCELLANEOUS

4.1      SURVIVAL OF WARRANTIES

         All agreements, representations and warranties made herein shall
         survive the execution and delivery of this guarantee.

4.2      FAILURE OR INDULGENCE NOT WAIVER

         No failure or delay on the part of the Lender in the exercise of any
         power, right or privilege hereunder shall operate as a waiver thereof,
         nor shall any single or partial exercise by the Lender of any such
         power, right or privilege preclude any other or further exercise of any
         such power, right or privilege. All powers, rights and privileges of
         the Lender are cumulative to, and not exclusive of, any powers, rights
         or privileges otherwise available.

4.3      MODIFICATION OF GUARANTEE

         No alteration, modification or waiver of this guarantee or any of its
         terms, provisions or conditions shall be binding on the Lender unless
         made in writing over the signature of a duly authorized officer of the
         Lender.

4.4      GOVERNING LAW

         This Agreement shall be construed, performed and enforced in accordance
         with, and governed by, the internal laws of Switzerland, without giving
         effect to the principles of conflict of law thereof.

4.5      ENTIRE AGREEMENT

         Upon the execution and delivery by the Guarantor to the Lender of this
         guarantee, the guarantee shall be deemed to be finally and
         unconditionally executed and delivered by the Guarantor and shall not
         be subject to or affected by any promise or condition affecting or
         limiting the liability of the Guarantor except as expressly set forth
         herein. No statement, representation, agreement or promise on the part
         of the Lender or any officer, employee or agent thereof unless
         expressly stated herein forms any part of this guarantee or has induced
         the making hereof or shall be deemed to affect the Guarantor's
         liability hereunder. There are no agreements, promises,
         representations, warranties, or other statements, express or implied,
         made by or on behalf of the Guarantor which are collateral hereto.

4.6      SEVERABILITY

         In case any provision in this guarantee shall be invalid, illegal or
         unenforceable, such provision shall be severable from the remainder of
         this guarantee and the validity, legality and enforceability of the
         remaining provisions shall not in any way be affected or impaired
         thereby.

4.7      ENUREMENT AND ASSIGNABILITY

         This guarantee shall be binding upon the Guarantor and its successors
         and assigns and shall enure to the benefit of the Lender and its
         successors and assigns. The Lender may assign this guarantee or any of
         its rights and powers hereunder without notice and free of all
         equities, with respect to all or any of the Guaranteed Indebtedness and
         in such event the assignee and further assignees shall have the same
         rights and remedies as if originally named herein in place of the
         Lender, free of all intervening equities.

4.8      MULTIPLE GUARANTORS

         If more than one party executes this instrument as Guarantor, then the
         provisions hereof shall be read with all grammatical changes thereby
         rendered necessary and each reference to the Guarantor shall include
         each and every one of them severally, all representations, warranties,
         covenants and agreements of the Guarantor herein shall be deemed to be
         joint and several representations, warranties, covenants and agreements
         of each such party, and any notice shall be deemed to have been given
         to each party comprising the Guarantor when such notice is first given
         to any such parties.

4.9      HEADINGS

         Headings of the articles and sections of this guarantee are inserted
         for convenience only and shall not be deemed to constitute a part
         hereof or considered in its interpretation.

4.10     TIME OF THE ESSENCE

         Time shall be of the essence hereof.

4.11     EXPENSES AND FEES

         The Guarantor hereby agrees to be responsible for and to pay all costs
         and expenses, including, without limitation, all fees and disbursements
         of accountants, lawyers and other advisors and consultants which are
         incurred by the Lender in connection with the creation, execution and
         delivery, administration and enforcement of this guarantee and the
         collection of the Guaranteed Indebtedness or any part thereof, whether
         such collection be from the Borrower or from the Guarantor or anyone
         else.

4.12     ASSIGNMENT AND POSTPONEMENT

         All debts and liabilities of every nature and kind, whether now or
         hereafter in existence, of the Borrower to the Guarantor and all
         security therefor (the "Subject Indebtedness") are hereby assigned and
         transferred to the Lender as continuing collateral security for the
         obligations of the Guarantor hereunder. The Guarantor shall not assign
         the Subject Indebtedness or any part thereof to any person other than
         the Lender. The Subject Indebtedness shall be held in trust by the
         Guarantor for the Lender and shall be collected, enforced or approved
         subject to and for the purpose of this guarantee and any payments
         received by the Guarantor in respect thereof shall be segregated from
         other funds and property held by the Guarantor and forthwith paid over
         to the Lender on account of the Subject Indebtedness. The Lender shall
         be entitled to receive payment of the Guaranteed Indebtedness in full
         before the Guarantor shall be entitled to receive any payment on
         account of the Subject Indebtedness. The Subject Indebtedness shall not
         be released or withdrawn by the Guarantor unless the Lender's written
         consent to such release or withdrawal is first obtained and the
         Guarantor shall not permit the prescription of the Subject Indebtedness
         by any statute of limitations or ask for or obtain any security or
         negotiable paper for or other evidence of the Subject Indebtedness
         except for the purpose of delivering the same to the Lender.

4.13     GUARANTOR NOT TO TAKE SECURITY

         Without the prior written consent of the Lender, the Guarantor will not
         take or hold security from the Borrower for any purpose. The Guarantor
         agrees that any security from time to time held by the Guarantor,
         whether or not with the consent of the Lender, and all proceeds of such
         security, shall be held in trust for the Lender and dealt with as
         directed by the Lender.

4.14     INTERPRETATION

         Wherever the singular or masculine or neuter is used herein, the same
         shall be construed as meaning the plural or the feminine or body
         corporate or vice-versa, where the context or the parties hereto so
         require.

4.15     GUARANTEE NOT IN SUBSTITUTION

         This guarantee is in addition to and not in substitution for any other
         guarantee or other security held or which may hereafter be held by the
         Lender.

4.16     FURTHER ASSURANCES

         The Guarantor agrees to promptly do all such further acts, and promptly
         execute and deliver all such further documents, as the Lender may
         consider necessary or advisable for the purpose of giving effect to or
         carrying out the provisions and intent of this guarantee.

4.17     COPY OF GUARANTEE

         The Guarantor acknowledges receipt of a copy of this guarantee.

4.18     COUNTERPARTS

         This guarantee may be executed in several parts in the same form and
         such parts as so executed shall together constitute one original
         document, and such parts, if more than one, shall be read together and
         construed as if all the signing parties had executed one copy of the
         said guarantee.

IN WITNESS WHEREOF the Guarantor has caused this guarantee to be duly executed under seal, in the case of a corporation by its duly authorized officer or officers, as of the date first written above.

MFC BANCORP LTD.

By: /s/ [illegible]
    ----------------------------------------

Name:                                                       c/s
      --------------------------------------

Title:
       -------------------------------------

This is page 11 of a Deed of Guarantee by MFC Bancorp Ltd.
in favour of MFC Merchant Bank S.A. dated for reference the 28th day of February, 2003.


Exhibit 10.21

FIRST AMENDMENT
TO
CONSULTING AGREEMENT

This First Amendment (this "AMENDMENT") is entered into this 21st day of August, 2002 between Mymetics Corporation, a Delaware corporation (the "COMPANY"), and Michael Allio, an individual resident of Rhode Island (the "CONSULTANT").

PREAMBLE

The parties entered into that certain Consulting Agreement (the "AGREEMENT") dated as of August 31, 2001. The Company and the Consultant are desirous of amending the Agreement in accordance with the provisions of this Amendment. Therefore, the parties, intending to be legally bound hereby, agree as follows:

AGREEMENT

1. All defined terms used herein and not otherwise defined shall have the meaning set forth in the Agreement.

2. The term of the Agreement shall be extended to February 28, 2003, unless terminated earlier in accordance with the provision of Section 3 of the Agreement.

3. Effective July 1, 2002, the monthly amount payable to the Consultant in accordance with Section 2(a) of the Agreement shall be increased to $16,500. If the Consultant's engagement hereunder should require more than the 7.5 days of full time work per month alloted under the Agreement, the Consultant shall invoice the Company for such additional time at a rate of $2,500 per diem, and the Company shall pay such invoices within 30 days of receipt thereof.

4. Section 2(b) of the Agreement is deleted in its entirety and in its stead is inserted the following:

"(b) Stock Options. In addition to the compensation set forth in (a) above, the Consultant shall be granted stock options to purchase up to 50,000 shares of the Company's common stock, $0.01 par value, pursuant to the Company's 2001 Stock Option Plan (the "INITIAL STOCK OPTION"). The exercise price for the Initial Stock Option will be $2.50 per share of commons stock, which represents the average of the bid and ask price of such shares as of September 1, 2001. In addition, the Company agrees to grant the Consultant stock options for an additional 100,000 shares of the Company's common stock, $0.01 par value, pursuant to the Company's 2001 Stock Option Plan (the "SECONDARY STOCK OPTION" and, together with the Initial Stock Option, the "STOCK OPTIONS"). The exercise price for the Secondary Stock Option will be $0.55 per share,


which represents the average of the bid and ask price of such shares as of August 15, 2002. The Consultant agrees to execute a Stock Option Agreement in substantially the form of Exhibit A, attached hereto an incorporated by reference herein, upon the grant of each of the Stock Options. Each of the Stock Options will vest upon being granted."

5. All other provisions of the Agreement shall continue to remain in effect.

ATTEST:                                 MYMETICS CORPORATION



_________________________________       By: /s/ Peter P. McCann
                                           -----------------------------------
                                        Name:  Peter P. McCann
                                        Title:  President and CEO

WITNESS:

_________________________________       /s/ Michael Allio
                                        --------------------------------------
                                        Michael Allio


Exhibit 10.23

SEPARATION AGREEMENT AND RELEASE

THIS AGREEMENT is entered into this 31st day of January, 2003, by and between MYMETICS CORPORATION, a Delaware corporation ("Mymetics"), and DR. PETER P. MCCANN ("Employee").

WHEREAS, Employee has been employed by Mymetics as its President and Chief Executive Officer as set forth in the Employment Agreement by and between Mymetics and Employee dated March 18, 2002 (the "Employment Agreement"); and

WHEREAS, Mymetics has decided to terminate the Employment Agreement; and

WHEREAS, Employee has agreed to resign from his position on the Board of Directors of Mymetics and resign from all other positions he holds with Mymetics and its affiliates and subsidiaries; and

WHEREAS, Mymetics and Employee desire to set forth the terms and conditions of Employee's resignation; and

WHEREAS, this Agreement is being offered solely for the purpose of attempting to settle any and all existing or potential outstanding disputes between the parties and is not an admission of any obligations or liability;

NOW THEREFORE, in consideration of the settlement of any claims that either party to this Agreement may have against the other arising out of the employment relationship between the parties hereto and/or the termination of the Employee's employment with Mymetics and/or the March 18, 2002 Employment Agreement and/or any and all claims arising thereunder now or hereafter, and intending to be legally bound, the parties do hereby agree as follows:

AGREEMENT

1. TERMINATION OF EMPLOYMENT AGREEMENT. The Employment Agreement, which is incorporated herein by reference, is terminated effective as of January 31, 2003, except for Sections 5.1, 5.2, 5.3, and 5.4, which will survive the termination of the Employment Agreement and shall remain in full force and effect.

2. RESIGNATION FROM EMPLOYMENT. Employee agrees to resign from his position on the Board of Directors of Mymetics and resign from all other positions he holds with Mymetics and its affiliates and subsidiaries effective as of January 31, 2003. Employee agrees that he will leave Mymetics in an orderly, non-disruptive fashion.


3. CONSIDERATION. As consideration for entering into this Agreement, Mymetics agrees to grant, pursuant to Mymetics Stock Option Plan, to Employee seventy-five thousand (75,000) options for Mymetics stock at a price to be determined as the trading value of Mymetics stock on January 31, 2003. Said grant will be made on January 31, 2003.

Employee acknowledges that the consideration set forth in this Agreement constitutes consideration over and above anything of value that he would be entitled to but for this Agreement. Employee's acceptance of the consideration to be made hereunder is in full accord and satisfaction of all claims arising out of Employee's employment with Mymetics and/or the termination of the Employment Agreement, including but not limited to breach of contract, tort, or any federal, state, or municipal statute or ordinance relating to employment including, without limitation, any claim for wrongful discharge (under any state or federal law or statute), breach of contract, benefits under the plans, incentive compensation, vacation benefits, or other common law claims or claims in equity. Employee agrees that all benefits and incidents of his employment relationship with Mymetics ceased on January 31, 2003.

4. NON-DISPARAGEMENT AND CONFIDENTIALITY.

(a) Employee agrees that he will not in any way disparage or make negative comments regarding Mymetics or its directors, officers, employees, agents, attorneys, or consultants to any person. Mymetics, its directors, officers, employees, agents, attorneys, and consultants agree that they will not in any way disparage or make negative comments regarding Employee.

(b) The terms, conditions, amount, and fact of this Agreement (other than the fact of Employee's prior employment and his resignation), and the reasons therefor, shall at all times remain confidential. Neither Employee nor Mymetics will make, facilitate, or authorize any disclosure concerning this Agreement, or the reasons therefor, except for disclosures to Employee's immediate family, legal counsel and/or accountants for the respective parties, or as may be required by applicable laws, regulations, or judicial, governmental, or similar order or decree.

5. NO ADMISSION OF LIABILITY. This Agreement will not constitute nor be deemed or construed to be an admission by Mymetics of discrimination of any kind or nature whatsoever against Employee or of any breach of any obligation of any kind or nature whatsoever, express or implied, to Employee. This Agreement shall not be deemed or construed to be an admission by Employee of any act of impropriety or wrongdoing.


6. COOPERATION AND RETURN OF PROPERTY.

(a) Employee agrees to cooperate fully with Mymetics, its counsel, and other representatives with respect to any and all legal disputes involving matters arising during his employ in which he was involved or in which he is knowledgeable of relevant information. Employee further agrees to cooperate fully with Mymetics to complete the transition of all matters with which Employee is familiar or for which Employee has responsibility and to be reasonably available to answer questions and assist in such matters.

(b) Promptly following the execution hereof, Employee shall return to Mymetics any and all tangible personal property that belongs to Mymetics and that is in Employee's possession. Such property may consist of, without limitation, computers, fax machines, books and other resource materials, office supplies, communications equipment, documents, files, computer disks and other electronic media, tools, equipment, and other property of Mymetics, including all correspondence, memoranda, drawings, blueprints, manuals, letters, notes, reports, flow-charts, training and marketing materials, and related documents, proposals, plans, and any documents concerning Mymetics' customers or prospective customers or concerning products or processes used or developed by Mymetics. Without limiting the foregoing, Employee will promptly deliver to Mymetics any and all other documents or materials containing or constituting confidential or proprietary information (as described in the Employment Agreement).

7. RELEASE. Employee does hereby absolutely, irrevocably, and unconditionally release and forever discharge Mymetics and its successors, assigns, directors, officers, employees, agents, and attorneys from any and all actions, causes of actions, damages (including but not limited to wages, benefits, emotional distress, pain and suffering, humiliation), suits, claims, complaints, costs, and demands whatsoever, at law or in equity, which he ever had, now has, or hereafter may have, whether known or unknown by him as of the date hereof, by reason of or in any way related to his employment, separation from employment, loss of employment, ownership (if any) of equity or stock options to purchase equity in Mymetics, or the forfeiture or termination of such equity or the right to obtain such equity, including but not limited to breach of contract, breach of fiduciary duty, shareholder derivative claims (or similar shareholder claims), tort, or any federal, state, or municipal statute or local ordinance relating to employment including, without limitation, any claim for wrongful discharge, breach of contract, benefits under plans or programs, including without limitation, any severance or termination pay program, or other common law claims or claims in equity and all statutes and ordinances concerning employment discrimination on account of, but not limited to, sex, race, age, religion, national origin, familial status, military status, and disability, including without limitation, Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act, as amended, the Older Workers Benefit Protection Act, the Americans with Disabilities Act, the Employee Retirement Income Security Act, Delaware's Discrimination in Employment Law, Maryland's fair


employment practices laws, Delaware's Wage Payment and Collection Act, and the Maryland Wage Payment and Collection Law. In addition, Employee also releases Mymetics and waives any right to or claim for any and all attorneys' fees, including litigation expenses and costs that Employee or his counsel may claim under any statute, regulation, or at common law or in equity, including but not limited to those set forth in this Section.

8. RECOVERY OF PAYMENTS. This Agreement may be pled as a complete defense and bar to any claims Employee may bring against Mymetics arising in any way from his employment with Mymetics or resignation therefrom. In the event a court of competent jurisdiction determines that Employee breached any of his obligations hereunder, Mymetics will be entitled to recover the consideration given under this Agreement and to obtain all other relief provided by law or equity.

9. JUDICIAL ENFORCEMENT. Ten (10) days before any party hereto institutes any action to enforce the rights set forth in this Agreement, written notice of the intention to sue shall be given by certified mail by said party to the other party. During the above-mentioned ten (10) day period, the parties hereto will make a reasonable effort to amicably resolve any disagreement that has arisen between them.

10. GOVERNING LAW. Should any dispute arise concerning the interpretation of this Agreement, it will be interpreted under the laws of the State of Delaware.

11. CONSULTATION WITH COUNSEL. Employee is advised to consult an attorney about this Agreement, and by executing this Agreement, Employee acknowledges that he has been so advised.

12. ATTORNEYS' FEES. Each party shall pay its own legal fees and expenses in connection with this Agreement.

13. ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties with respect to the matters contemplated hereby and supersedes all prior written and oral agreements, and all contemporaneous oral agreements, relating to such transactions.

14. ARBITRATION. Any controversy, claim, or dispute between the parties concerning this Agreement or the breach thereof shall be finally settled by arbitration in Pittsburgh, Pennsylvania, pursuant to the rules of the American Arbitration Association regarding employment disputes. In such instances, it is agreed that the dispute shall be submitted to final and binding arbitration by one arbitrator; provided, however, that either party may request that there be three arbitrators, in which case each party shall select one arbitrator, and the two arbitrators so selected shall select a third. All costs of arbitration
(other than the costs of a party's own witnesses and professional advisors) shall be split equally between the parties.


15. EQUITABLE RELIEF. Notwithstanding Section 14 "Arbitration," the parties acknowledge and agree that each would be irreparably damaged in the event that any of the provisions of this Agreement are not performed by the other in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that the non-breaching party shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by the other party and shall have the right to specifically enforce this Agreement and the terms and provisions hereof against the breaching party in addition to any other remedy to which the non-breaching party may be entitled at law or in equity. The parties further agree that Section 14 "Arbitration" is not intended to be a bar to either party seeking injunctive relief by filing an action in an appropriate court.

16. HEADINGS. All titles and headings in this Agreement are intended solely for convenience of reference and shall in no way limit or otherwise affect the interpretation of any of the provisions hereof.

17. ASSIGNMENT. This Agreement shall inure to the benefit of, and be binding upon, the heirs, executors, administrators, and assigns of the Employee and upon the successors and assigns of Mymetics and the other members of Mymetics, provided that this clause does not in any way alter the rights of the Employee with respect to the Mymetics Stock Option Plan or grant to the Employee the right to assign the Mymetics Stock Option Plan or any of them, or any of his rights thereunder.

18. SEVERABILITY. Should any provision of this Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable, including the general release language, such provision shall immediately become null and void, leaving the remainder of this Agreement in full force and effect. However, if any portion of the general release language were ruled to be unenforceable as a result of an action filed by Employee or at Employee's direction, Employee shall return the consideration given hereunder to Mymetics. Provided, however, Mymetics and Employee shall first use their best efforts to negotiate in good faith an enforceable general release.


By signing this Separation Agreement and Release, the parties hereto acknowledge that they understand this Agreement and enter into it voluntarily, that this is a complete settlement and release agreement and that there are no written or oral understandings or agreements that are not set forth herein.

WITNESS the due execution hereof as of the date first set forth above.

MYMETICS CORPORATION

By:/s/Michael K. Allio
   ------------------------------------
   MICHAEL K. ALLIO
   CHAIRMAN OF THE BOARD

Dated:
      ---------------------------------

WITNESS:

____________________________            /s/ Peter P. McCann
                                           ------------------------------------
                                        DR. PETER P. MCCANN

                                        Dated:
                                              ---------------------------------


Exhibit 10.29

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Dr. Pierre-Francois Serres
50-52 Avenue Chanoine
Cartellier 69230
Saint-Genis-Laval, France

Dear Dr. Serres:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement


2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.

The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts


applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.

The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.


It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.

This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
    ------------------------------------------

Title: Corporate Secretary
      ----------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Pierre-Francois Serres
--------------------------------------------
Signature of Optionee

Print Name: Pierre-Francois Serres

DATE:

Exhibit 10.30

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Mr. Patrice Pactol
130 Route des Bouleau
69126 Brindas, France

Dear Mr. Pactol:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement

2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.


The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.


The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.

It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.


This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By:/s/ John M. Musacchio
   -------------------------------------------

Title: Corporate Secretary
      ----------------------------------------

Receipt Acknowledged and
Option Accepted:


Signature of Optionee

Print Name:

DATE:

Exhibit 10.31

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Mr. Robert Demers
3537 Aylmer
Montreal, Canada H2X 2B9

Dear Mr. Demers:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement

2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.


The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.


The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.

It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.


This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
    ---------------------------------------------

Title: Corporate Secretary
      -------------------------------------------

Receipt Acknowledged and
Option Accepted:


Signature of Optionee

Print Name:

DATE:

Exhibit 10.32

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Mr. John M. Musacchio
507 Lakewood Drive
Monroeville, PA 15146

Dear Mr. Musacchio:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement

2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.


The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.


The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.

It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.


This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
    ------------------------------------------
Title: Corporate Secretary
      ----------------------------------------

Receipt Acknowledged and
Option Accepted:


Signature of Optionee

Print Name:

DATE:

Exhibit 10.33

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Mr. Michael K. Allio
34 Pratt Street
Providence, RI 02906

Dear Mr. Allio:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement

2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.


The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.


The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.

It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.


This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
   ----------------------------------------

Title: Corporate Secretary
      -------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Michael K. Allio
-------------------------------------
Signature of Optionee

Print Name: Michael K. Allio

DATE:

Exhibit 10.34

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

February 6, 2003

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Mr. Michael K. Allio
34 Pratt Street
Providence, RI 02906

Dear Mr. Allio:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 100,000 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $0.55 per share (the "OPTION"). A summary of all options that have been granted to you under the Plan is set forth on Exhibit A, attached hereto.

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on February 20, 2013 . The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement


2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.

The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts


applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.

The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.


It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.

This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement and the attached Exhibit A in the spaces provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland 21401-1472, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
   --------------------------------------------

Name: John M. Musacchio
     ------------------------------------------

Title: Corporate Secretary
      -----------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Michael K. Allio
----------------------------------------
Signature of Optionee

Print Name: Michael K. Allio

DATE:

EXHIBIT A

MICHAEL K. ALLIO STOCK OPTIONS

(granted as of February 6, 2003)

----------------------------------------------------------- ---------------------------- -----------------------------
                     BASIS FOR GRANT                           EXERCISE PRICE/SHARE          NO. OF OPTION SHARES
----------------------------------------------------------- ---------------------------- -----------------------------
Consulting Agreement (2001)                                            $2.50                        50,000
----------------------------------------------------------- ---------------------------- -----------------------------
Initial Director Options (2001)                                        $3.15                        10,000
----------------------------------------------------------- ---------------------------- -----------------------------
Annual Director Options (2002)                                         $3.50                         1,250
----------------------------------------------------------- ---------------------------- -----------------------------
Amendment to Consulting Agreement (2002)                               $0.55                       100,000
----------------------------------------------------------- ---------------------------- -----------------------------
                                                                                  TOTAL            161,250
----------------------------------------------------------- ---------------------------- -----------------------------

Acknowledged and agreed:

/s/ Michael K. Allio
---------------------------------------------
Michael K. Allio                   Date


Exhibit 10.35

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

June 20, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Dr. Peter P. McCann
Chief Executive Officer and President
706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

Dear Dr. McCann:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 10,000 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on December 19, 2012. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement


2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.

The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts


applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.

The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.


It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.

This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
   -------------------------------------------

Name: John M. Musacchio
     -----------------------------------------

Title: Corporate Secretary
      ----------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Peter P. McCann
-----------------------------------------
Signature of Optionee

Print Name: Peter P. McCann

DATE:

Exhibit 10.36

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

July 23, 2002

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Dr. Peter P. McCann
Chief Executive Officer and President
706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

Dear Dr. McCann:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 1,250 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $3.50 per share (the "OPTION").

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on January 22, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement


2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.

The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts


applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.

The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.


It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.

This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
   -----------------------------------------

Title: Corporate Secretary
      --------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Peter P. McCann
--------------------------------------
Signature of Optionee

Print Name: Peter P. McCann

DATE:

Exhibit 10.37

MYMETICS CORPORATION

706 Giddings Avenue, Suite 1C
Annapolis, Maryland 21401-1472

February 6, 2003

DIRECTOR AND NON-EMPLOYEE
STOCK OPTION AGREEMENT
(Non-Statutory)

Dr. Peter P. McCann
1669 Chinford Trail
Annapolis, MD 21401

Dear Dr. McCann:

I am pleased to advise you that as of the date hereof, the Administrator appointed by the Board of Directors of Mymetics Corporation (f/k/a Ichor Corporation) (the "CORPORATION"), which administers the Mymetics Corporation 2001 Stock Option Plan (the "PLAN"), has granted you an option to purchase 75,000 shares of Common Stock (the "COMMON STOCK") of the Corporation at a price of $0.14 per share (the "OPTION"). A summary of all options that have been granted to you (including the Options) under the Plan is set forth on Exhibit A, attached hereto.

The terms applicable to the Option are set forth below and in the Plan, a copy of which accompanies this Agreement.

1. Term and Vesting.

The Option shall expire at the close of the business on July 31, 2013. The Option granted hereby shall be fully vested as of the date of this Stock Option Agreement

2. Other Option Terms.

The Option has been granted pursuant to the Plan, and the terms and conditions of the Plan are incorporated by reference in this Agreement as though set forth herein in their entirety.


The Option is a "Non-Statutory Stock Option" as defined in the Plan.

If your relationship with the Corporation (or a Subsidiary) terminates for a reason other than death, voluntary termination with the written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall terminate immediately. If your relationship with the Corporation terminates because of death, voluntary termination with written consent of the Corporation (or a Subsidiary) or involuntary termination without cause, the Option shall be exercisable to the extent permitted by Section 7 of the Plan; provided, however, that if you engage in the operation or management of a business (whether as owner, partner, officer, director, employee or otherwise) which is in competition with the Corporation (or a Subsidiary), the Administrator in its sole discretion may immediately terminate the Option.

Subject to the foregoing and the provisions of the Plan, the Option may be exercised at your election, in whole or in part, at any time prior to its expiration. The Option may be exercised by (a) delivery of written notice to the Corporation setting forth your election to exercise and the number of shares of Common Stock to be purchased and (b) payment of the purchase price for the shares to be purchased. The notice must be dated and signed by the person exercising the Option. If the Option is exercised by someone other than you, the notice must be accompanied by proof, satisfactory to the Administrator, of the right of such person(s) to exercise the Option under the Plan.

The date of exercise of the Option is the date on which the notice of exercise, proof of right to exercise (if required) and payment of the exercise price are received by the Corporation at its principal executive office, to the attention of the Corporation's Secretary. As of the date of exercise, you will be considered by the Corporation for all purposes to be the owner of the shares of Common Stock purchased, subject to the terms set forth in this Agreement.

3. Securities Law Matters.

Neither this Option nor the shares of Common Stock issuable upon exercise of the Option (the "SHARES") have been registered under the Securities Act of 1933 (the "1933 ACT") or any other securities laws (together with the 1933 Act, the "ACTS"). Therefore, in order to ensure compliance with the Acts, notwithstanding anything else in the Option to the contrary, you (and any successive holder) agree by accepting the Option as follows: This Option and the Shares may not be sold, transferred, pledged or hypothecated in the absence of
(i) an effective registration statement under the Acts applicable to the Option or the Shares or (ii) the availability of an exemption from the registration requirements of the Acts and, at the reasonable request of the Corporation, an opinion of counsel reasonably satisfactory to the Corporation that registration is not required under the Acts.


The Corporation is under no obligation to register the Option or the Shares, or take any other action in connection with the offer or sale of the Shares.

Prior to the issuance or delivery of any Shares pursuant to the exercise of the Option in whole or in part, you may be required to represent and warrant (i) that the Shares to be acquired upon exercise of the Option are being acquired for investment for your own account and not with a view to resale or other distribution thereof and (ii) that you will not sell or otherwise transfer any such Shares unless the Shares are registered under the Acts or an exemption from registration is available. The certificate or certificates representing any Shares issued or delivered upon exercise of the Option shall bear a legend to this effect (and a legend evidencing any other restrictions on transfer set forth in the Plan) and other legends required by any applicable securities laws.

4. Other Transfer Restrictions.

The Option may not be transferred except as permitted under the Plan.

5. Tax and Withholding Matters.

Under current federal income tax laws, upon exercise of the Option you may recognize compensation income equal to the amount (if any) by which the fair market value (on the date of exercise) of the Shares acquired upon such exercise exceeds the purchase price paid for such Shares. You will be notified by the Corporation of the amount of any state and local income taxes and employment taxes required to be withheld by the Corporation on any compensation income resulting from the exercise of the Option, and the Corporation in its sole discretion may require you to provide the funds necessary to satisfy such withholding obligation or may provide such funds on your behalf, subject to your obligation, which you hereby assume, to reimburse the Corporation for the amount (or portion of the amount) so withheld.

6. Miscellaneous.

When accepted by you, this Agreement shall constitute an agreement which shall be binding upon the successors and assigns of the Corporation and your heirs and legal representatives.

This Agreement does not confer any right on you to continue as a director of the Corporation or any Subsidiary or interfere in any way with the rights of the Corporation's shareholders to remove you as a director of the Corporation.

It is suggested that you obtain competent advice as to the tax consequences of the exercise of the Option prior to the time you exercise any part of the Option.


This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Any dispute or disagreement which shall arise under or in any way relate to the interpretation or construction of the Plan or this Agreement shall be resolved by the Board, and its decision shall be final, binding and conclusive for all purposes.

This Agreement is the Stock Option Agreement referred to in Section 7(F) of the Plan and has been prepared in duplicate. Please execute both copies of this Agreement and the attached Exhibit A in the space provided and return one copy to Mymetics Corporation, 706 Giddings Avenue, Suite 1C, Annapolis, Maryland, Attn: Corporate Secretary.

Very truly yours,

MYMETICS CORPORATION

By: /s/ John M. Musacchio
   --------------------------------------------

Name: John M. Musacchio
     ------------------------------------------

Title: Corporate Secretary
      -----------------------------------------

Receipt Acknowledged and
Option Accepted:

/s/ Peter P. McCann
---------------------------------------
Signature of Optionee

Print Name: Peter P. McCann

DATE:

EXHIBIT A

DR. PETER P. MCCANN STOCK OPTIONS

(granted as of February 6, 2003)

----------------------------------------------------------- ---------------------------- -----------------------------
                     BASIS FOR GRANT                           EXERCISE PRICE/SHARE          NO. OF OPTION SHARES
----------------------------------------------------------- ---------------------------- -----------------------------
Initial Director Options (2002)                                        $3.50                         10,000
----------------------------------------------------------- ---------------------------- -----------------------------
Annual Director Options (2002)                                         $3.50                          1,250
----------------------------------------------------------- ---------------------------- -----------------------------
Separation Agreement (2003)                                            $0.14                         75,000
----------------------------------------------------------- ---------------------------- -----------------------------
                                                                                  TOTAL              86,250
----------------------------------------------------------- ---------------------------- -----------------------------

Acknowledged and agreed:

/s/ Peter P. McCann
---------------------------------------
Peter P. McCann           Date


Exhibit 10.38

PATENT PLEDGE AGREEMENT

THIS PATENT PLEDGE AGREEMENT (this "AGREEMENT"), is made as of November __, 2002, by MYMETICS, S.A., a corporation formed under the laws of France ("Mymetics S.A."), MYMETICS DEUTSCHLAND GMBH, a German limited liability company ("Mymetics GmbH"), and MYMETICS CORPORATION, a corporation formed under the laws of the United States of America ("Mymetics Corporation" and together with Mymetics S.A. and Mymetics GmbH, the "ASSIGNORS"), in favor of MFC MERCHANT BANK S.A., a Bank organized under the laws of Switzerland (the "ASSIGNEE").

WITNESSETH

WHEREAS, Mymetics Corporation, the parent company of Mymetics S.A. and Mymetics GmbH, is party to that certain Credit Facility Agreement (as amended from time to time, the "CREDIT AGREEMENT"), dated as of July 27, 2000, by and among Mymetics Corporation (as successor in interest to Hippocampe S.A.) and the Assignee, providing for the Assignee to make available to the Assignors, directly or indirectly, certain credit facilities on the terms and conditions set forth therein; and

WHEREAS, in accordance with provisions of the Credit Agreement, and as further consideration for the extension of additional credit to Mymetics Corporation under the Credit Agreement, which funds have been and will continue to be used to fund the operations of each of the Assignors, Assignors have agreed to deliver patent pledge agreements with respect to all currently existing, pending and newly developed patents to serve as security for the Obligations (as that term is defined in the Credit Agreement).

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows, with the intent to be legally bound:

1. As security for the full and timely payment of the Obligations under the Credit Agreement and the other Loan Documents, the Assignors hereby grant, assign and convey to the Assignee their entire right, title and interest in and to the patent applications and patents listed in Exhibit A which is attached hereto and incorporated herein by this reference, including, without limitation, all proceeds thereof (for example, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof (collectively, the "PATENTS").


2. The Assignors covenant and warrant that:

(a) The Patents are subsisting and have not been adjudged invalid or unenforceable, in whole or in part;

(b) To the best of the Assignors' knowledge, each of the Patents is valid and enforceable;

(c) Except as may have already been pledged by the Assignors to the Assignee, the Assignors are the sole and exclusive owner of the entire and unencumbered right, title and interest in and to each of the Patents, free and clear of any liens, charges and encumbrances, including without limitation pledges, assignments, licenses and covenants by the Assignor not to sue third persons; and

(d) Each of the Assignor has the unqualified right to enter into this Agreement and perform its terms and has entered and will enter into written agreements with each of its present and future employees, agents and consultants responsible for generating inventions incident to their employment, agency or consulting relationship which will enable such Assignor to comply with the covenants herein contained.

3. Each of the Assignor agrees that, until all of the Obligations shall have been satisfied in full , it will not enter into any agreement (for example, a license agreement) which is inconsistent with such Assignor's obligations under this Agreement, without the Assignee's prior written consent. Each of the Assignors acknowledges that it has derived benefits from the funds made available pursuant to the Credit Agreement and expect to continue to do so until the Obligations are satisfied.

4. If, before the Obligations shall have been satisfied in full, any of the Assignors shall obtain rights to any new patentable inventions, or become entitled to the benefit of any patent application or patent for any reissue, division, continuation, renewal, extensions, or continuation-in-part of any patent or any improvement on any patent worldwide (in addition to the Patents) or any other intellectual property, the provisions of Section 1 above, shall automatically apply thereto and such Assignor shall give to the Assignee prompt notice thereof in writing.

5. Each of the Assignor authorizes the Assignee to modify this Agreement by amending Exhibit A to include any future patents and patent applications which are Patents under Section 4 above.

6. Unless and until there shall have occurred and be continuing an Event of Default (as that term is defined in the Credit Agreement), the Assignee hereby grants to each of the Assignors the exclusive, nontransferable right and license under the Patents to make, have made for it, use and sell the inventions disclosed and claimed in the Patents for the Assignors' own benefit and account and for none other. Each of the Assignors agrees not to sell or assign its interest in, or grant any sublicense under, the license granted to such Assignor in this section, without the prior written consent of the Assignee.

2

7. If any Event of Default shall have occurred and be continuing, the Assignors' license under the Patents as set forth in Section 6 above shall terminate forthwith, and the Assignee shall have, in addition to all other rights and remedies given it by this Agreement, those allowed by law, and the rights and remedies of a secured party under applicable federal, state or local laws as enacted in any jurisdiction in which the Patents may be located and without limiting the generality of the foregoing, the Assignee may immediately, without demand of performance and without other notice (except as set forth below) or demand whatsoever to Assignors, all of which are hereby expressly waived, and without advertisement, sell at a public or private sale or otherwise realize upon, the whole or, from time to time any part of the Patents, or any interest which the Assignors may have therein, and after deducting from the proceeds of sale or other disposition of the Patents all expenses (including all reasonable expenses for brokers' fees and legal services), shall apply the residue of such proceeds toward the payment of the Obligations. Any remainder of the proceeds after payment in full of the Obligations shall be paid over to the Assignors pro rata. Notice of any sale or other disposition of the Patents shall be given to the Assignors at least five (5) days before the time of any intended public or private sale or other disposition of the Patents is to be made, which Assignors hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition, Assignee may, to the extent permissible under applicable law, purchase the whole or any part of the Patents sold, free from any right of redemption on the part of the Assignors, which right is hereby waived and released.

8. If any Event of Default shall have occurred and be continuing, each of the Assignors hereby authorizes and empowers the Assignee to make, constitute and appoint any officer or agent of the Assignee, as the Assignee may select in its exclusive discretion, as such Assignor's true and lawful attorney-in-fact, with the power to endorse such Assignor's name on all applications, documents, papers and instruments necessary for Assignee to use the Patents, or to grant or issue any exclusive or nonexclusive license under the Patents to any third person, or necessary for Assignee to assign, pledge, convey or otherwise transfer title in or dispose of the Patents to any third person. Each of the Assignors hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. The Assignors acknowledge that this power of attorney is coupled with an interest and shall be irrevocable for the life of this Agreement.

9. At such time as the Assignors shall completely satisfy all of the Obligations, this Agreement shall terminate and the Assignee shall execute and deliver to the Assignors all deeds, assignments and other instruments as may be necessary or proper to revest in the Assignors full title to the Patents, subject to any disposition thereof which may have been made by the Assignee pursuant hereto.

10. Any and all fees, costs and expenses, including the reasonable attorney's fees and legal expenses incurred by the Assignee in connection with the preparation of this Agreement and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment of discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining or preserving the Patents, or in defending or prosecuting any actions or proceedings arising out of or related to the Patents, shall be borne and paid to the Assignors on

3

demand by the Assignee and until so paid shall be added to the principal amount of the Obligations and shall bear interest at the applicable rate prescribed in the Credit Agreement.

11. The Assignors shall have the duty, through counsel acceptable to the Assignee, to prosecute diligently any patent applications of the Patents pending as of the date of this Agreement or thereafter until the Obligations shall have been paid in full, to make application on unpatented but patentable inventions and to preserve and maintain all rights in patent applications and patents of the Patents, including without limitation the payment of all maintenance fees. Any expense incurred in connection with such an application shall be borne by the Assignor. The Assignors shall not abandon any right to file a patent application, or any pending patent application or patent without the consent of the Assignee, which consent shall not be unreasonably withheld.

12. Each of the Assignors shall have the right, with the consent of the Assignee, which shall not be unreasonably withheld, to bring suit in its own name, and to join the Assignee, if necessary, as a party to such suit so long as the Assignee is satisfied that such joinder will not subject it to any risk of liability, to enforce the Patents and any license thereunder. The Assignors shall promptly, upon demand, reimburse and indemnify the Assignee for all damages, costs and expenses, including legal fees, incurred by the Assignee pursuant to this section.

13. No course of dealing between the Assignors and the Assignee, nor any failure to exercise, nor any delay in exercising, on the part of the Assignee, any right, power or privilege hereunder or under the Credit Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

14. All of the Assignee's rights and remedies with respect to the Patents, whether established hereby or by the Credit Agreement, or by any other agreements or by law shall be cumulative and may be exercised singularly or concurrently.

15. The provisions of this Agreement are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any clause or provision of this Agreement in any jurisdiction.

16. This Agreement is subject to modification only by a writing signed by the parties, except as provided in Section 5 above.

17. The benefit and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successor and permitted assigns of the parties.

18. This Agreement shall be governed by, construed and enforced in accordance with, the laws of the State of Delaware.

4

19. This Agreement and any amendment hereto may be executed in several counterparts and by each party on a separate counterpart, each of which, when so executed and delivered, shall be an original, but all of which together shall constitute but one and the same instrument. In proving this Agreement or any amendment hereto, it shall not be necessary to produce or account for more than one such counterpart signed by the other party against whom enforcement is sought.

20. Capitalized terms used in this Agreement as defined terms which are not defined herein but which are defined in the Credit Agreement shall have the meanings herein which are given to them in the Credit Agreement.

21. This Agreement is being made pursuant to the Credit Agreement. Nothing contained in this Agreement shall in any way supersede, modify, replace, amend, change, rescind, waive or otherwise affect any of the provisions, including the representations, warranties, covenants and agreements of the parties set forth in the Credit Agreement. This instrument is intended only to effect the transfer of the Patents assigned by the Assignor to the Assignee pursuant to the Credit Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

5

IN WITNESS WHEREOF, the Assignor has executed this Agreement as of the day and year first above written.

MYMETICS CORPORATION

By:

Name:
Title:

By:
Name:
Title:

MYMETICS S.A.

By:

Name:
Title:

By:
Name:
Title:

MYMETICS DEUTSCHLAND GMBH

By:

Name:
Title:

By:
Name:
Title:

Acknowledged:

MFC MERCHANT BANK S.A.

By:
Name:
Title:

EXHIBIT A

(a) PATENTS/PATENT APPLICATIONS

I. UNITED STATES

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS;
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 09/570921
FILING DATE: 15-May-2000
STATUS: issued September 24, 2002 as US Patent No 6,455,265

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS;
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 10/198938
FILING DATE: 22-Jul-2002
STATUS: Pending, filed as divisional of allowed US application 09/570921

TITLE: USE OF ANTIBODIES IDENTIFYING THE INTERLEUKIN-2 RECEPTOR FOR PREVENTING AND/OR TREATING HIV INFECTIONS
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 09/979271
FILING DATE: 17-Jan-2002
STATUS: Pending, abandonment in favor of new CIP is under consideration

TITLE:POLYPEPTIDE INHIBITER OF HIV INFECTIVITY
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/340492
FILING DATE: 18-Dec-2001
STATUS: Pending, this is a US provisional application that will be converted to US utility and PCT applications by Dec 18, 2002.


TITLE: POTENT INHIBITION OF HIV-1 IN VITRO BY GP41-DERIVED SYNTHETIC PEPTIDES INVENTORS: SERRES, PIERRE-FRANCOIS, KAZMI, S H; SATTENTAU, Q J CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/386754
FILING DATE: 10-Jun-2002
STATUS: Pending, this is a US provisional application that will be converted to US utility and PCT applications by June 10, 2003.

TITLE: NEW PEPTIDES AND USE THEREOF IN THERAPEUTIC AGENTS AGAINST FELINE FIVE INFECTION.
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): MYMETICS SA
SERIAL NO.: 10/222976
FILING DATE: 19-Aug-2002
STATUS: Pending, this is a US utility application based on French applications 01 10910 and 01 15424.

TITLE: PEPTIDES AS INHIBITORS OF HIV INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS,
CURRENT OWNER(S): MYMETICS CORP
SERIAL NO.: 60/413919
FILING DATE: 27-Jul-2002
STATUS: Pending, this is a US provisional application that will be converted to US utility and PCT applications by July 27, 2003.


INTERNATIONAL

INTERNATIONAL FAMILY A:

TITLE: METHOD FOR OBTAINING VACCINES FOR PREVENTING THE PATHOGINIC EFFECTS RELATED TO A RETROVIRAL INFECTION
INVENTORS: SERRES, PIERRE-FRANCOIS; GEOURJON, CHRISTOPHE; DELEAGE, GILBERT; COMBET, CHRISTOPHE
CURRENT OWNER(S): HIPPOCAMPE CHANGE TO MYMETICS SA IN PROGRESS
PCT/FR98/02447 WO 99/25377 filed 17-Nov-1998 Published 27-May-1999

African Regional Industrial                  AP/P/00/01841           filed 17-Nov-1998
Australia                                    12434/99                filed 17-Nov-1998
Brazil                                       PI9814204               filed 17-Nov-1998
Canada                                       2309676                 filed 17-Nov-1998
China                                        98811909.9              filed 17-Nov-1998
Eurasian Patent Organization                 200000528               filed 17-Nov-1998
European Patent Convention                   98955673.3              filed 17-Nov-1998
France                                       9714387                 filed 17-Nov-1997
Israel                                       136163                  filed 17-Nov-1998
Japan                                        2000-520810             filed 17-Nov-1998
Republic of Korean                           2000-7005402            filed 17-Nov-1998
Mexico                                       4633                    filed 17-Nov-1998
New Zealand                                  505152                  filed 17-Nov-1998
African Union Territories OAPI               1200000145              filed 17-Nov-1998
Viet Nam                                     S20000544               filed 17-Nov-1998

INTERNATIONAL FAMILY B:

TITLE:USE OF ANTIBODIES IDENTIFYING THE INTERLEUKIN-2 RECEPTOR FOR PREVENTING AND/OR TREATING HIV INFECTIONS
INVENTOR: SERRES, PIERRE-FRANCOIS
CURRENT OWNER(S): HIPPOCAMPE SA CHANGE TO MYMETICS SA IN PROGRESS
PCT/FR00/01399 filed 22-May-2000

France                                       99/0652                 filed 21-May-1999
  Pending
ARIPO (Africa)                               AP/P/0102354            filed 22-May-2000
  Pending Abandonment under consideration
Canada                                       2373991                 filed 22-May-2000
  Pending
European Patent Convention                   00931335.4              filed 22-May-2000
  Pending
Eurasian Patent Organization                 2001011228              filed 22-May-2000
  Pending  Abandonment under consideration
OAPI (Africa)                                1200100307              filed 22-May-2000


  Pending  Abandonment under consideration
South Africa                                 2001/9664               filed 22-May-2000
  Pending  Abandonment under consideration

FRENCH APPLICATIONS:

French Application No. 01 10910 (the `910 application), filed August 17, 2001, novel peptides useful in the treatment of FIV in cats, inventor Pierre-Francois Serres Pending

French Application No. 01 15424 (the `424 application), filed November 29, 2001, novel peptides useful in the treatment of FIV in cats, inventor Pierre-Francois Serres, Pending

French Application No. 01 16290, December 17, 2001. novel peptides useful in the treatment of FIV in cats, inventor Simone Giannecchini, Pending


Exhibit 11

STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS

COMPUTATION OF PER SHARE EARNINGS

For the Years Ended December 31, 2002, 2001, and 2000


(In Thousands of Euros, Except for Per Share Amounts)

                                                 BASIC EPS

                                                        2002                2001                 2000
                                                  -----------------    ----------------     ----------------

Net loss per financial statements                 EURO    (3,622)      EURO   (15,701)      EURO   (1,314)
                                                  =================    ================     ================

Weighted average shares outstanding                   50,045,658           42,459,784          33,311,361

     Basic earnings (loss) per share              EURO      (.07)     EURO      (.37)      EURO     (.04)
                                                  =================    ================     ================



                                                DILUTED EPS

                                                        2002                2001                 2000
                                                  -----------------    ----------------     ----------------

Net loss per financial statements                 EURO      (.07)     EURO   (15,701)      EURO   (1,314)
                                                  =================    ================     ================

Weighted average shares outstanding                   50,167,085          43,671,784          33,391,361

     Diluted earnings (loss) per share*           EURO      (.07)     EURO      (.36)      EURO     (.04)
                                                  =================    ================     ================

* - Anti-dilutive


Exhibit 21

SUBSIDIARIES

Mymetics Corporation has three subsidiaries:

1. 6543 Luxembourg S.A. (a majority-owned subsidiary of Mymetics Corporation) is a joint stock company organized under the laws of Luxembourg and does business under the name "6543 Luxembourg S.A."

2. Mymetics S.A. (a wholly-owned subsidiary of 6543 Luxembourg S.A.) is a company organized under the laws of France and does business under the name "Mymetics S.A."

3. Mymetics Deutschland GmbH (a wholly owned subsidiary of Mymetics Corporation) is a company organized under the laws of Germany and is inactive.


Exhibit 24.1

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned director of Mymetics Corporation, a Delaware Corporation, does make, constitute and appoint John M. Musacchio, with full power and authority, his true and lawful attorney-in-fact and agent, for him and his name, place and stead in any and all capacities, to sign the Annual Report of Mymetics Corporation on Form 10-K for the year ended December 31, 2002, and to file such Annual Report, so signed, with all exhibits thereto, with the Securities and Exchange Commission, hereby further granting unto said attorney-in-fact full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as he might or could do in person, the undersigned hereby ratifies and confirms all that said attorney and agent shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, THE UNDERSIGNED HAS HEREUNTO SET HIS HAND AND SEAL

THIS 25TH DAY OF MARCH, 2003.

/s/ PIERRE-FRANCOIS SERRES
-----------------------------------
Pierre-Francois Serres, Director


Exhibit 24.2

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned director of Mymetics Corporation, a Delaware Corporation, does make, constitute and appoint John M. Musacchio, with full power and authority, his true and lawful attorney-in-fact and agent, for him and his name, place and stead in any and all capacities, to sign the Annual Report of Mymetics Corporation on Form 10-K for the year ended December 31, 2002, and to file such Annual Report, so signed, with all exhibits thereto, with the Securities and Exchange Commission, hereby further granting unto said attorney-in-fact full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as he might or could do in person, the undersigned hereby ratifies and confirms all that said attorney and agent shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, THE UNDERSIGNED HAS HEREUNTO SET HIS HAND AND SEAL

THIS 27TH DAY OF MARCH, 2003.

/s/ ROBERT DEMERS
-----------------------------------
Robert Demers, Director


Exhibit 24.3

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned director of Mymetics Corporation, a Delaware Corporation, does make, constitute and appoint John M. Musacchio, with full power and authority, his true and lawful attorney-in-fact and agent, for him and his name, place and stead in any and all capacities, to sign the Annual Report of Mymetics Corporation on Form 10-K for the year ended December 31, 2002, and to file such Annual Report, so signed, with all exhibits thereto, with the Securities and Exchange Commission, hereby further granting unto said attorney-in-fact full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as he might or could do in person, the undersigned hereby ratifies and confirms all that said attorney and agent shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, THE UNDERSIGNED HAS HEREUNTO SET HIS HAND AND SEAL

THIS 27TH DAY OF MARCH, 2003.

/s/ MICHAEL K. ALLIO
-----------------------------------
Michael K. Allio, Director


Exhibit 99.1

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002 (SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF
TITLE 18, UNITED STATES CODE)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Mymetics Corporation, a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Annual Report on Form 10-K for the fiscal year ended December 31, 2002 (the "Form 10-K") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

                                       /s/ Michael K. Allio
                                       ----------------------------------------
Dated: March 27, 2003                  Interim Chief Executive Officer


                                       /s/ John M. Musacchio
                                       ----------------------------------------
Dated: March 27, 2003                  Chief Financial Officer

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as a separate disclosure document.